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1. Oral Vaccines: immunological basis and strategies 
for vaccine development 
 
1.1. Introduction 
Gut-borne illnesses have been responsible for high negative impacts on global 
public health. The pathogens causing these illnesses include colonizing 
enteropathogens, whose pathogenicity is confined to the gut mucosa and that can   
be responsible for life-threatening diarrhea (e.g. Vibrio cholerae, pathogenic 
Escherichia coli and rotaviruses), and invasive pathogens, (e.g. polioviruses and 
Salmonella Typhi), which exploit the gut mucosa as a portal of entry to other target 
organs, resulting in serious systemic diseases (e.g. poliomyelitis and typhoid fever, 
respectively). The best strategy to protect against these pathogens is the induction of 
a protective intestinal mucosal immunity. Clinical vaccine development has been 
largely based on injectable vaccines. However, injectable vaccines typically induce 
systemic immune responses, and thus can provide protection against invasive 
pathogens, while being mostly ineffective against colonizing enteric pathogens 
(Czerkinsky & Holmgren, 2012). Additionally, administration of injectable vaccines 
results in patient non-compliance and is associated with risks of cross infection by 
contaminated needle, especially in developing countries. Alternatively, oral    
vaccines offer important immunologic and practical advantages for protection 
against enteric pathogens: (1) unlike injectable vaccines, oral vaccines are properly 
capable of stimulating mucosal immune responses in the gut. These responses can 
prevent the interactions of pathogens with the gut mucosa and thereby, prevent the 
associated diseases (Czerkinsky & Holmgren, 2012); (2) comparable to injectable 
vaccines, oral vaccines are capable of inducing systemic immune responses, and thus 
provide an extra layer of protection against invasive enteric pathogens; (3) oral 
vaccines are remarkable for their easy and safe administration, and thus are 
particularly amenable for application in mass vaccination programs aiming to 
eradicate certain enteric diseases (e.g. the oral polio vaccine, OVP).            
Despite these merits, the development of oral vaccines represents a difficult 
challenge for immunologists (Neutra & Kozlowski, 2006), for a number of reasons. 
First, the harsh gastrointestinal conditions, including acidic pH and digestive 
enzymes, which can cause degradation or denaturation of antigens, in addition to 
the dilution and dispersion of these antigens within the gastrointestinal contents.  
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Second, the poor immunogenicity of most orally delivered antigens, which is 
either due to their poor uptake by mucosal immune cells or to the induction of oral 
tolerance. The latter refers to the tendency of the gut immune system to maintain a 
state of hypo- or unresponsiveness to oral antigens, a mechanism by which the 
undesirable inflammatory responses to dietary antigens and microbiota can be 
avoided. With the increasing knowledge of the mechanisms underlying the induction 
of mucosal adaptive immunity and the advances in biotechnology, several vaccine-
design strategies have been developed to overcome the described challenges.  
In the present chapter we describe the adaptive immune responses induced by 
oral vaccination. Additionally, we review the strategies employed in oral vaccine 
development and antigen delivery, in order to effectively elicit mucosal immunity in 
the gut.  
1.2.  The gut immune system 
The immune system of the gut consists of a number of diffuse and organized 
lymphoid tissues, which comprise the gut-associated lymphoid tissue (GALT) and 
the mesenteric lymph nodes (MLNs) (Cesta, 2006) (Figure 1.1). The organized 
lymphoid tissues of GALT include Peyer’s patches (Knappstein et al., 2004a), the 
appendix and other isolated lymphoid follicles (ILFs). These represent the major 
inductive sites for mucosal immune responses in the gut. The diffuse lymphoid tissue 
comprises antigen-presenting cells and lymphocytes, which are scattered throughout 
the gut mucosal lamina propria to perform both effector and inductive functions 
(Cesta, 2006).  
PPs are large organized lymphoid structures that are situated in the submucosa 
along the length of the small intestine (Cesta, 2006). They are composed of B cell 
follicles that contain germinal centers, surrounded by T cell rich interfollicular 
regions. These follicles are covered with follicle-associated epithelium (FAE), which 
bears an underlying area of connective tissue known as the subepithelial dome. The 
FAE comprise specialized antigen-sampling epithelial cells termed, microfold or 
membranous cells (M-cells), which have a folded luminal surface instead of the 
microvilli present on conventional enterocytes, and also lack the glycocalyx layer. 
These adaptations enable M-cells to capture luminal pathogens and particulate 
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antigens and translocate them to the subepithelial dome. This zone is abundantly 
rich in dendritic cells (DCs), which immediately take up the translocated antigens. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Schematic representation of the lymphoid elements of the intestinal immune 
system. The organized tissues of the Peyer’s patches and mesenteric lymph nodes are 
involved in the induction of immunity. Effector lymphocytes are scattered throughout the 
lamina propria and epithelium of the mucosa. Both the Peyer’s patches and villus lamina 
propria are drained by afferent lymphatics that go to the MLNs. SED, subepithelial dome. 
Figure adapted from (Mowat, 2003).   
 
MLNs are also organized lymphoid tissues that constitute a part of the intestinal 
immune system, but are not considered as a mucosa-associated lymphoid organ, 
since they do not sample antigen directly from the intestinal lumen. However, they 
obtain antigens via antigen-loaded DCs that migrate from the PPs or directly from 
mucosal surfaces (Brandtzaeg & Pabst, 2004). In addition, antigens can drain directly 
from GALT and mucosa to the MLN via the lymph (Mowat, 2003). In both PPs and 
MLNs, antigen-loaded DCs migrate to interfollicular regions, where they present 
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antigenic peptides to CD4+ T cells, which subsequently stimulates the differentiation 
and maturation of T- and B cells with immune effector functions (Mowat, 2003). 
ILFs are small lymphoid aggregates that are scattered throughout the intestinal 
mucosa (Hamada et al., 2002). They structurally resemble PPs and are similarly 
covered with FAE, containing M-cells. However, each consists of a single follicle, 
predominately contains B cells and few DCs and thus, lacks the T cell-rich 
interfollicular regions (Hamada et al., 2002). This suggests the involvement of a T 
cell-independent mechanism for the induction of effector immune responses by ILFs 
(discussed below).    
1.3.  Induction of mucosal immunity by oral vaccines 
Following oral vaccination, a series of cellular events, are initiated in both 
organized lymphoid tissues and the mucosal lamina propria of the gut, involving 
DCs, naïve T and B lymphocytes, as to generate antigen-specific antibodies and 
cytotoxic T lymphocytes (CTLs) for mucosal protection against pathogens. In 
particular, secretory IgA (sIgA) plays the most important role in protecting the gut 
mucosal surface against pathogens and/or the toxins they elaborate. 
1.3.1. IgA antibody responses 
The production of IgA antibodies in the gut is ruled by the coordinating functions 
of mucosal DCs, T-helper lymphocytes and B lymphocytes (Figure 1.2). Hereto, 
antigen loaded DCs secrete in PPs and MLNs a subset of cytokines and stimulatory 
molecules, such as TGFβ, IL-10, IL-6 and retinoic acid (vitamin A derivative), which 
promote the development of antigen-specific T-helper lymphocytes type 2 (Th2) and 
Foxp3+T regulatory cells (Treg) (Coombes et al., 2007; Iwasaki & Kelsall, 1999; Sato et 
al., 2003; Sun et al., 2007). It has been shown that Treg can differentiate into T-
follicular helper cells (Tfh) (Tsuji et al., 2009). These T-helper cell subtypes interact 
with B lymphocytes and induce IgA class switching. The latter is mediated by the 
signals triggered by the interaction of the B cell receptor, CD40 with the CD40 ligand 
present on T-helper cells, in addition to the secretion of cytokines such as IL-4, IL-5 
and IL-6 produced by the Th2 cells, IL-10 and TGF-β produced by the Treg and Tfh 
cells, and IL-21 produced by the Tfh cells (Cerutti et al., 1998; Zan et al., 1998; Zhang 
et al., 1994).   
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Figure 1.2. Mechanisms of IgA antibody induction in the mouse gut. (A) In organized lymphoid 
follicles such as present in Peyer's patches, a T cell-dependent pathway exists. Orally administered 
antigens are taken up by M cells in follicle-associated epithelium of PP and then processed and 
presented by dendritic cells (DCs) and macrophages for the generation of helper T (Th) cells  and IgA-
committed B cells. IL-4, IL-5, IL-10, and TGF-β produced by Th cells and nitric oxide (NO) and IL-6 
produced by PP DCs allow B cells to undergo IgA class switching. Simultaneously, retinoic acid (RA) 
produced by DCs increases gut homing receptors (α4β7 integrin and CCR9) on antigen-primed Th cells 
as well as IgA-committed B cells. These antigen-primed Th cells and IgA-committed B cells migrate to 
effector sites such as intestinal lamina propria for terminal differentiation to IgA producing plasma 
cells. (B) IgA-committed B cells can also be generated via a T cell-independent mechanism. In the latter 
case, intestinal DCs directly sample antigen from the lumen and present it to the B cells, which under 
the influence of cytokines such as BAFF, APRIL, and TGF-β1, and NO derived from DCs, start the 
process of isotype switching and differentiation to IgA producing plasma cells. Figure adapted from 
(Takahashi et al., 2009). 
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Besides the role of conventional DCs, PPs possess other specialized DCs types, 
which enhance the IgA class switching induced by activated T-helper cells. Tumor-
necrosis factor (TNF)/ inducible nitric oxide synthase (iNOS)-producing DCs (Tip-
DCs) increase the availability of nitric oxide, which in turn increases TGF-β receptor 
expression on naïve follicular B cells to enhance IgA class switching (Tezuka et al., 
2007a). Additionally, Tip-DCs, in addition to other DCs subsets in PPs and MLNs 
(plasmacytoid and follicular DCs) can induce IgA class switching of B cells in the 
follicles in a T cell-independent fashion (Suzuki et al., 2010b; Tezuka et al., 2011). This 
IgA class switching is independent of the B cells CD40/CD40L signaling, but is 
facilitated by secretion of cytokines such as the B cell activating factor (BAFF) (a 
member of the TNF-ligand family) and a proliferation-inducing ligand (APRIL) (He 
et al., 2010; Litinskiy et al., 2002).  
Together with PPs and MLNs, ILFs and the lamina propria represent additional 
important sites for induction of IgA responses. However, IgA class switching in ILFs 
and the lamina propria only occurs mainly via the T cell-independent pathway 
(hitherto only described in mice). In ILFs, DCs release active TGF-β1, and in   
response to microbial toll-like receptor (TLR) signaling can, together with other 
stromal cells, release BAFF and APRIL (Tsuji et al., 2008a). In the LP, a unique subset 
of DCs, expressing TLR5 (TLR5+ DCs), secretes retinoic acid and IL-6 in response to 
bacterial flagellin (TLR5 ligand) (Uematsu et al., 2008; Uematsu & Akira, 2009). 
Additionally, TLR signaling also induces the secretion of BAFF and APRIL by lamina 
propria TNF-α+/iNOS+ DCs (Tezuka et al., 2007b). Epithelial cells can also enhance 
the release of BAFF and APRIL by DCs in the lamina propria through the release of 
thymic stromal lymphopoietin (Xu et al., 2007).  
In addition, epithelial cells can release BAFF and APRIL in response to bacterial 
TLR signaling (He et al., 2007). All of these cytokines induce and promote T cell-
independent IgA class switching (Fagarasan et al., 2010; Suzuki et al., 2010a; Tsuji et 
al., 2008b). In humans, however, the anatomic location of the T cell-independent 
immunoglobulin class-switch recombination is still controversial (Berkowska et al., 
2011). 
Generated IgA-committed B cells, via both T cell-dependent and -independent 
pathways, finally differentiate into dimeric IgA producing plasma cells in the lamina 
propria, under the influence of another group of IgA inducing cytokines, the Th2 
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cytokines IL-5 and IL-6. Dimeric IgA antibodies are transported across epithelial cells 
into mucosal secretions via polymeric Ig-receptor-mediated transcytosis which 
results in the release of sIgA in the gut lumen (Brandtzaeg, 2013).  
One of the main roles of sIgA is to serve as an immunological barrier, preventing 
the attachment of pathogens to the mucosal surfaces (Brandtzaeg, 2007). IgA binds 
surface proteins that mediate the attachment of enteric pathogens to enterocytes and 
thereby prevents colonization and invasion. The large complexes of the sIgA-bound 
pathogens are easily entrapped in the mucus and subject to peristaltic or ciliary 
clearance, a process known as “immune exclusion” (Corthesy, 2013). In addition to 
pathogens, sIgA can neutralize bacterial enterotoxins. Furthermore, IgA can trap 
incoming organisms within the epithelial cell vesicular compartments, exporting 
them back into the lumen (Hutchings et al., 2004). Finally, it can also neutralize 
viruses intracellularly, and this mechanism of defense is particularly relevant for 
enteric viruses (Hutchings et al., 2004; Mazanec et al., 1992; Schwartz-Cornil et al., 
2002). 
1.3.2. IgG and other antibody isotypes 
Although IgA is the main isotype in the mucosal secretions, IgG is also present 
and may contribute to the adaptive immune defenses in the gut. IgG is believed to 
reach luminal secretions mainly by transudation of serum, although small amounts 
are also synthesized locally (Brandtzaeg, 2007). However, receptor-mediated IgG 
transport can occur. Indeed, it has been shown that a neonatal IgG-specific receptor, 
FcRn is expressed by epithelial cells in the intestine and can mediate IgG transport in 
both directions across the epithelium (Dickinson et al., 1999). Expression of FcRn is 
downregulated to nearly undetectable levels after weaning in rodents. However, in 
human, pigs and cattle, absorptive intestinal epithelial cells continue to express FcRn 
in adult life (Israel et al., 1997). Interestingly, FcRn can also transport IgG-antigen 
complexes from lumen across the intestinal barrier into the lamina propria, where it 
can be delivered to antigen-presenting cells (Yoshida et al., 2004). Mucosal sIgM is 
less abundant than sIgA but is also present in gut secretions. In addition, IgE can be 
produced by plasma cells in the lamina propria and is believed to mediate protection 
against certain intestinal helminthes through the activation of local mast cells 
(Brandtzaeg, 2007). 
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1.3.3. Cytotoxic T lymphocytes (CTLs) 
Mucosal CTLs constitute a second response that can be induced by oral 
vaccination (Klavinskis et al., 1996). These cells play an important role against 
invasive pathogens that exploit the mucosal surface to enter the body, such as 
viruses and intracellular bacteria. CTLs are generated in the PPs from CD8+ 
lymphocytes by a subset of CD8α+ DCs, and/or by activated Th1 cells. Of the 
various CD8+ lymphocyte populations found in mucosal tissues, those expressing 
the T cell receptors αβ (TCRαβ) and CD8αβ or CD8αβ and CD8αα have mostly 
effector/cytotoxic activity (Cheroutre & Madakamutil, 2004). For instance, CD8αβ+ 
TCRαβ+ CTLs exhibit potent cytotoxic activity against cells infected with viruses 
and intracellular protozoan parasites (Cheroutre & Madakamutil, 2004; Muller et 
al., 2000). Also, IFN-γ and TNF-α secreted by CD8+ T cells may play a key role in 
enhancing pro-inflammatory responses in the lamina propria, enabling phagocytic 
cells to scavenger microorganisms that have breached the mucosal barrier.  
1.3.4. Gut-homing potential of mucosally primed effector cells 
Effector B and T cells primed in the gut mucosal inductive sites are specifically 
programmed to home to gut mucosal effector sites (Agace, 2010; Mora et al., 2006). 
After priming, these cells lose their adhesion to the stromal cells, leaving the 
organized lymphoid tissues. Cells primed in PPs, disseminate via draining lymph to 
MLNs, where they undergo further differentiation and amplification. Later, 
mucosally primed cells disseminate via the blood circulation to home back to gut 
mucosal lamina propria (Mowat, 2003). The gut-homing specificity of effector 
lymphocytes is determined by complex interactions between lymphocyte homing 
receptors and their respective ligands expressed on the gut mucosal vascular 
endothelium. Gut-homing receptors are upregulated on antigen-primed B and 
T lymphocytes by intestinal DCs in a mechanism involving DCs release of retinoic 
acid. These receptors include α4β7 integrin, which binds to mucosal addressin cell 
adhesion molecule-1 (MadCam-1), and the CCR9 and CCR10 chemokine receptors, 
which bind to the intestinal chemokines CCL25 and CCL28, respectively (Agace, 
2010; Mora et al., 2006).  
This pattern of adhesion-molecule and chemokine-receptor expression is 
distinct from that of lymphocytes primed in peripheral lymphoid organs. Those 
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acquire the α4β1 integrin, L-selectin receptor and the chemokine receptor CCR4 
and therefore, cannot migrate to mucosal surfaces (Campbell & Butcher, 2002). 
This is the molecular explanation as to why oral vaccines, but not injectable 
counterparts, induce mucosal immunity.  
1.4. Systemic antibody responses elicited by oral vaccines 
As described above, B and T lymphocytes primed in the gut preferentially 
undergo IgA class switching and selectively home to gut mucosal effector sites. 
However, it is well established that oral vaccines are capable of inducing systemic 
IgG responses. In this regard, mucosal immunization via the intranasal route has 
been shown to induce activated B cells with a “mixed” gut and systemic lymphoid 
tissue homing-specificity (El-Kamary et al., 2010). Therefore, a similar outcome 
presumably occurs after oral vaccination. In such a case, MLNs, which are 
anatomically recognized as a crossroad between gut mucosal and systemic immune 
compartments, are likely the site where lymphocytes with mixed homing potential 
are produced (Mowat, 2003). Presumably, MLNs DCs, probably in cooperation with 
other local stimuli, can promote the differentiation of B lymphocyte subsets that 
express homing- and chemokine-receptors specific to both gut mucosal and 
peripheral lymphoid tissues. These subsets should also show parallel IgA and IgG 
class switching.      
1.5.  Strategies for oral vaccine development 
As discussed above, the harsh gastrointestinal environment and the tolerogenic 
arm of the gut immune system are bottlenecks for oral vaccine development. 
Therefore, several strategies have been explored to design effective oral vaccines 
against enteric infections.       
1.5.1. Live-attenuated vaccines 
Live-attenuated vaccines are composed of live bacteria or viruses that are made 
much less virulent than the pathogenic wild type. This class of vaccines notably 
mimics the routes of natural infection, provide a high level of antigen exposure,   
and effectively stimulate innate and adaptive immunity via the pathogen-
associated molecular patterns (Manicassamy & Pulendran, 2009). The majority of 
the currently licensed oral vaccines are based on attenuated pathogens (Holmgren 
& Svennerholm, 2012). These vaccines were successfully used to prevent various 
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gut-borne diseases, such as poliomyelitis, typhoid fever and rotavirus-induced 
diarrhea (Holmgren & Svennerholm, 2012). Nevertheless, the safety and stability of 
live-attenuated vaccines remains major concern. Attenuated vaccines are 
developed from wildtype pathogens that were subjected to multiple or prolonged 
passages in foreign host or tissue (mainly for viruses) or to genetic deletion or 
modification of major virulence genes. However, reversion to virulence can occur 
as a result of acquisition of wildtype virulence genes or chromosomal 
rearrangements that may lead to gene duplication or the activation of dormant 
genes. Additionally, attenuated vaccines can still be pathogenic to 
immunocompromised individuals such as the elderly and infants (National Center 
for Immunization and Respiratory Diseases, 2011). For instance, a rotavirus live-
attenuated quadrivalent oral vaccine (RotaShield) based on a Rhesus monkey 
rotavirus strain equipped with human rotavirus genes (Clements-Mann et al., 2001), 
was withdrawn from the market after being implicated to cause intussusceptions in 
vaccinated children (Murphy et al., 2001). Therefore, efforts in vaccine design 
should focus on developing alternatives to live-attenuated vaccines, with higher 
safety and comparable efficacy.    
1.5.2. Subunit vaccines 
To improve the safety of oral vaccines, design strategies have been focusing     
on developing vaccines based on one or more of pathogen-derived antigens. 
However, individual (soluble) antigens are mostly vulnerable to the gastrointestinal 
conditions, poorly taken up at the gut mucosal inductive sites, or have low 
immunogenicity. Therefore, to further improve the efficacy of subunit-based oral 
vaccines, a variety of delivery systems and mucosal adjuvants have been explored. 
However, we still lack licensed vaccines based on these approaches.   
1.5.3. Delivery systems 
Delivery systems primarily serve to protect oral vaccine antigens against the 
detrimental gastrointestinal conditions and to enhance the antigen uptake by      
the cellular components of the intestinal immune system. Nevertheless, some 
delivery systems also possess adjuvant properties. A variety of the common oral 
vaccine delivery systems are reviewed in Table 1.1, in terms of their 
nature/composition, immunological characteristics, advantages and disadvantages, 
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and status of clinical testing. Live-attenuated pathogens, mainly of bacterial and 
viral origins, have been commonly used as vectors for oral vaccine delivery (Brave 
et al., 2007; Carleton, 2010). They can be engineered to express antigens from other 
pathogens and thus deliver these antigens to the intestinal immune system. 
Enteropathogen-based vaccine vectors are used for their inherent ability to resist 
the gastrointestinal conditions and to penetrate mucosal epithelial and antigen-
presenting cells. Additionally, the pathogen-associated molecular patterns of these 
vectors stimulate innate immunity, which enhances the adaptive immune 
responses to the carried antigens (adjuvanticity). Among bacterial vectors, 
Salmonella, which is an invasive enteropathogen, has been widely investigated for 
oral vaccine delivery (Galen et al., 2009; Paterson & Maskell, 2010; Wang et al., 
2013), building on the extensive knowledge available on its physiology and 
pathogenesis (Basso et al., 2000; Galen et al., 2009; Sirard et al., 1999). Other 
intracellular bacteria such as Mycobacterium (Kawahara et al., 2006; Kawahara, 
2008) and Listeria (Bruhn et al., 2007; Saklani-Jusforgues et al., 2003) are also 
considered suitable candidate vectors for oral vaccine delivery. Listeria-based 
vectors are particularly notable for their ability to invade a variety of host cells, 
including antigen-presenting cells and CD4+ and CD8+ T lymphocytes (Cossart & 
Mengaud, 1989; Kaufmann, 1993; Pamer et al., 1997). Similarly, various viral vectors 
have been successfully tested as oral vaccine vectors, generally resulting in the 
induction of strong CTL responses. In the veterinary field, there are numerous 
virus-based oral vaccines that are currently licensed for use in livestock and 
domesticated animals (Meeusen et al., 2007). Based on their safety records in the 
veterinary field, many viruses have been studied for potential use in humans as oral 
vaccine delivery vectors. These include attenuated Poxvirus (Esteban, 2009; Weyer 
et al., 2009), vaccinia virus and adenovirus (Esteban, 2009; Rimmelzwaan & Sutter, 
2009). Adenovirus is to date one of the most widely evaluated viral vectors for oral 
vaccine delivery, due to ease of production, safety profile, genetic stability, the ease 
of DNA genome manipulation, and the ability to stimulate both innate and 
adaptive immune responses (Lasaro & Ertl, 2009; Vemula & Mittal, 2010).  
As discussed for live-attenuated vaccines, the use of attenuated pathogens as 
vaccine delivery vectors is similarly associated with the risk of reverted 
pathogenicity and the potential for disease development in immunocompromised 
individuals. Additionally, a major disadvantage of pathogen-based vectors is the 
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preexisting immunity against them in vaccinated individuals, due to previous 
exposure. Preexisting vector-specific immunity could potentially lower vaccine 
efficacy, as has been reported with Salmonella- (Attridge et al., 1997; Gahan et al., 
2008; Sevil Domenech et al., 2007) and adenovirus-based vectors (Tucker et al., 
2008).  
Protein or peptide antigens as well as live-vaccines can be partially protected 
from degradation by oral delivery in enteric-coated gelatin capsules (Levine, 2000) 
or by inclusion in particulate carrier systems such as co-polymeric microparticles 
(Chablani et al., 2012; Eldridge et al., 1989; Garg et al., 2010; O'Hagan, 1998) and 
liposomes (Nordly et al., 2009). The latter provide the important advantages of 
protecting the antigens from degradation and promote their uptake by PPs M-cells 
following oral administration. The retention of vaccine antigens on mucosal 
surfaces by delivery in adherent gel-forming polymers, such as chitosan, has been 
shown to increase antigen uptake and immune responses (Garg et al., 2010; van der 
Lubben et al., 2001). Immune-stimulating complexes (ISCOMs) are another type of 
adhesive delivery systems, which also has adjuvant effects and known to 
particularly stimulate CTLs responses (Sanders et al., 2005; Sun et al., 2009). Virus-
like particles are another delivery system based on recombinant production of non-
replicating viral core structures, typically from non-enveloped viruses. They are 
used as both delivery vectors and adjuvants, inducing IgA and CTLs responses 
(Schneider-Ohrum & Ross, 2012).  
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Table 1.1. Oral vaccine delivery systems 
Delivery 
system 
Nature/ 
composition 
Immunological characteristics 
Advantages disadvantages 
Clinical 
testing 
References 
Target 
T 
lymphocyte 
response 
IgA 
 
 
Live-
attenuated 
pathogens 
 
 
 
 
 
 
 
 
 
Bacteria:  
e.g. Salmonella 
Typhimurium and 
Listeria 
Viruses: 
e.g. Adenovirus, 
Poxvirus and 
Vacinia virus 
  
Epithelial 
and 
antigen- 
presenting 
cells 
 
Th1, CTLs, 
Th2 
 
++ 
 
- Ability to survive GI 
conditions 
- Inherent adjuvanticity 
- Interaction with, and 
penetration of host 
immune cells 
 
- Pathogenicity reversion  
- Unsafe for 
immunocompromised 
individuals 
- Side effects due to 
systemic spread and 
allergy  
 
yes 
 
National Center 
for Immunization 
and Respiratory 
Diseases, 2011; 
Esteban, 2009; 
Gahan et al., 2008; 
Paterson & 
Maskell, 2010; 
Tucker et al., 
2008; Vemula & 
Mittal, 2010; 
Wang et al., 2013 
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Chitosan 
 
 
 
 
Natural 
mucoadhesive 
polymer 
Epithelial 
tight 
junctions 
Th2 ++ - Long-term depot and 
Pulsatile release of 
antigens 
- Can mimic prime-
boost effects of 
conventional vaccines 
- Issues on antigen 
stability in microcapsules 
- Issues antigen dose 
optimization 
yes Garg et al., 2010; 
O'Hagan, 1998 
Particles:         
PLG  Poly-lactic 
coglycolic acid 
micro and 
nanoparticles  
ND Th1, CTLs + - Controlled, 
sustainable antigen 
release 
- Mimic prime-boost 
effects of vaccines   
Issues on antigen loading 
capacity and stability  
yes Peek et al., 2008; 
Sharma et al., 2014 
Liposomes Phospholipids 
microparticles 
ND Th1, Th2 + Strong immune 
stimulants 
- Issues on formulation 
stability 
- Costly production  
yes Kersten & 
Crommelin, 2003; 
Nordly et al., 2009 
ISCOMS or 
ISCO-
MATRIX 
 Quillaia 
saponines: Quil A 
or QS-21 
DCs Th1, Th2, 
CTLs 
++ - Strong CTLs responses 
- Adjuvant effects  
Toxicity due to 
saponines- induced 
hemolysis 
yes Kersten & 
Crommelin, 2003; 
Sanders et al., 
2005; Sun et al., 
2009 
Virus-like 
particles 
virus envelopes 
(capsids)  
ND Th1, CTLs, 
Th2 
+ - Easy production 
- Safer than live viruses 
Non-invasive  yes Schneider-Ohrum 
& Ross, 2012 
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Emulsions:         
Cationic 
DDA or 
liposomes 
Cationic DDA or 
liposomes 
DCs Th1, CTLs + Slow antigen release Moderate 
immunostimulatory 
effect 
yes Christensen et al., 
2009 
 
Th, T helper; CTLs, cytotoxic T lymphocytes; GI, gastrointestinal; DCs, dendritic cells; DDA, dimethyldioctadecylammonium; ND, not 
determine
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1.5.4. Mucosal adjuvants 
The most potent and well-studied mucosal adjuvants in experimental systems 
are cholera toxin and E. coli heat-labile enterotoxins (Holmgren et al., 2005; Liang 
& Hajishengallis, 2010; Sanchez & Holmgren, 2008). Much effort has been made to 
generate safe derivatives of these toxins with retained adjuvant activity for human 
use. An example of these derivatives is the nontoxic recombinantly produced 
cholera toxin B subunit (CTB), which promotes mucosal immunity (mainly sIgA) to 
oral antigens (Holmgren et al., 2005; Sanchez & Holmgren, 2008). Mutant heat-
labile enterotoxin or cholera toxin, devoid of the toxic activity of the A subunit 
were also developed. Some of these toxin mutants retain adjuvanticity and can be 
used as mucosal adjuvants (Lu et al., 2002; Lycke, 2005; Pizza et al., 2001; Sanchez 
et al., 2002). A second category of bacterial toxin-based adjuvants is developed as 
hybrid molecules, in which the fully active cholera toxin A1 subunit, lacking its 
binding domain, is linked to an engineered specific APC-binding protein derived 
from Staphylococcus aureus protein (Lycke, 2004; Lycke, 2005). The mucosal 
adjuvanticity of the latter, however, is only proven in mice. 
Bacterial DNA or synthetic oligodeoxynucleotides containing unmethylated 
“CpG motifs” represent another type of mucosal adjuvant, which interact with 
TLR9, initiating an immunomodulating cascade (Holmgren et al., 2003; McCluskie 
et al., 2001). Although being mainly considered for systemic use, CpG motifs were 
also found to markedly enhance both innate and adaptive mucosal immunity in 
animal models after oral administration (Liu et al., 2010a; McCluskie et al., 2001). 
Also, bacterial cell-wall components such as monophosphoryl lipid A derived from 
lipopolysaccharides of Gram-negative bacteria has immunomodulatory properties, 
mainly by interacting with TLR4 or by inducing proinflammatory cytokines (Moore 
et al., 1999; Reed et al., 2009; Salkowski et al., 1997).  
Cytokines are normally secreted during immune responses and they have been   
used during antigen administration to potentiate, modify or direct the immune 
response. Several cytokines have been used in mucosal immunization (Villinger, 
2003) including, IL-1 (Staats & Ennis, 1999), IL-12 (Boyaka et al., 1999; Lee et al., 
2003; Staats et al., 2001) and type I Interferon (Bracci et al., 2005). 
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2. Lactococcus lactis as a live-vector for oral vaccine 
delivery 
 
2.1. Introduction  
Lactococcus lactis (L. lactis) is a Gram-positive lactic acid bacterium that has been 
widely used in dairy and fermented food industry. However, over the last two   
decades, and with the recent advances in biotechnology and molecular biology, the 
application of L. lactis has been extended into oral vaccine design and delivery. In 
principle, L. lactis can be genetically engineered for the recombinant expression of the 
target vaccine antigen. The generated recombinant strain is thereafter administered 
orally for the delivery of the vaccine antigen to the gut immune system. Currently, a 
significant number of studies have been published describing induction of mucosal 
and systemic immune responses to antigens orally delivered using recombinant L. 
lactis strains (reviewed below).   
L. lactis offers a number of significant advantages as a vector for oral vaccine 
delivery: (1) it provides a safe alternative to engineered live-attenuated pathogens, 
which are commonly used to deliver oral vaccines (e.g. Salmonella Typhimurium). 
These vectors are associated with risks of reverted pathogenicity and can induce 
diseases in immunocompromised individuals, the elderly and infants (National Center 
for Immunization and Respiratory Diseases, 2011). On the contrary, L. lactis is a non-
pathogenic bacterium that is traditionally used in the food industry and that is 
generally regarded as safe for oral consumption (Casalta & Montel, 2008). Additionally, 
being a Gram-positive bacterium, L. lactis lacks the cell wall expression of endotoxic 
lipopolysaccarides, which exist in vectors based on Gram-negative pathogens. (2) L. 
lactis exhibits immunoadjuvant properties (Yam et al., 2008), which can enhance the 
immune responses to expressed antigens, despite the weak responses elicited to the 
bacterium itself (Robinson et al., 1997). The latter is particularly important because 
preexisting immunity against vaccine vectors can reduce their activity upon 
consequent use for the delivery of other antigens (Attridge et al., 1997; Roberts et al., 
1999). On the other hand, the non-colonizing nature of L. lactis minimizes the 
potential of developing immunotolerance since the bacterium exhibits a short 
gastrointestinal transit. (3) The oral delivery of antigens vectored on L. lactis might 
enhance their uptake by M cells in the gut. L. lactis is similar in size and dimensions to 
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microparticles, a delivery system known to be taken up by M cells (Challacombe et al., 
1992; Robinson et al., 2004).  
2.2. L. lactis– origin, classification and food-grade applications  
L. lactis are non-sporulating, non-motile, facultative anaerobe cocci of 0.5 - 1.5 µm 
in size and are typically arranged in pairs or short chains. Milk is the common source 
for isolation of L. lactis and therefore, is being considered as a natural habitat for the 
bacterium (Sandine, 1977). L. lactis was isolated in 1873 by Lister, being the first 
microorganism ever isolated in a pure culture, and the first recognized cause of     
lactic acid fermentation of milk. The isolated bacterium was designated Bacterium 
lactis. In 1909 and based on morphology, L. lactis was included into the genus 
Streptococcus, and thus renamed Streptococcus lactis. This name was used till 1985, 
when a phylogenetic study reclassified the members of the diverse genus Streptococcus 
into the genera Lactococcus, Enterococcus and Streptococcus, under the family 
Streptococcaceae (Ludwig et al., 1985). Also, according to the same study, 
Streptococcus lactis and Streptococcus cremoris were designated L. lactis ssp. lactis 
and L. lactis ssp. cremoris, respectively.  
L. lactis is capable of converting hexose sugars (e.g. lactose and glucose), into lactic 
acid (lactic acid fermentation) (Vandenbergh, 1993). By fermentation, food or milk is 
being modified to acquire desired flavor and texture. Additionally, fermentation serves 
as a method of food preservation (Vandenbergh, 1993). Both L. lactis ssp. lactis and L. 
lactis ssp. cremoris have been used in single and mixed cultures for the production of 
different kind of cheeses, fermented milks, cultured butter, casein, vegetables like 
sauerkraut and olives, wine, beer and meat, like salami (Coffey et al., 1998).  
Due to the long history of safe use in the food industry, and since the bacterium  
has never been associated with infectious diseases, L. lactis was granted a “GRAS” 
(generally recognized as safe) status by the US Food and Drug Administration (Casalta 
& Montel, 2008). Similarly, in Europe, the safety of L. lactis as a food-grade bacterium 
is authorized according to the QPS (Qualified Presumption of Safety) assessment. The 
latter is a system adopted by the EU for pre-market safety assessment of 
microorganisms proposed for use in food production (www.efsa.europe.eu).  
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2.3. Recombinant protein expression in L. lactis 
Most of the industrially important characteristics of L. lactis strains (e.g. lactose 
catabolism) are encoded on plasmids, which might constitute a large and often 
unstable DNA complement to the cell. The development of the plasmid-free L. lactis 
strain MG1363 (a L. lactis ssp. cremoris strain) in the early 1980’s has opened the doors 
for heterologous protein expression in L. lactis (Gasson, 1983). MG1363 is stable and 
relatively amenable to genetic modification. Additionally, many genetic systems are 
currently available for L. lactis, allowing expression and targeting of antigens to 
various cellular locations, including secretion and cell-wall display (Le Loir et al., 
2005). These tools were utilized for the generation of numerous recombinant L. lactis 
strains, designated for the oral delivery of various bacterial, viral, protozoan and 
eukaryotic antigens (reviewed in details in section 2.5).   
2.3.1.  L. lactis Promoters  
Several lactococcal promoter sequences have been isolated, characterized and made 
available to establish L. lactis gene expression systems for the production of 
heterologous proteins. Before the availability of the first L. lactis full genomic  
sequence (was identified for L. lactis ssp. lactis (Bolotin et al., 2001)), a variety of 
constitutive promoters were randomly isolated from an L. lactis genomic library by 
fusions to promoterless reporter genes (Vandervossen et al., 1987; Waterfield et al., 
1995). Strong (e.g. P1, P21, P23 and P59) and weak (e.g. P32 and P44) promoters were 
distinguished by measuring the activity levels of the reporter gene products 
(Waterfield et al., 1995).  
Other lactococcal promoters were isolated from specific characterized lactococcal 
genes. These include the promoter of the usp45 gene (van Asseldonk et al., 1990), 
which encodes for the unknown secretory protein of L. lactis (Usp45), in addition to 
the PnisA, promoter which regulates the production of nisin, a lactococcal bacteriocin 
produced by some L. lactis strains. Today, with the availability of a full lactococcal 
genomic sequence (Wegmann et al., 2007), new promoters can easily be identified by 
screening genome sequences. Microarray data can also be used for selection of 
promoter sequences (Kim et al., 2009).  
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2.3.2. Heterologous gene expression systems in L. lactis 
The first class of expression vectors used in L. lactis was based on the endogenous 
pWVO1 replication group of plasmids isolated from L. lactis subsp. cremoris (de Vos et 
al., 1989; Kok et al., 1984; Leenhouts et al., 1998; Vandervossen et al., 1985). For 
instance, plasmid pGKV2 that utilizes the SOP2 promoter from Bacillus subtilis was 
one of the first lactococcal expression vectors described (Vandervossen et al., 1985). 
Although pWVO1 plasmids are characterized by a wide host range, they are inherently 
less stable in structure, because of their rolling circle type replication (Gruss & Ehrlich, 
1989). In order to overcome these limitations, a second class of heterologous plasmids 
was developed, based on heterologous (non-lactococcal) operons. These vectors 
already encoded antibiotic resistance markers and were found operational in L. lactis 
with respect to both replication stability and functional expression of the selection 
marker. An example is the pAMβ1 plasmid, which displays a high copy number and 
shows high structural and segregational stability in L. lactis, even when a large DNA 
sequence is inserted. These features made it the plasmid of first choice for the 
development of several lineages of cloning vectors for L. lactis. A series of expression 
vectors which incorporate the replicon of pAMβ1 are designated pTREX (for theta 
replicating expression vectors) (Brehm et al., 1987). The expression cassette in pTREX 
incorporates the PlacA promoter and the following E. coli bacteriophage T7 expression 
signals: i) a putative RNA stabilizing sequence and ii) the translation initiation region 
of gene 10 which has been modified to increase the complementarity of the Shine 
Dalgarno (SD; also known as the ribosomal binding site) sequence to the ribosomal 16S 
RNA of L. lactis and iii) the T7 RNA polymerase transcription terminator.  
2.3.2.1. Constitutive expression systems 
Constitutive expression of a gene means that the gene product is constantly 
expressed without regulation. Several constitutive lactococcal promoters have been 
cloned into pTREX plasmids to develop lactococcal expression systems. For instance, 
pTREX1 is an expression system that has been developed by replacing the PlacA 
promoter of pTREX by the strong constitutive lactococcal promoter P1 (Wells and 
Schofiled, 1996). Since pTREX1 combines the stability of the theta replicons with a 
strong promoter, a variety of heterologous proteins have been expressed in L. lactis 
using pTREX1, such as tetanus toxin fragment C (TTFC) from Colistridium tetani 
(Robinson et al., 1997), interleukin 2 (IL-2) (Steidler et al., 1995), IL-6 (Steidler et al., 
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1998) and IL-10 (Schotte et al., 2000). However, continuous high-level production of 
protein might lead to intracellular aggregation or degradation of the protein in the 
cytoplasm. These phenomena can be deleterious to the bacterial cell. These adverse 
effects were resolved by developing expression systems based on inducible promoters.  
2.3.2.2. Inducible expression systems  
Inducible promoters are generally known to regulate the expression of genes related 
to adaptation of the bacteria to environmental stresses. Many L. lactis promoters were 
found to be induced by shifts in temperature and pH or the presence of certain sugars 
and ions in the medium. Inducible expression systems allow the control of 
heterologous protein production, which can be initiated by the addition of the specific 
inducer to the culture medium at a certain phase of the bacterial growth. This feature 
is particularly useful to reduce the stress exerted on bacterial cells by continuous 
production of the heterolougs protein or in case the target protein is toxic to the 
lactococcal system.  
 The NICE system 
The most commonly used expression system in L. lactis today is the nisin-
controlled gene expression (Brigotti et al., 2010) system (de Ruyter et al., 1996b; 
Kuipers et al., 1995). Nisin synthesis is encoded by a cluster of 11 genes, present in some 
L. lactis strains (Ra et al., 1996; Siegers & Entian, 1995). The first gene in the cluster, 
nisA, encodes the nisin peptide itself. The nisR and nisK genes constitute a two-
component regulatory system; nisR is a sensor histidine kinase and nisK is the 
response regulator. Other genes in the cluster are associated with nisin modification, 
translocation, processing or with the immunity of the bacterial host cell to the peptide 
(Mierau & Kleerebezem, 2005b).  
The NICE system utilizes the promoter of nisA gene and requires the presence of 
the nisR and nisK genes, either integrated into the genome or carried on the cloning 
plasmid (Figure 2.1). The transcriptional fusion of the gene of interest to the nisA 
promoter sequence allows transcription initiation by addition of sub-inhibitory levels 
of nisin to the culture medium (0.01 – 10 ng/ml). 
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Figure 2.1. Schematic representation of the NICE system. Heterologous gene expression in 
response to a nisin stimulus involves a membrane-located sensor protein (Rimpilainen et al., 
1986) and a cytoplasmic response regulator (NisR) that controls transcriptional activation from 
the NisA gene promoter (PnisA). The auto-induction mechanism of nisin is used as a controlled 
heterologous gene expression system in L. lactis. Figure adapted from (Pontes et al., 2011). 
 
This system for controlled expression has been found to show many desirable 
characteristics: i) Nisin is a wide spectrum bacteriocin that has been used in food 
industry and thus, it is an ideal molecule to be used as an inducer (food-grade); ii) 
protein expression using the NICE system seems to be very tightly controlled, since the 
protein is undetectable in not induced strains. This even made the expression of lethal 
proteins in L. lactis possible (de Ruyter et al., 1997); iii) very high protein expression 
levels, since a protein yield of up to 100 mg/L was obtained in the 3000-L scale and the 
yield was further increased to 300 mg/L in optimized culture conditions (de Ruyter et 
al., 1996a; Kuipers et al., 1995; Mierau & Kleerebezem, 2005b; Mierau et al., 2005); iv) 
The availability of various host strains and expression plasmids, including food-grade 
systems that utilize the lacF marker instead of antibiotics (Eichenbaum et al., 1998; 
Kuipers et al., 1997). Therefore, the NICE system has been used for the production of 
variety of proteins of different origins in L. lactis and other bacterial hosts (Mierau & 
Kleerebezem, 2005a; Zhou et al., 2008). 
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2.3.2.3. Cellular targeting of heterologous proteins 
Several systems have been designed to specifically target proteins to the cytoplasm, 
the cell wall or the extracellular medium in L. lactis (Bermudez-Humaran et al., 2003; 
de Vos, 1999; Dieye et al., 2001). Insertion of the heterologous gene downstream the 
promoter in absence of secretion or cell-wall targeting motifs designates the antigen 
expression to the cytoplasm. Cytoplasmic expression of antigens in L. lactis has some 
draw backs for antigen expression yields. L. lactis possesses at least two cytoplasmic 
house-keeping proteases, clpP (Frees & Ingmer, 1999) and FtsH (Nilsson et al., 1994), 
as well as DnaK, a cytoplasmic chaperon that may promote proteolysis by maintaining 
the protein in an unfolded state (Koch et al., 1998). The proteolytic activity of these 
enzymes can negatively influence the cytoplasmic designated expression of 
heterolougs proteins. Additionally, cytoplasmic expression of proteins, which are lethal 
to the lactococcal cells, might influence cell viability and thus protein expression yield 
(Le Loir et al., 2005; Miyoshi et al., 2006). 
The general secretory pathway in L. lactis as well as in other Gram-positive bacteria 
is the Sec-dependent translocation. Proteins are synthesized in the cytoplasm as 
precursors containing the mature protein and an N-terminal signal peptide (SP) that is 
an essential signature for protein secretion (von Heijne, 1990). Absence of the coding 
sequence of SP upstream the target heterologous gene designates the protein 
expression to the cytoplasmic compartment. If present, SP is recognized and cleaved 
by the secretion machinery, allowing the protein to be transferred through the 
membrane and released into the extracellular medium. For this translocation system a 
variety of proteins including SecA, SecY and SecE are required. SecY (Koivula et al., 
1991) is an essential component of the protein export machinery and interacts with the 
SP of secretory proteins, but also interacts with the peripheral membrane protein SecA 
and the integral membrane protein SecE. This, in combination with the action of Sec-
specific chaperones retards precursor folding (Pugsley, 1993; Tjalsma et al., 2000). 
Secretion often allows the heterologous protein to escape the cytoplasmic proteases of 
L. lactis leading to a better expression yield (Le Loir et al., 2005). Additionally, it has 
been shown that antigen secreting L. lactis strains can accumulate the precursor of the 
antigen to be secreted in their cytoplasm, at levels higher than those of the mature 
protein expressed by designated cytoplasmic expression. This phenomenon was 
reported, for example, to the expression of proteins such as the Staphylococcus Nuc 
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and the Brucella abortus antigen L7/L12 in L. lactis (Bermudez-Humaran et al., 2003; 
Ribeiro et al., 2002). A possible explanation is that the engagement of the cytoplasmic 
precursor with the lactococcal secretion machinery in the cytoplasm protects the 
precursor against proteolysis by cytoplasmic housekeeping enzymes (Le Loir et al., 
2005).       
To identify SP’s for protein secretion in L. lactis, several L. lactis strains were 
screened for endogenous secreted proteins in their culture supernatants. One protein, 
designated as unknown secreted protein of 45 kDa (Usp45), was particularly abundant 
and its chromosomal located gene usp45 was isolated from L. lactis subsp. cremoris 
MG1363 (van Asseldonk et al., 1990). The secretion efficiency of the Usp45 SP was 
superior to other new homologous SP’s identified in L. lactis (Ravn et al., 2003). Only 
one report showed that a Lactobacillus brevis SP drove the secretion of FedF adhesin 
more efficiently than the Usp45 SP in L. lactis (Lindholm et al., 2004).  
Even with a homologous SP, secretion may be inefficient, and some heterologous 
proteins are poorly or not at all secreted (Enouf et al., 2001; Puohiniemi et al., 1992; 
Ravn et al., 2000). Notably, charges at the N terminus of the mature protein may 
greatly affect the translocation across the cytoplasmic membrane (Andersson & von 
Heijne, 1991; Steidler et al., 2003). In this regard, according to several reports, protein 
conformation rather than protein size seems to influence the efficiency of 
heterologous protein secretion in L. lactis (Enouf et al., 2001; Le Loir et al., 2005; 
Nouaille et al., 2005).   
Heterologous proteins can also be targeted to the cell wall of L. lactis by an 
anchoring signal sequence (cell wall anchor, CWA) containing a conserved LPXTG 
motif. This anchor is a transmembrane fragment with a charged C terminus which, 
when fused to the carboxyl terminal of the protein, remains covalently attached to the 
cell wall by transpeptidation between the LPXTG motif and peptidoglycan. Anchoring 
of heterologous proteins in L. lactis using the CWA of proteins A and M6 of 
Staphylococcus aureus and Staphylococcus pyogenes respectively, was demonstrated to 
be efficient (Dieye et al., 2001; Piard et al., 1997; Ribeiro et al., 2002; Steidler et al., 
1998). 
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2.3.2.4.  Codon optimization of heterologous genes  
As defined by the degeneracy of the genetic code, the majority of amino acids can 
be encoded by more than one codon. Different bacterial species vary in their codon 
usage preference, according to their genomic GC (Guanines/cytosines) content. 
Bacteria with genomes rich in GC content prefer codons with guanidine and cytosine, 
whereas bacteria with genomes of lower GC content (including L. lactis) prefer codons 
with adenines and thymines (Fuglsang, 2003). Codon usage preference is an important 
factor for efficient heterologous protein expression. Heterologous genes with codon 
sequences rarely used by the host organism will likely result in a poor protein 
production due to insufficiency of the corresponding tRNA required for proper mRNA 
translation (Fuglsang, 2003).  
The availability of cost-effective tools for codon adaptation and DNA synthesis has 
facilitated the use of the codon optimization approach in order to enhance 
heterologous protein expression. Several reports have described the usefulness of this 
strategy in heterologous protein expression in L. lactis (Berlec et al., 2006; Fuglsang, 
2003; Steidler et al., 2003; Vandenbroucke et al., 2004). A different approach to 
overcome codon preference bias of L. lactis was used by Hernandez et al., in order to 
optimize the expression of two chromosomally inserted plant genes related to the 
production of strawberry flavor in L. lactis. A vector plasmid carrying the encoding 
gene of the rare tRNA AGG was introduced into L. lactis to overcome its codon 
preference bias (Hernandez et al., 2007). Nevertheless, the efficiency of this approach 
is not superior to codon adaptation (Hernandez et al., 2007). 
2.4. Pharmacological and immunological aspects of oral vaccine delivery 
using L. lactis  
 
2.4.1. Modes of antigen delivery by L. lactis 
Generally live-vaccine delivery vectors can deliver recombinant antigens to the 
inductive sites of the gut immune system, either via the release of antigens in the 
intestinal environment, or via the uptake of the vector and the enclosed antigen by gut 
antigen-presenting cells. Depending on the target cellular location of the antigen, L. 
lactis either actively secretes the antigen in the gut lumen (strains designated for 
antigen secretion), and/or releases the antigen present in the cytoplasm upon its lysis 
in the gastrointestinal tract (strains designated for cytoplasmic expression) (Figure 
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2.2). The uptake of bacteria and other particulate antigens is a characteristic feature of 
M cells and other antigen-presenting cells in the gut. However, in a study that 
investigated the interactions of an IL-10-secreting L. lactis strain with the intestinal 
mucosa of mice, the transcellular uptake of the bacterium was described as a rare 
event (Waeytens et al., 2008). Moreover, although L. lactis was found adjacent to M 
cells, no bacteria were found on the cell membrane or in the cytoplasm. (Waeytens et 
al., 2008). Thus, an evidence of the cellular uptake of viable L. lactis in the gut is 
currently lacking. 
2.4.2. Influence of the antigen cellular location on immunogenicity 
The final cellular location of antigens expressed in L. lactis (i.e. cytoplasmic, 
secreted or cell-wall anchored) can influence the immunogenicity of these antigens 
upon oral delivery. A possible explication is that the cellular location of antigen 
expression can directly affect the amount of the antigen released and its availability for 
interaction with the gut immune system. Cytoplasmic expression of antigens often 
results in weak immune responses (Pei et al., 2005; Pontes et al., 2004; Rodriguez-Diaz 
et al., 2011). As discussed above, antigens targeted to the cytoplasmic compartment of 
L. lactis can be degraded by the housekeeping proteases, which can result in low 
antigen-expression levels (Le Loir et al., 2005). Additionally, the release of 
cytoplasmically expressed antigens in the intestine is subject to lysis of the bacteria in 
the stomach and duodenum (Figure 2.2).           
Secretion can be favored for obtaining higher immune responses to antigens orally 
delivered using recombinant L. lactis (Pei et al., 2005; Perez et al., 2005; Rodriguez-
Diaz et al., 2011). Secreted antigens are readily available for interaction with epithelial 
and antigen-presenting cells in the gut. Additionally, secretion may allow the delivery 
of higher antigen dose to immune-inductive sites. Following oral administration, 
viable L. lactis cells are metabolically active in the gastrointestinal tract and thus, 
antigen synthesis and secretion continues in situ (Drouault et al., 1999; Huibregtse et 
al., 2007; Steidler et al., 2000). Also, antigen secreting strains simultaneously 
accumulate the antigen in the cytoplasm (the precursor of the secreted protein), 
usually at higher amounts compared to strains designated to cytoplasmic expression 
(Bermudez-Humaran et al., 2003; Ribeiro et al., 2002). This enables additional antigen 
release by lactococcal cells, which will be lysed in the gastrointestinal tract or which 
are taken up by M cells or sampled by dendritic cells (DCs).        
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Figure 2.2. Schematic representation of antigen delivery using L. lactis vectors in the gut. 
Recombinant L. lactis expressing the antigen reaches the intestinal tract and secretes the 
antigen or releases it after lysis. The bacteria carrying the antigen and/or the free antigen are 
taken up by dendritic cells or M cells. Figure adapted from (LeBlanc et al., 2013). 
          
There are only few studies that have compared immune responses to antigens 
expressed in the different cellular locations of L. lactis upon oral immunization 
(Marelli et al., 2011; Perez et al., 2005). While secretion of Rotavirus VP7 antigen 
induced higher immune responses than did cytoplasmic expression or cell-wall 
anchoring (Perez et al., 2005), higher immune responses were obtained by cell-wall 
anchoring of the Rotavirus VP8 antigen and the staphylococcal Nuc compared to other 
cell-targeting locations (Dieye et al., 2003; Marelli et al., 2011). Although cell-surface 
location of antigens is believed to improve the presentation to antigen-presenting 
cells, in these studies the high immune responses obtained to cell-wall anchored 
antigens was suggested to be a result of the presence of high amounts of the antigen 
precursor in the cytoplasm of the recombinant strains (the cytoplasmic precursor of 
the to-be-anchored antigen). 
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2.4.3. Adjuvant and immunostimulatory effects of L. lactis 
Several in vitro studies have suggested adjuvant properties of L. lactis, which further   
support the value of the bacterium as a vaccine delivery vector. L. lactis ssp. cremoris 
was shown to stimulate the induction of pro-inflammatory cytokines such as IL-6, IL-
12 and TNF-α upon incubation with a macrophage-like cell line (Suzuki et al., 2008). A 
second study showed the ability of L. lactis MG1363 to induce the secretion of TNF-α, 
when incubated with murine macrophages (Audouy et al., 2007). Additionally, a recent 
study performed in a murine air pouch model demonstrated the ability of L. lactis 
MG1363 to recruit leukocytes, which were mainly neutrophils (95%), but also 
eosinophils, monocytes, macrophages and lymphocytes. These cells were found to 
contain significant levels of the chemokine legends (McCluskie et al., 2001) CCL1, 
CCL2, CCL3, CCL4, CXCL2 and CXCL10 mRNA (Yam et al., 2008). The latter are known 
to mediate the recruitment of the leukocytes (Mantovani et al., 2004). Also, in the 
same study L. lactis was shown to stimulate DCs to upregulate the mRNA expression 
of cytokines with adjuvant activities such as IL-1β (Yam et al., 2008).  
The oral delivery of antigen using recombinant L. lactis strains has been shown       
to induce a mixed Th1/Th2 cell response (Cauchard et al., 2011; Lee et al., 2009; 
Robinson et al., 2004; Villena et al., 2008; Villena et al., 2010). The type of T-helper cell 
induced, is   largely determined by the function of DCs (Rescigno, 2010). In this 
context, in vitro studies have shown the ability of L. lactis ssp. cremoris to induce the 
maturation of DCs (Audouy et al., 2007; Yam et al., 2008), as well as the secretion of 
cytokines known to direct the differentiation of both Th1 (IFN-γ and IL-12) and Th2 
(IL-6 and IL-10) cell types (Latvala et al., 2008; Yam et al., 2008).  
2.4.4. Gastrointestinal transit and survival of L. lactis. 
It should be noted that the two major subspecies of the lactococcus genus (L. lactis 
ssp. lactis and ssp. cremoris) have different gastrointestinal transit and survival profiles 
(Kim et al., 1999; Kimoto et al., 2003). Hence, in this section we specifically review the 
literature on L. lactis ssp. cremoris to which the vaccine vector strain MG1363 belongs. 
L. lactis is a non-colonizing bacterium and does not integrate with microbiota 
inhabiting the mammalian intestine. In mice L. lactis ssp. cremoris has a 
gastrointestinal transit time of approximately 12 hours (Kimoto et al., 2003). In 
humans, a trial where L. lactis was fed to volunteers twice a day for four days showed 
that viable bacteria were detected in the feces for three days after the end of the 
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feeding period, whereas Bacillus stearothermophilus (currently known as Geobacillus 
stearothermophilus), which is known for its capacity to survive the gastrointestinal 
passage, could be detected for up to seven days (Klijn et al., 1995).   
Consistent with its relatively short gastrointestinal transit, L. lactis also show a 
moderate capacity to survive gastrointestinal tract compared to other commensal or 
probiotic bacteria. In a study performed in pigs, a low survival of L. lactis was observed 
in the stomach and upper jejunum compared to Bacillus subtilis spores, which are 
known for their tolerance to gastrointestinal transit (Drouault et al., 2002). Similarly, 
data available for humans show a recovery of only 1% of the bacteria from the ileum         
four hours after ingestion, compared to the probiotic bacterium, Lactobacillus 
fermentum (Vesa et al., 2000). With regard to experimental immunizations in mice, 
noteworthy that the use of a buffered medium (e.g. BM9) to neutralize gastric acidity 
and provide nourishment to the bacteria, resulted in the recovery of more than 50% of 
the bacteria one hour after inoculation (Huibregtse et al., 2007).    
2.5. Current status of L. lactis-based oral vaccines.  
The first attempt to use L. lactis as an oral vaccine delivery vector was performed in 
1990 by Iwaki et al., (1990). A killed recombinant strain displaying a Streptococcus 
mutans protective antigen (PAc) on the cell-wall was used to immunize mice orally 
and induced specific serum IgG and intestinal IgA antibodies (Iwaki et al., 1990). These 
findings provided the first evidence on the feasibility of using L. lactis to present 
antigens to the immune system. Soon after, Robinson et al., reported for the first time 
the use of live recombinant lactococci for the oral delivery of vaccine antigen to the gut 
immune system (1997). In their study, a recombinant strain secreting the Clostridium 
tetani TTFC induced specific serum IgG responses and fecal IgA responses, and 
immunized mice were protected against a lethal challenge with tetanus toxin 
(Robinson et al., 1997). Currently, a vast collection of published studies are available 
describing the oral delivery of viral, bacterial, protozoan and eukaryotic antigens using 
recombinant L. lactis as a vector. These studies are reviewed in Table 2.1, with a 
qualitative overview of the immune responses elicited and the associated pattern of 
protection, when applicable. Besides the numerous studies describing the efficient oral 
delivery of antigens by L. lactis, few studies have demonstrated the   ability of the 
bacterium to deliver DNA vaccines to the gut immune system (Chatel et al., 2008; 
Guimaraes et al., 2005; Pontes et al., 2014). The concept of DNA vaccination is based on 
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the utilization of the host cell translation machinery for the presentation of antigenic 
epitopes to the immune system. The early study demonstrated the delivery of green 
fluorescent protein (GFP) encoding DNA (Guimaraes et al., 2005). To allow its 
penetration into the host cell, the recombinant strain also expressed the Listeria 
monocytogenes internalin on the cell-wall (Guimaraes et al., 2005). However, native 
non-invasive L. lactis were recently shown to delivery DNA encoding bovine β-
lactoglobulin, which elicited mucosal and systemic immune responses (Chatel et al., 
2008; Pontes et al., 2014).   
 Despite the extensive preclinical research involving the use of L. lactis for the 
delivery of oral vaccines against infectious agents, to date, there is not a single   L. 
lactis-based vaccine under clinical trials. However, at the present time, a patented 
technology (ActoBioticsTM) exists, based on the use of freeze-dried recombinant 
lactococci for the topical intestinal delivery of biomolecules (TopActTM). These 
technologies are owned by ActoGeniX (www.ActoGeniX.com), a Belgian biotechnology 
company that was founded in 2006, as a spin-off of the life science research institute, 
VIB and the University of Ghent. Interestingly, the safety and tolerability of the 
ActoBioticsTM was evaluated in a phase I clinical trial, in which patients of moderate 
colitis were treated orally with a L. lactis strain secreting the anti-inflammatory 
cytokine IL-10 (Braat et al., 2006). The findings of this clinical trial open the doors to 
the therapeutic application of the technology in humans. Mimopath® is a second 
technology developed by the Dutch company, Mucosis (www.Mucosis.com), involving 
the utilization of inactivated L. lactis to develop bacterial-like particles for mucosal 
vaccine delivery. Currently, Mucosis is pursuing the preclinical phase for the 
development of an oral Mimopath®-based Shigella vaccine.      
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Table 2.1. Summary of oral vaccination studies involving the use of L. lactis as a vaccine delivery vector  
Infectious agent Antigen 
Bacterial 
location 
Immune responses Protection pattern 
Animal 
model 
References 
 
Bacteria: 
  
Clostridium tetani 
(Tetanus) 
Tetanus toxin 
fragment C 
(TTFC) 
CYT -Serum IgG and fecal IgA                       
-Mixed Th1/Th2 cytokine response 
in PP and MLN 
Survival after a lethal 
challenge with tetanus toxin 
Mouse Grangette et al., 
2002; Grangette et 
al., 2004; Robinson 
et al., 1997; 
Robinson et al., 
2004 
Brucella abortus 
 
 
 
 
 
 
 
L7/L12 CYT Fecal IgA -Partial protection against 
intraperitoneal challenge  
with B. abortus 
Mouse Pontes et al., 2004 
Cu-Zn 
superoxide 
dismutase 
(SOD)  
SEC -Serum IgM and IgG, fecal IgA 
-Lymphocyte proliferation 
-Responses improved by co-
administration of  
L. lactis secreting IL-12 
-Reduced B. abortus counts 
in spleen after challenge  
Mouse Saez et al., 2012 
 
 
Helicobacter pylori Urease B (UreB) CYT Serum IgG - Mouse Lee et al., 2001 
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Helicobacter pylori Urease B (UreB) SEC Serum IgG and fecal IgA Reduced H. pylori gastric 
counts and urease activity 
Mouse Gu et al., 2009 
 Cag12 CYT Serum IgG - Mouse Kim et al., 2006 
 Cholera toxin B 
subunit plus T 
and B cell 
epitopes of UreB 
SEC Serum IgG and fecal IgA Reduced H. pylori gastric 
counts 
Mouse Li et al., 2014 
 UreB and IL-2  CYT Serum IgG and fecal IgA 
IFN-γ and IL-4 in serum 
Reduced H. pylori gastric 
colonization and urease 
activity 
Mouse Zhang et al., 2014 
Clostridium 
difficile 
nontoxic tetanus 
toxin fragment C 
(TETC), and 14 
C-terminal 
repeats 
(14CDTA) of 
nontoxic C. 
difficile toxin A 
(TcdA) 
 
SEC, CWA IgG in serum and intestinal fluid -Increased survival upon 
lethal challenge with TcdA 
-Reduced cytotoxicity and 
enterocyte apoptosis in vitro 
-Reduced expression of 
mucosal inflammatory 
cytokines, ICAM-1, MCP-1, 
IL-6, and Gro-1 
Hamster Yang et al., 2013 
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Staphylococcus 
aureus 
SEB CYT, SEC Serum IgG and fecal IgA Increased survival after 
intraperitoneal challenge 
with SEB-producing S. 
aureus strain 
Mouse Asensi et al., 2013 
Enterotoxigenic 
Escherichia coli 
(ETEC) 
(Neonatal porcine 
diarrhea) 
F4 (K88) 
fimbrial adhesin 
FaeG 
SEC -Serum IgG and fecal IgA  
-Antibody secreting cells in spleen, 
MLN and PP 
- Mouse Liu et al., 2013 
SEC Serum IgG Reduced mortality after 
challenge 
Mouse Hu et al., 2009 
CYT -Serum IgG and fecal IgA 
-Antibody secreting cells in spleen, 
MLN and PP 
- Mouse Liu et al., 2010b 
Vibrio cholerae Wzm SEC Serum IgG and fecal IgA Absence of diarrhea after 
challenge 
Rabbit Zamri et al., 2012 
Streptococcus 
pneumoniae 
PppA CWA -IgM, IgG and IgA in serum and 
intestinal and bronchial fluids 
-Intestinal IgA
+
 cells 
-Mixed Th1/Th2 response 
(splenocyte cytokines and IgG 
subtypes analysis) 
Reduced pulmonary 
colonization and bacteremia  
Mouse Villena et al., 2010 
Villena et al., 2008 
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Enterohemorrhagic 
Escherichia coli 
(EHEC) 
EspA SEC Serum IgG Reduced cell cytoskeletal 
changes in vitro  
Mouse Luan et al., 2010 
Rhodococcus equi 
 
 
VapA SEC -Serum IgG and fecal IgA 
-Splenocytes mixed Th1/Th2 
cytokine responses 
Reduced  liver and spleen 
counts of R. equi 
Mouse Cauchard et al., 2011 
 
Virus: 
 
Human 
immunodeficiency 
virus (HIV) 
V2-V4 loop of 
gp120 
CWA -Serum IgG and fecal IgA 
-IFN-γ producing CD8
+
 T cells in 
peritoneal lymph node and spleen 
Decreased virus load after a. 
challenge with HIV Env-
expressing vaccinia virus  
Mouse Xin et al., 2003 
Gag CWA -IgG and IgA in serum, feces and 
vaginal fluid 
- Rectal IL-2, IFN-γ, TNF-α and IL-17 
producing CD4
+
 cells 
- Mouse 
Rhesus 
monkey 
Chamcha et al., 2012 
Rotavirus  VP7 CYT, SEC, 
CWA 
Serum antibodies Virus neutralization in an in 
vitro assay 
Mouse Perez et al., 2005 
 VP8 
 
 
CYT, SEC, 
CWA 
Serum IgG and fecal IgA Block infection in an in vitro 
cell line-based assay 
Mouse Marelli et al., 2011 
 
 
 
CYT, SEC Serum IgG and fecal IgA - Mouse Rodriguez-Diaz et 
al., 2011 
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Rotavirus VP4 CYT IgA and IgG were found in feces, 
ophthalmic and vaginal washes and 
in serum 
Virus in vitro neutralizing 
effect  
Mouse Li et al., 2010 
Human papilloma 
virus-16 
(HPV-16) 
L1 capsid protein CYT, SEC Serum IgG and vaginal IgA - Mouse Cho et al., 2007 
Sever Acute 
Respiratory 
Syndrome (SARS)-
coronavirus 
Nucleocapsid 
(N) protein 
CYT, SEC Serum IgG - Mouse Pei et al., 2005 
Dengue virus Envelope protein 
E domain 
III (EDIII) 
CYT Serum IgG Virus neutralization in an in 
vitro assay 
Mouse Sim et al., 2008 
Chicken infectious 
bronchitis virus 
(IBV) 
Multiple epitope 
antigen EpiC 
CWA Serum IgG and intestinal IgA Absence of clinical signs Chicken Cao et al., 2013 
CYT, SEC  Protection against lethal 
IBV challenge 
Chicken Berlec et al., 2013 
Hepatitis A virus  VP1-P2a CYT, CWA Serum IgG and fecal IgA No protection in in vitro 
neutralization assay 
Mouse Berlec et al., 2013 
Hepatitis B virus  PreSa SEC Serum IgG and fecal IgA - Mouse Zhang et al., 2011a 
Avian influenza 
virus 
 
Hemagglutinin 1  
(HA-1) 
 
CYT -Serum IgG and fecal IgA 
-Splenocyte secretion of IFN-γ and 
 IL-4 
Protection against lethal 
H5N1 challenge 
Mouse Wang et al., 2012 
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Avian influenza 
virus 
 
Hemagglutinin 1  
(HA-1) 
CWA Serum IgG and fecal IgA 
Splenocyte cell proliferation and    
IFN-γ secreting cells 
Protection against lethal 
H5N1 challenge 
Mouse Lei et al., 2011 
Porcine transmissible 
gastroenteritis virus 
SN protein SEC Serum IgG and fecal IgA virus neutralization in vitro Mouse Tang & Li, 2009 
 
Protozoa: 
  
Plasmodium yoelii 
(Malaria) 
MSP-1 CYT - Reduced parasitemia after 
challenge with Plasmodium 
yoelii 
Mouse Zhang et al., 2005 
MSA2cP CYT,CWA Serum IgG and fecal IgA - Mouse Moorthy et al., 2009 
Giardia lamblia Cyst wall 
protein-2 (CWP-
2) 
CWA Serum IgG and fecal IgA 
Mixed Th1/Th2 cytokine response in 
MLN and PP 
Reduced cyst fecal output 
after oral Giardia lamblia 
challenge  
Mouse Lee et al., 2009 
Eimeria tenella 
 
3-1E CYT - Reduced fecal oocyst release 
and cecal lesion score 
Chicken Ma et al., 2013 
Leishmania major LACK plus IL-12 CYT, SEC, 
CWA 
Intestinal IgA 
Th1 response in spleen and MLN 
Reduced food-pad swelling 
and parasitic burden 
Mouse Hugentobler et al., 
2012 
 
-
 Not performed 
 CYT, cytoplasmic expression; SEC, secretion; CWA, cell-wall anchoring; MLN, mesenteric lymph nodes; PP, Peyer’s Patches
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3. Enterohemorrhagic Escherichia coli 
 
3.1. Introduction and historical perspective 
Enterohemorrhagic E. coli (EHEC) are a subset of shiga toxin- (or verocytotoxin-) 
producing E. coli that can cause hemorrhagic colitis (HC) and the hemolytic     
uremic syndrome (HUS) (Janot et al., 2009). EHEC are zoonotic enteropathogens 
transmitted from ruminants to humans through ingestion of contaminated food and 
water or through direct contact. The disease usually occurs in epidemic outbreaks, 
which have been frequently reported worldwide. Following infection, patients 
develop hemorrhagic colitis, which is manifested clinically as bloody diarrhea. In 
severe cases, HC usually progresses to hemolytic uremic syndrome (Janot et al., 
2009), which is a clinical pathological triad consisting of impaired renal functions, 
microangiopathic hemolytic anaemia and thrombocytopenia (Serna & Boedeker, 
2008). HUS causes high fatalities among patients (up to 50% in some outbreaks) 
(Griffin & Tauxe, 1991a), while a significant percentage of survivors (approximately 
30%) suffer a range of permanent disabilities including renal insufficiency, 
hypertension and neurological deficits (Serna & Boedeker, 2008).  
The production of shiga toxins by E. coli was first recognized in the late 1970’s, 
when Konowalchuk et al. (Konowalchuk et al., 1977) found that culture filtrates of E. 
coli strains, isolated from infants with diarrhea, exerted irreversible cytopathic 
effects on Vero cells (Konowalchuk et al., 1977). These effects differed from those 
caused by the known diarrheagenic E. coli heat labile toxin. Soon after, and in 1983, 
O’Brien and LaVeck could purify the novel toxin from Konowalchuk prototype strain 
H30, and showed it has a polypeptide nature and that it is similar in structure, 
antigenicity and biological activity to shiga toxins produced by Shigella dysenteriae 
type 1 (O’Brien & Laveck, 1983). Therefore, they designated the toxin “shiga-like 
toxin”. However, the same group showed that this shiga-like toxin is the same toxin 
that killed Vero cells and was previously designated “vero cytotoxin” (O'Brien et al., 
1983). It was also demonstrated that different types of these toxins existed. Boths 
terms, Shiga toxin (Stx) and Vero cytotoxin (VT), are interchangeably used.   
The clinical association of EHEC with human disease was recognized for the  
first time in the early 1980’s, when reports by Riley et al. (1983) and Karmali et al. 
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(1983) linked the bacteria to HC and HUS, respectively, diseases of unknown 
aetiology hitherto. Riley et al. (1983) investigated two outbreaks of HC, which 
occurred in Oregon and Michigan, USA and found a significant link between the 
disease, the consumption of undercooked beef from a fast-food chain, and a “rare” E. 
coli serotype, O157:H7. Similarly, Karmali et al. (1983) established a link between 
various EHEC serotypes, including serotype O157:H7, and sporadic cases of HUS. 
This link was based on the detection of Stx in stool of all examined HUS patients and 
the presence of significant antibody responses against Stx in the serum of several of 
them. These findings were confirmed by Karmali et al. in a later study (Karmali et al., 
1985), which has led them to speculate a direct role of Stx in the pathogenesis of 
HUS.     
3.2. Transmission    
Various animal species have been reported as reservoirs for EHEC. However, 
ruminants, particularly cattle, are the main reservoir associated with human 
infections. Humans typically acquire the infection through the ingestion of meat and 
dairy products, vegetables and water, which are contaminated with ruminant faeces, 
in addition to direct contact with animal reservoirs and contaminated objects 
(Crump et al., 2002; Grant et al., 2008; Swerdlow et al., 1992; Varma et al., 2003). 
Human fecal contamination of food and water could also play a role in transmission, 
especially in developing countries. Person-to-person contact seems to play a major 
role in transmission of EHEC, since up to 20 % of EHEC outbreaks are believed to 
occur due to secondary transmission rather than to the exposure to the original 
contaminated source (Snedeker et al., 2009).   
3.3. Serotypes and incidence 
Over 130 EHEC serotypes have been isolated from humans with diseases, and 
many of these serotypes have been recovered from animals (Blanco et al., 2003). 
However, only a limited number of serotypes have been responsible for the majority 
of human cases. These include the members of the O serogroups 26, 91, 103, 111, 113, 
121, 145 and 157 (Karmali et al., 2003). Among these serotypes, E. coli O157:H7, the 
first reported EHEC serotype, has been most commonly associated with severe 
outbreaks as well as sporadic cases of EHEC infections worldwide (Griffin & Tauxe, 
1991b). Recent surveillance data from the US FoodNet (2013) estimate 1.15 infections 
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per 100, 000 population for the O157 serotype, which is only slightly lower than that 
of non-O157 serotypes collectively (1.17) (Crim et al., 2014). In Europe, the incidence 
of EHEC infections has markedly increased in 2011 compared to years from 2008-
2010, but this was mainly due to the inclusion of a large outbreak of O104:H4 that 
occurred in Germany (2.3 per 100, 000 population). However, O104:H4 was an 
enteroaggregative strain which gained the capacity to produce Stx. The most recent 
report of the European Food Safety Authority (EFSA) indicates an incidence of 1.15 
infections per 100, 000 population, with O157 serotype being the most prevalent 
(41%). With a particular regard to Belgium, the report estimates incidences of 65 
infections per year for the O:157 serotype versus 22 infections with non-O157 
serotypes. 
3.4. Virulence factors 
The pathogenicity induced by EHEC involves two major processes; the intestinal 
colonization, and the induction of HC and HUS. Therefore, EHEC combines two 
main types of virulence factors, which are directly responsible for these processes. 
3.4.1. Colonization factors   
In order to colonize the intestine, EHEC establish an intimate tight adherence to 
enterocyte, giving rise to a characteristic lesion, known as “attaching and effacing” 
A/E lesion (Frankel et al., 1998; Kaper et al., 2004; Nataro & Kaper, 1998). This 
process involves drastic morphological and cytoskeletal changes to enterocytes 
including the notable loss of enterocyte microvilli (effacement) and the organized 
accumulation of cytoskeletal actin filaments beneath adherent bacteria, forming 
what is called the “actin pedestal” (Donnenberg et al., 1997). The virulence factors 
involved in the formation of A/E lesion are typically categorized on basis of the 
genetic elements encoding them, and thus can be described as follows:  
3.4.2. The locus of enterocyte effacement (LEE) 
LEE is a large well-known pathogenicity island (42 kb) that encodes some 
adhesion factors and a type III secretion system, which are responsible for the 
formation of the A/E lesion (Frankel et al., 1998). This locus consists of three 
segments, encoding five operons. The first segment includes the LEE1, LEE2 and 
LEE3 operons, which contain the genes encoding for the majority of the structural 
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and chaperon proteins of the T3SS. The second segment contains operon LEE5, 
which encodes genes of an adherence system consisting of an outer membrane 
protein, intimin, and its receptor, translocated intimin receptor (Tir). The third 
segment contains LEE4, which encodes for E. coli secreted proteins (Esp) such as 
EspA, EspB and EspD (Frankel et al., 1998). Together, these secreted proteins forms a 
complex (EspABD complex), which constitute the translocation apparatus of the 
T3SS. Nevertheless, some of its members, particularly EspB, are effector proteins 
themselves, playing a role in mediating enterocyte cytoskeletal changes (discussed 
below). 
3.4.3. Non-LEE pathogenicity islands and plasmid O157 
Several EHEC flagellins and fimbrial and outer membrane adhesins encoded on 
non-LEE pathogenicity islands (mainly the O-islands) have been identified and 
might significantly contribute to the adherence of the bacteria to enterocytes (Perna 
et al., 2001). These mainly include the H7, H10 and H21 flagellins (Rogers et al., 2006), 
the EHEC factor for adherence (Efa1) (Nicholls et al., 2000; Stevens et al., 2002), the 
outer membrane proteins, Iha (Nicholls et al., 2000) and A (OmpA) (Torres & Kaper, 
2003), long polar fimbria variant 1 (Lpf1) (Doughty et al., 2002; Torres et al., 2002; 
Torres et al., 2004) and the hemorrhagic coli pilus adhesin, HCP (Ledesma et al., 
2010). Plasmid O157 is another genetic element that is believed to play a role in EHEC 
virulence (Levine et al., 1987; Ostroff et al., 1989; Ratnam et al., 1988). The complete 
pO157 sequence, which has been determined (Burland et al., 1998), has led to the 
identification of some factors that were suggested to play a role in adherence (e.g. an 
outer membrane adhesin, ToxB) (Tatarczak et al., 2005; Tatsuno et al., 2001; Toma et 
al., 2004). However, there have been conflicting in vitro and in vivo findings with 
regard to the role of pO157 in adherence to epithelial cells (Fratamico et al., 1993; 
Karch et al., 1987; Nataro & Kaper, 1998; Tzipori et al., 1987).      
3.4.4.  Shiga toxins (Stx) 
EHEC produce one or more of Stx, whose prototype is produced by Shigella 
dysenteriae type 1 (Strockbine et al., 1986; Takao et al., 1988). Stx1 is almost identical 
to the latter, differing only in one amino acid, whereas Stx2 shares a 56% of 
homology with Stx1, and is antigenetically distinct. A number of Stx2 variants have 
been identified, among which, Stx2c and Stx2d are associated with HC and HUS 
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(Karch et al., 2006). These variants are encoded as a single transcriptional unit by 
bacteriophages. Stx molecules have an A1B5 structure, in which one enzymatic active 
A subunit is linked to a pentamer of receptor binding subunits (B subunits) (Fraser et 
al., 1994; Stein et al., 1992). The A subunit possesses a RNA N-glycosidase activity 
that enables the toxin to cleave a specific adenine base (A4324) from the 28 S rRNA of 
the 60S ribosome (Endo et al., 1988). This process prevents the binding of elongation 
factor I-dependent aminoacyl-tRNA, inhibits protein synthesis, and induces cell 
apoptosis as a ribonucleic stress response (Smith et al., 2003) or due to Stx related 
signaling (Cherla et al., 2003). The B subunits enable the toxin to bind to specific 
glycolipid receptor, globotariosylcermide (Gb3), which is present on the cell 
membrane of epithelial and endothelial cells. The toxin binding to Gb3 permits the 
internalization of STs into target host cell by receptor-mediated endocytosis 
(Lingwood, 1994; Waddell et al., 1996). Thereafter Stx are transported into a vesicle 
to the Golgi apparatus and the endoplasmic reticulum by retrograde transport 
(Sandvig & van Deurs, 2002). In the Golgi apparatus, the A fragment is cleaved by the 
enzyme furin into two fragments, A1 and A2, which remain covalently linked by a 
disulphide bond. The latter is thought to be reduced in the endoplasmic reticulum. 
Then the A1 fragment is transported to the cytoplasm to target the rRNA as 
described above (O'Loughlin & Robins-Browne, 2001).  
Although epithelial cytotoxicity is the main feature of Stx pathogenicity, it is 
noteworthy to mention the toxin was also found to play a role in adherence of EHEC   
to enterocytes. Indeed, Stx2 were shown to induce localization of nucleolin in Hep-2 
cells (Robinson et al., 2006). Nucleolin is a cell surface molecule which binds to 
intimin (Sinclair & O'Brien, 2002) before Tir is translocated into the cell membrane. 
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3.5. Pathogenicity    
3.5.1.  The A/E lesion 
Enterocyte adherence and the formation of the A/E lesion are important 
characteristics of EHEC pathogenicity. These processes involve three typical stages, 
which can be described as follows:   
3.5.1.1. Initial non-intimate adherence 
At first EHEC establish a non-intimate adherence to enterocytes. The 
mechanisms and the particular virulence factors involved in this process are poorly 
characterized. However, a role of the H7 flagellin in primary adherence of O157:H7 to 
epithelial cells have been reported (Mahajan et al., 2009). Other factors such as EfaI, 
Iha, OmpA and ToxB have been shown to promote adherence of the EHEC to 
epithelial cell lines and thus, might play a role in early adhesion. Additionally, factors 
such as Lpf1, have been suggested to be particularly involved in the process of the 
early adherence (Torres et al., 2002; Torres et al., 2004). However, these speculations 
require further confirmation.  
3.5.1.2. Signal transduction   
Following the early adherence, EHEC induces a series of structural and 
morphological changes in the host cells in order to establish a firm adherence. These 
changes occur with the aid of the LEE-encoded T3SS, which mediates a contact-
dependent translocation of effector proteins into the host cell (Campellone & Leong, 
2003; Tobe et al., 2006) (Figure 3.1). The translocated effector proteins induce a cell 
signalling cascade leading to the formation of the actin pedestal and Tir, which is 
essential for the establishment of intimate adherence. To translocate effector 
proteins, EspA forms a needle-like filamentous structure which extends to the host 
cell membrane (Ebel et al., 1998; Knutton et al., 1998). At the tip of this molecular 
needle the translocon proteins EspB and EspD, which form a pore in the cell 
membrane (Ide et al., 2001), through which the translocated proteins are delivered. 
Tir is one of the first translocated proteins, which is directly injected into the host 
cell membrane, taking a hairpin loop confirmation that allows its extracellular 
domain to bind with intimin on the bacterial outer membrane.   
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EspB is a particular T3SS protein that in addition to its role in translocating other 
effector proteins plays a major effector role in the formation of the A/E lesion. It 
binds to host proteins such as α-catenin (Kodama et al., 2002), α1-antitrypsin 
(Knappstein et al., 2004b) and myosin (Lizumi et al., 2007) in order to regulate the 
host-cell actin networks, resulting in the formation of the actin pedestal structure 
and effacement of enterocytes’ microvilli (Kodama et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Schematic representation of EHEC type 3 secretion apparatus. EspA subunits 
polymerize to form the needle-like EspA filament. EspB and EspD form the translocation 
pore in the host cell plasma membrane, connecting the bacteria with enterocyte cell 
membrane via EspA. Adapted from (Garmendia et al., 2005).  
 
Other translocated effector proteins include EspG, EspF, EspH and MAP 
(mitochondrial associated protein), which are believed to interfere with host cell 
signalling (Ritchie & Waldor, 2005). Noteworthy, the T3SS was also found to 
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translocate other non-LEE encoded effector proteins such as NleH, which alters the 
transcription process in host cells (Gao et al., 2009b). 
3.5.1.3. Intimate adherence      
The binding of intimin to its translocated receptor Tir on the cell membrane 
constitutes the firm attachment of EHEC to enterocytes, which is morphologically 
characterized by effacement of the microvilli. Additionally, although the role of the 
cytoskeletal arrangements and actin pedestal formation is hitherto speculative, the 
establishment of firm anchorage of the bacteria is an obvious possibility. 
3.5.2. Inflammation 
Inflammation is a prominent feature of the intestinal lesion caused by EHEC. 
Adhesins such as the HCP and the flagellins (H7, H10, and H21) induce local cytokine 
production (such as IL8, TNF-alpha, or CCL20) within the intestine (Gobert et al., 
2008; Ledesma et al., 2010) or attract subepithelial neutrophils (de Boer et al., 2000) 
and as a consequence, cause localized inflammation. Additionally, bacteria that 
produce A/E lesions induce IL22, a cytokine that may increase intestinal damage 
(Zheng et al., 2008). A possible role of intestinal inflammation in EHEC 
pathogenicity is to impair the intestinal barrier function, thereby facilitating the 
passage of Stx to the submucosa. The inflammatory responses extend beyond the 
intestine to other organs, such as the kidneys. HUS patients have been shown to 
have high urinary level of IL-8 and monocytes chemoattractant 1 (de Boer et al., 
2000). This can be attributed to the role of Stx and EHEC lipopolysaccharides (LPS), 
which were shown to stimulate microvascular endothelial cells to release these 
factors (Stahl et al., 2006). Furthermore, binding to and transport of Stx by 
granulocytes is thought to be responsible for the inflammatory responses and 
transfer of the toxin to organs such as the kidneys (te Loo et al., 2000). 
3.5.3. Vascular injury   
After their release, Stx cross the intestinal barrier in order to reach the 
circulation. The mechanisms of such translocation are different for Stx1 and Stx2, 
which follow transepithelial and paracellular routes, respectively (Acheson et al., 
1996; Hurley et al., 1999; Philpott et al., 1997). In the blood stream, Stx are carried to 
their Gb3 receptors by polymorphonuclear cells, particularly neutrophils (Brigotti et 
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al., 2010). Gb3 receptors are abundantly expressed by endothelial cells of the kidneys, 
colon and brain, organs where Stx mainly induce endothelial damage and vascular 
injury. However, renal glomerular and tubular vessels are considered the main target 
(Obata et al., 2008; Obrig et al., 1993; Richardson et al., 1992). The vascular injury 
caused by Stx also involves a pathologic lesion, defined as thrombotic 
microangiopathy. This lesion is characterized by endothelial cell swelling and 
detachment from the basement membrane, and thrombosis of the microvasculature 
of the colon and the kidneys (Richardson et al., 1988). Shiga toxin upregulates the 
expression of adhesion molecules (e.g. E-selectin) on the endothelial cell surface, and 
facilitates adherence and subsequent degranulation of neutrophils (Morigi et al., 
1995). Degranulated neutrophils release elastase, which can disrupt the extracellular 
matrix resulting in endothelial cell detachment. Stx also increase cell-surface 
expression of P-selectin, and both induce the release and prevent the cleavage of the 
ultra-large von Willebrand factor, and thereby the toxins promote platelet adhesion 
to the endothelial cell surface, resulting in thrombosis (Morigi et al., 2001; Nolasco et 
al., 2005). LPS has also been shown to play a role in thrombus formation in HUS 
patients. They were detectable on platelets surface of preHUS patients before HUS is 
developed, and additionally, O157 LPS was shown to bind to and activate human 
platelets. Providing that LPS can also bind to endothelial cells, the former might play 
a role in thrombus formation by mediating the platelets-endothelial adhesion (Stahl 
et al., 2006).      
3.6. Pathophysiology and clinical presentation of EHEC diseases 
The establishment of EHEC disease is thought to require the ingestion of a 
relatively low dose of the bacteria, ranging from 50 to few hundred organisms 
(Tilden et al., 1996). However, recent analyses of outbreaks have shown that the dose 
necessary to cause disease depends on the EHEC strain involved, the matrix in which 
the bacterium is present when ingested and the host susceptibility (Teunis et al., 
2008). Following ingestion, EHEC is well-adapted to endure gastric acidity, which 
enables the majority of them to reach the intestine. Furthermore, the stimulus 
resulting from the exposure of EHEC to the acidic pH in the stomach has been 
shown to induce the upregulation of intimin and T3SS protein expression, which 
prepares the bacteria for intestinal colonization (House et al., 2009). 
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As the bacteria reach the intestine, they immediately initiate the colonization 
process. In most EHEC infections an average incubation period of 3 days, is required 
before the onset of clinical signs, but the period can vary from 2 to 13 days (Bell et al., 
1994). Thereafter, and as a result of enterocyte adherence and the accompanying 
mucosal inflammation, fluid absorption in the large intestine is disrupted, resulting 
in non-bloody diarrhea and severe abdominal pain. These symptoms are typically 
encountered during the first 1 to 3 days of illness and can be accompanied by 
vomiting (Tarr et al., 2005). Transient fever has also been reported in up to 50% of 
patients. It usually resolves as the patient is presented to the medical care.  
After intestinal colonization, EHEC release Stx, which disseminate through the 
blood circulation and reach the colon and the kidneys to induce microvascular 
injuries. The latter is the proposed mechanism leading to bloody diarrhea and the 
acute renal injury of HUS during EHEC infections. About 10–15% of patients infected 
with E. coli O157, mostly children younger than 5 years old (Garg et al., 2008), 
develop haemolytic uraemic syndrome 5–13 days after the onset of diarrhea 
(Scheiring et al., 2008; Tarr et al., 2005). HUS patients are often clinically presented 
with microangiopathic hemolytic anaemia due to lysis of RBCs (haemoglobin < 10 
g/dL) flowing in damaged microvasculature, thrombocytopenia (platelet count 
< 15×10⁹ cells/L) due to excessive platelet activation and precipitation in the damaged 
vessels and impaired renal function (oliguria or anuria and high concentrations of 
serum urea and creatinine) due to renal glomerular and tubular vascular damage 
(Michael et al., 2009). The brain involvement can be a major complication of HUS 
and may manifest clinically as seizures, coma, and/or dysregulated breathing 
(Theobald et al., 2001).  
3.7. Animal models of EHEC infection 
The available knowledge of the pathogenesis of EHEC-mediated diseases in 
humans is to a great extent limited. Additionally, due to the possible risks that a 
human volunteer develops HUS, the use of human subjects to study the 
pathogenicity of EHEC or to evaluate new therapies and vaccines is ethically 
unacceptable. Therefore, numerous animal models have been developed for these 
essential purposes. However, studies have evidently shown that not a single animal 
model is valid to recapitulate the full aspects of EHEC pathogenicity in humans 
(Mohawk & O'Brien, 2011a). Alternatively, all the available animal models are chosen 
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based on the desirable study endpoint. Generally, models exist in two main varieties: 
those reproducing the effects of Stx (in the absence of bacteria) and those that 
explore the intestinal infection. Models employed to evaluate toxicity rely on 
injection of Stx, with or without LPS, and often select mortality as a study endpoint 
(Armstrong et al., 2006; Bentancor et al., 2009; Sauter et al., 2008; Sheoran et al., 
2005). However, for the purpose of this thesis, the models reviewed under this 
section are those essentially mimicking the intestinal colonization and pathology, 
whether or not showing other aspects of systemic pathogenicity.  
3.7.1.  Mouse models 
As a small animal species, the mouse particularly offers a number of benefits 
including: relatively low costs of purchase and maintenance, ease of care and 
handling, availability of numerous immunological reagents, variations in genetic 
backgrounds among inbred strains, and very importantly, the feasibility of using 
sufficient numbers of animals in a single study, which allows drawing statistically 
supported conclusions from the obtained data. 
Although in a variety of animal models, EHEC was shown to colonize mice    
under physiological intestinal conditions (Brando et al., 2008; Conlan & Perry, 1998b; 
Karpman et al., 1997a; Nagano et al., 2003a), many other researchers adopted various 
manipulations to enhance EHEC colonization and pathogenicity (Table 3.1). They 
included strategies that: (1) reduce the facultative commensal flora, to decrease the 
bacterial competition for the colonizing EHEC (streptomycin treatment prior and 
during the study) (Lindgren et al., 1993; Wadolkowski et al., 1990b); (2) reduce the 
bacterial competition and induce phage expression to increase the toxin expression 
by the bacteria (e.g. by incorporating mitomycin C with a streptomycin treatment) 
(Fujii et al., 1994; Shimizu et al., 2003; Teel et al., 2002); (3) adopt anexic (germ-free) 
mice, strictly lacking other competing intestinal bacteria (Aiba et al., 2002; Jeon & 
Itoh, 2007; Sawamura et al., 1999); (4) induce an underdevelopment of enterocytes to 
increase predisposition of mice to EHEC colonization (by adoption of low protein-
calorie diet) (Kurioka et al., 1998). Whereas high doses of the bacteria were 
occasionally used to achieve sufficient levels of intestinal colonization and disease in 
these models, particularly low protein-calorie malnutrition and anexic mice models 
required lower doses of EHEC to induce the same pathology (Aiba et al., 2002; Jeon & 
Itoh, 2007; Kurioka et al., 1998; Sawamura et al., 1999).    
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The influence of mouse strain variation on the capacity of EHEC to colonize the 
gut has also been studied. Comparing BALB/c (inbred), C57BL/6 (inbred) and CD-1 
(or ICR) (outbred) mouse strains for colonization by E. coli O157:H, no differences in 
duration of shedding was observed. Bacterial fecal shedding generally lasted for 1 to 2 
weeks (Conlan & Perry, 1998a). However, in another study DC-1 mice remained 
infected till the end of the study period (28 days), in contrast to BALB/c, C3H/HeN, 
C3H/HeJ, and A/J mice which stopped shedding one week after the infection 
(Nagano et al., 2003b). Noteworthy that BALB/c mice showed resistance to 
reinfection (shorter duration of fecal shedding compared to C57BL/6 (inbred) and 
CD-1 (outbred) strains) (Conlan & Perry, 1998a). This observation was coupled to the 
presence of O157-specific IgA (both serum and fecal). This makes BALB/c mice a 
potential candidate model for EHEC oral vaccination studies (Conlan & Perry, 
1998a). 
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Table 3.1. Examples of commonly used mice models of EHEC intestinal colonization. Adapted from (Mohawk & O'Brien, 2011b).   
Model Mouse strains 
Inoculum 
(CFU) 
Inoculation 
method 
Outcomes Pathology References 
 
Conventional 
 
 
C3H/HeN, 
C3H/HeJ 
 
107, 108 
 
Intragastric 
 
Morbidity, mortality 
 
Kidney, intestine 
 
Karpman et al., 1997 
CD1, BALB/c, 
C57BL/6 
~ 2 × 10
10
 Intragastric Colonization - Conlan & Perry, 1998a 
ICR (CD-1) 10
11
/kg body weight Intragastric Colonization - Nagano et al., 2003b 
BALB/c 6 × 10
9
/kg Intragastric Morbidity and mortality Kidney, intestine Brando et al., 2008 
Streptomycin-
treated 
 
CD-1 10
10
 Feeding Colonization, morbidity, 
mortality 
Kidney Wadolkowski et al., 
1990a 
CD-1 ≤ 10
1
 Feeding Colonization, morbidity, 
mortality 
Kidney Lindgren et al., 1993 
Mitomycin C 
and 
streptomycin 
ICR > 10
9
 Intragastric Colonization, morbidity, 
mortality 
Kidney, brain Fujii et al., 1994 
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Protein-
calorie 
malnutrition  
 
C57BL/6 2 × 10
5 
– 2 × 10
7
 Intragastric Colonization, morbidity, 
mortality 
Kidney, intestine, brain Kurioka et al., 1998 
Germ-free IQI 5 × 10
7
 Intragastric Colonization, morbidity, 
Mortality with 
hypertoxigenic strain 
Kidney, intestine, brain Taguchi et al., 2002 
Swiss-
Webster 
10
2
–10
6
 Intragastric Colonization, morbidity, 
mortality 
Kidney Eaton et al., 2008 
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3.7.2. Pig models 
Pigs are a particularly interesting animal species that offers a good model for 
humans in studies of gastrointestinal physiology, pathology, infection and immunity 
(Meurens et al., 2012). Indeed, pigs share various aspects of gastrointestinal 
physiology and mucosal immunology with humans, which distinguish them from 
other animals as a model for human gastrointestinal infections. Additionally, several 
enteropathogens can commonly infect pigs and humans. Gnotobiotic piglets can be 
infected with EHEC strains (Francis et al., 1986; Tzipori et al., 1986; Tzipori et al., 
1989; Tzipori et al., 2004), and show a pathogenesis that closely mimics that 
occurring in humans. In this model, the EHEC infection caused both intestinal 
lesions and a watery diarrhea. In fact, the A/E lesions evoked by E. coli O157:H7 were 
first described in vivo in gnotobiotic piglets (Francis et al., 1986). Renal damage and 
neurological manifestations are also features of this model, and fatality from 
systemic complications may occur. The gnotobiotic piglet model is quite well 
established and has been applied by several groups for the study of E. coli O157:H7 
pathogenesis as well as in preclinical evaluation of EHEC therapeutics (Tzipori et al., 
1988). 
3.8. Vaccination against EHEC infection 
Unlike the majority of other bacterial diseases, previous clinical studies did not 
demonstrate beneficial effects of antibiotic therapy on the outcome of EHEC 
infection (Bell et al., 1997; Ryan et al., 1986). Moreover, several retrospective studies 
have linked antibiotic therapy to higher rates of HUS development, a prolonged 
period of symptomatic disease, and a prolonged bacterial shedding (Carter et al., 
1987; Pavia et al., 1990; Wong et al., 2000). These outcomes can be attributed to the 
undesirable release of Stx by destroyed bacterial cells (Wong et al., 2000). 
Additionally, in vitro subinhibitory concentrations of antibiotics may increase 
production and release of Stx via bacteriophage induction (Zhang et al., 2000). 
However, animal studies, involving mice (Kurioka et al., 1999) and pigs (Zhang et al., 
2009), suggested that the antibiotic fosfomycin could be used to treat human 
infection. However, only one non-randomized prospective study has been conducted 
on the use of fosfomycin for prevention of HUS (Ikeda et al., 1999). This study 
suggested that the use of fosfomycin within the first 3 days and especially within the 
first two days significantly decreased the risk for HUS. However, the data obtained 
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have been questioned (Iijima et al., 2008). Recent evidence supported the risk 
associated with the use of β–lactams and other bactericidal antibiotics in EHEC 
infections (Smith et al., 2012). Considering these facts, it has been accepted that 
vaccination could represent the best way to control EHEC infections and prevent the 
disease outbreaks. 
The vast majority of the preclinical vaccination studies performed to develop a 
human vaccine against EHEC have been performed in mouse models. These studies 
used several virulence factors as antigens and utilized various vaccination routes. 
However, there is currently no vaccine available for humans. In this section we will 
review the studies currently published on EHEC vaccines.  
3.8.1. Subunit vaccines 
3.8.1.1. Type III secretion system-based vaccines 
Humans infected with EHEC show serum antibody responses against T3SS 
proteins such as Tir, intimin, EspB, EspA and NleA (Asper et al., 2011; Li et al., 2000). 
Also in animals experimentally infected with EHEC the proteins elicit antibody 
responses (Asper et al., 2011). This reflects the important role of these antigens in the 
infection process and their high immunogenicity, making these bacterial surface 
located and T3SS proteins potential vaccine candidates. The induction of specific 
immune responses against T3SS proteins is expected to interfere with the intestinal 
colonization process, and thus prevents the infection. 
A mixture of T3SS proteins has been evaluated as an EHEC vaccine in a mouse 
model using mucosal and systemic vaccination routes. Intranasal (i.n.) immunization 
using T3SS proteins in combination with an adjuvant resulted in serum and fecal       
antibody responses that could recognize Tir and EspA and that reduced EHEC fecal 
shedding (Babiuk et al., 2008). On the other hand, intramuscular (i.m.) 
immunization of mice eliminated bacterial fecal shedding in the absence of fecal 
anti-Tir and -EspA antibodies (Babiuk et al., 2008). These promising results have 
been the basis of a currently available cattle vaccine, commercially known as 
Econiche® (Potter et al., 2004). The results from the study in mice did not suggest an 
essential role for fecal secretory IgA in clearance of E. coli O157:H7 infection. 
However, it should be noted that although a mixture of T3SS proteins had been used 
to immunize mice, the serum and fecal immune responses were tested against only 
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two antigens. Therefore, the presence of specific fecal IgA responses against other 
antigens cannot be excluded. In agreement, a recent study in mice using Tir as a 
vaccine antigen showed that i.n. immunization induced IgG and IgA antibodies in 
serum and faeces, respectively, reducing shedding and protecting the mice against a 
lethal dose of E. coli O157:H7 (Fan et al., 2012). However, in     the same study the 
subcutaneous (SC) route, which increased serum IgG, but not fecal IgA against Tir, 
did not induce protection. Similar findings were reported for the KT-12 peptide, an 
intimin predicted B-cell epitope (Wan et al., 2011). 
Intranasal immunization of mice using EspB and the C-terminus of intimin (C-
280γ-intimin), in combination with the mucosal adjuvant MALP-2 induced serum 
specific IgG and fecal specific IgA responses (Cataldi et al., 2008). These responses 
were associated with mixed Th1/Th2 cytokine responses as IFNγ-, IL-2- and IL-4-
expressing lymphocytes were obtained from EspB- or C280 γ-intimin-vaccinated 
mice (Cataldi et al., 2008). Oral immunization of mice using intimin-derived vaccine 
delivered using non-pathogenic carrier strain of Salmonella enterica Typhimurium 
induced specific serum IgG and fecal IgA antibodies and reduced EHEC shedding 
after challenge (Oliveira et al., 2012). 
3.8.1.2. Stx-based vaccines 
Since Stx are the main virulence factor of EHEC pathogenicity, vaccination studies 
aim to induce an immunity which can prevent intoxication. Early work in mice and 
pigs demonstrated that parenteral vaccination with inactivated Stx effectively 
induced neutralizing antibodies and in some cases, protection against toxemia 
(Ishikawa et al., 2003; Marcato et al., 2001; Marcato et al., 2005; Oanh et al., 2012). 
Also, passive immunization of mice with human or murine antibodies raised against 
Stx inhibited their activity and resulted in protection (Akiyoshi et al., 2005; Jeong et 
al., 2010; Mohawk et al., 2010)  
Although Stx2 are more associated with human disease than Stx1, the induction of 
immune responses against both Stx is considered an important criterion of a good 
vaccine. In this regard, recent studies evaluated hybrid toxins via different 
immunization routes as vaccine candidates. A hybrid toxoid consisting of an 
inactivated mutant Stx2A subunit and a native Stx2B subunit induced neutralizing 
serum antibodies against both Stx in mice that were immunized intraperitoneally 
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(i.p.) and also protected them from challenge with either toxin types (Smith et al., 
2006). Similarly, i.n. immunization of mice with the Stx2B subunit induced systemic 
IgG and mucosal IgA antibodies, which protected mice against not only Stx2, but also 
Stx1 (B-subunit cross protection). On the other hand, mice immunized with Stx1B 
showed protection only against Stx1 (Tsuji et al., 2008c). A fusion protein comprising 
the B subunits of the both Stx types induced antibodies, which protected mice 
against a challenge with a lysate of E. coli O157:H7 (Gao et al., 2009a). Noteworthy, 
the antibody responses and the protective effect induced by the fusion construct 
were higher for Stx2 compared to vaccination with a mixture of non-fused Stx1B and 
Stx2B. This was thought to be due to an adjuvant effect of the fused Stx1B 
subunit (Gao et al., 2009a). Furthermore, a derivative of the fusion protein 
containing an enzymatically inactive Stx2A subunit instead of the Stx2B elicited 
higher levels of Stx2 neutralizing antibodies and a significantly higher level of 
protection against a lethal dose of E. coli O157:H7 lysate (Cai et al., 2011).  
The above studies mainly involved systemic vaccination routes. However, another 
study has also explored the oral route. Oral immunization of mice with a Salmonella 
enterica strain expressing a mutant Stx2 toxoid induced anti-Stx2B IgG antibodies. 
Although the anti-toxoid antibodies could neutralize Stx2 in vitro, only a limited 
protection was afforded against an intravenous challenge with Stx2 in mice (Rojas et 
al., 2010).   
3.8.1.3. Subunit fusion vaccines 
To improve the efficacy of EHEC vaccines, protein fusion vaccines have been 
developed combining subunits of T3SS proteins and Stx to achieve multivalent 
protective effects. A prominent example is the EIS (EspA-Intimin-Stx) fusion, 
comprising EspA, the C-terminal 300 residues of intimin and the Stx2B subunit. The 
fusion vaccine was shown to induce specific humoral antibodies against the three 
antigens and protected mice against EHEC challenge more efficiently than using 
each of the three antigens individually (Rojas et al., 2010). Further, oral inoculation of 
mice with a live-attenuated Salmonella strain expressing EIS produced specific IgA 
against EspA, intimin and ST2B (Gu et al., 2011). This immune response was long 
lasting, since even after 70 days it could be boosted subcutaneously and produced 
significant protection against a lethal challenge (Gu et al., 2011).  
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The subcutaneous immunization with a fusion protein consisting of the C-
terminal 120 residues of EspA, the C-terminal 282 amino acids of intimin and the Tir 
site for intimin interaction (EIT fusion), reduced the duration of EHEC shedding. 
This effect correlated with the generation of specific IgG antibodies, while no specific 
IgA was detected (Gu et al., 2011). However, specific serum IgG and fecal IgA are 
induced by a plant-based EIT fusion protein when it is orally delivered. This 
induction correlated with reduction in EHEC shedding (Amani et al., 2011).  
Other fused antigens evaluated in mice include a fusion protein comprising B 
subunits of the two types of Stx, Tir and the zonula occludens toxin of the              
Vibrio cholerae CTXφ bacteriophage, which improves antigen delivery by increasing   
epithelial permeability (Zhang et al., 2011b). Subcutaneous immunization with the 
ST2B-Tir-ST1B-Zot fusion protein produced antigen-specific systemic IgG antibodies, 
while i.n. immunization elicited both serum IgG and IgA. Both immunization routes 
decreased bacterial shedding after challenge. In another study, an SSI fusion protein, 
consisting of Stx2B, Stx1B and an intimin fragment, protected mice against large 
doses of EHEC (Gao et al., 2011). Finally, a fusion of the A1 peptide of Stx2 to EspA 
was shown to increase mice survival after intravenous challenge with a lethal dose of 
Stx2 (Cheng et al., 2009).  
3.8.2. Bacterial cell-based vaccines 
Traditional vaccine approaches using attenuated or killed bacteria are still 
evaluated for protection against EHEC infection. EHEC strain 86-24 ler/stx deletion 
mutant as well as its derivative expressing inactive Stx1 and Stx2 were shown to 
reduce the bacterial shedding in mice (Liu et al., 2009).   
Since attenuated pathogenic microorganisms can be associated with risks of 
reverted pathogenicity and side effects, a technology based on bacterial cells devoid 
of their cytoplasmic and nucleic acid contents, has been investigated (Cai et al., 2010; 
Mayr et al., 2005; Mayr et al., 2012). The bacterial ghosts retains intact cellular 
morphology and bacterial surface structures and thus, are highly immunogenic, 
possessing natural adjuvant activity. EHEC N°CIP 105282 bacterial ghosts have been 
produced. A single oral (Mayr et al., 2005) or rectal (Mayr et al., 2012) dose 
immunization was able to stimulate humoral and cellular immune responses and 
protect against a lethal EHEC challenge. Rectal immunization was sufficient to fully 
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protect against one LD50, whereas the protection obtained by oral immunization was 
significantly increased after a boost. Similar results were also obtained for oral 
immunization of mice using EHEC EDL933 bacterial ghosts (Cai et al., 2010), where 
protection increased after a boost. Bacterial ghosts vaccination induced specific IgG 
and IgA in serum and colon, accompanied by a mixed Th1/Th2 cytokine response, 
with Th-2 phenotype dominance (Vilte et al., 2012).  
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Background: 
Lactococcus lactis is a Gram-positive lactic acid bacterium that offers a promising 
biological tool for the delivery of oral vaccines. The bacterium has been traditionally 
used in the food industry and is generally regarded as safe for human consumption 
(FDA “SARG” status). Additionally, .L sitcal is amenable to genetic modification and 
capable of synthesizing heterologous proteins of various origins. Besides its potential 
for antigen delivery, .L sitcal possesses adjuvant properties, which are particularly 
useful to enhance the immune responses to vectored antigens.   
In the present thesis, we explored the utilization of .L sitcal for the development of 
an oral vaccine against Enterohemorrhagic Escherichia coli infection (EHEC) in 
humans. EHEC infection can result in hemorrhagic colitis and the hemolytic uremic 
syndrome, potentially life-threatening conditions that represent serious public health 
concern. Since antibiotic therapy appears to be ineffective in treatment of EHEC 
disease, preventing infection by vaccination would be the choice for people at higher 
risk. However, no vaccine is currently available to prevent the infection. Vaccines 
against enteropathogens should induce immune responses which eliminate or 
neutralize the microorganism. Toxins or structures involved in colonization are 
preferred targets. For EHEC, the type 3 secretion system is important for colonization. 
In this thesis we explored for the first time if intestinal mucosal immunization with 
BpsE, a protein at the tip of the needle formed by the type 3 secretion system, could be 
sufficient to clear infection. Hereto L. lactis strains where constructed that could 
produce the protein and could be used in oral immunization experiments. For a proof 
of concept, we evaluated the protective efficacy of our vaccine in a mouse model. 
However, since pigs offer a more reliable model for EHEC infection as well as for 
human immunity, we addressed the issue of the gastrointestinal survival of .L sitcal, 
one of the most important challenges for the validation of the EHEC .L sitcal-based 
vaccine in pig models.   
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The scope of our research included the following aims: 
1. The development of recombinant L. lactis strains that properly expresses the 
vaccine antigen, EspB, for oral vaccination purposes (Chapters 2 and 3). 
2. Evaluation of the mucosal and systemic antibody and cellular immune 
responses elicited by the vaccine strains in mice upon oral immunization 
(Chapters 2 and 3). 
3. Evaluation of the protective potential of the L. lactis-based EspB vaccine against 
a challenge infection with EHEC in a mouse model (Chapter 3). 
4. Optimization of the survival of the live vaccine-delivery vector in the 
gastrointestinal tract of pigs (Chapter 4).  
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Mucosal priming of the murine immune system 
against enterohemorrhagic Escherichia coli 
O157:H7 using Lactococcus lactis expressing 
the type III secretion system protein EspB 
 
 
 
 
 
 
 
 
 
 
Adapted from 
B. Ahmed, M. Loos, D. Vanrompay, E. Cox., 2013. Mucosal priming of the murine 
immune system against enterohemorrhagic Escherichia coli O157:H7 using Lactococcus 
lactis expressing the type III secretion system protein EspB. Veterinay Immunology 
and Immunopathology, 152, 141-5. 
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2.1. Abstract 
Enterohemorrhagic Escherichia coli (EHEC) have been responsible for multiple 
outbreaks of hemorrhagic colitis and hemolytic uremic syndrome in humans 
worldwide. Humans become infected by direct or indirect contact with feces of 
asymptomatic EHEC shedding ruminants. Currently there is no human vaccine 
available against EHEC infection. EHEC use a Type III secretion system (T3SS) to 
colonize the intestine and therefore eliciting mucosal immunity against T3SS proteins 
could be a potential vaccination strategy. To develop an oral vaccine against EHEC 
infection, EspB, a significant member of the T3SS, was expressed in the cytoplasm of 
Lactococcus lactis. The latter is a generally regarded as safe (GRAS) bacterium that   
has been used as a delivery vector for oral vaccines. The constructed recombinant 
strain (LL-pT:CYT:EspB) was used to immunize BALB/c mice via the oral route.         
Ten days post-immunization, no specific antibody response was detected in serum or 
feces of immunized mice. However, significant levels of specific serum Ig and faecal 
IgA were detected after intraperitoneal boosting of the orally immunized mice with 
purified EspB (P< 0.0001). Our results show that oral administration of LL-
pT:CYT:EspB resulted in mucosal priming of mice against the EHEC T3SS protein, 
EspB. Nevertheless, an optimized EspB expression in L. lactis may be required to 
obtain complete immune response. 
2.2. Introduction  
Enterohemorrhagic Escherichia coli (EHEC) is one group of colonizing 
enteropathogens that has been responsible for frequent outbreaks of diarrhea and 
hemorrhagic colitis (HC) worldwide (Griffin & Tauxe, 1991). HC occasionally 
progresses to hemolytic-uremic syndrome (Janot et al., 2009), which is the most 
common cause of acute renal failure in children (Trachtman et al., 2003) and results in 
fatality rates as high as 50% in the elderly (Carter et al., 1987). HC and HUS are caused 
by shiga-like toxins (Stxs), which are released by colonizing EHEC into the systemic 
circulation and induce endothelial damage in intestinal and renal vasculatures (Serna 
& Boedeker, 2008). Several studies have linked antibiotic therapy to higher rates of 
HUS development and prolonged duration of the symptomatic disease, probably due 
to the excessive release of Stxs upon bacterial lysis (Carter et al., 1987; Pavia et al., 1990; 
Wong et al., 2000; Wong et al., 2012). Therefore, current disease intervention strategies 
are rather focusing on vaccination. However, no vaccine is currently available for 
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EHEC infections. Since the Stxs-mediated EHEC diseases develop subsequent to the 
bacterial intestinal colonization, the latter is considered a key determinant of EHEC 
pathogenicity and represents a potential target for vaccine design. EHEC colonizes the 
intestine with the aid of a type III secretion system (T3SS) which enables the bacteria 
to establish a tight adherence to enterocytes and to modify their cytoskeletal proteins, 
leading to the characteristic attaching and effacing lesion (Hamada, 2010). EspB is a 
T3SS protein that plays a central role in mediating the EHEC enterocyte adherence 
(Frankel et al., 1998; Hamada, 2010; Iizumi et al., 2007; Knappstein et al., 2004; Kodama 
et al., 2002). Moreover, EspB is highly immunogenic in human patients (Asper et al., 
2011; Karpman et al., 2002; Li et al., 2000) and in infected or vaccinated animals (Asper 
et al., 2011; Cataldi et al., 2008). Therefore, EspB is a potential candidate antigen for 
vaccination against EHEC. Oral vaccination can be a particularly efficient approach to 
interfere with EHEC intestinal colonization, as it can effectively induce local immune 
responses at the intestinal mucosa, and concurrently elicit systemic immune responses 
(Neutra & Kozlowski, 2006). Nevertheless, oral vaccines are at the risk of being 
degraded by the harsh gastrointestinal conditions. Thus, vaccine delivery systems 
represent a useful strategy to ensure the efficient oral delivery of antigens (Lycke, 2012; 
Pavot et al., 2012). One of the interesting oral antigen delivery systems is based on 
genetically modified lactic acid bacteria (Yasar et al., 2011) that simultaneously express 
and deliver antigens to the intestinal mucosa (Berlec et al., 2012; Tarahomjoo, 2012). 
LAB have been traditionally used in food industry and are generally regarded as safe 
(GRAS) for human consumption. Therefore, they particularly offer a safe tool for the 
oral delivery of vaccines. Lactococcus lactis is a model LAB that has been extensively 
studied for oral vaccine delivery. Numerous bacterial, viral and parasitic antigens were 
expressed in L. lactis and the resultant recombinant strains were capable of inducing 
specific mucosal and systemic immune responses in mice upon oral administration 
(for a recent review, Wells, 2011). Here, we report the construction of a L. lactis strain 
which constitutively expresses the EHEC antigen, EspB in the cytoplasm (LL-
pT:CYT:EspB). Oral immunization of BALB/c mice with LL-EspB has resulted in 
mucosal priming of the immune system against EspB.  
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2.3. Material and methods 
2.3.1. Bacterial strains and media  
L. lactis subspecies cremoris MG1363 is a derivative of the dairy starter strain  
NCDO712, which was cured of all resident plasmids (Gasson, 1983). L. lactis was 
routinely grown overnight as a standing culture at 30°C in liquid M17 medium       
(Difco, Michigan, USA), supplemented with 0.5% glucose and 5μg/ml erythromycin     
(GM17E). The bacteria reach a saturation density of 2 x 109 cfu/ml within 18 hours of 
incubation. E. coli strains were grown in Luria-Bertani (LB) medium (Difco) at 37°C 
with vigorous shaking. When required, the medium was supplemented with 
ampicillin, at a concentration of 100 μg/ml. Stock suspensions of the recombinant 
strains were made in 50% glycerol and stored at -20°C.  
2.3.2. Plasmid construction for the cytoplasmic expression of EspB in     
L. lactis 
 
 
 
 
 
 
 
Figure 2.1 Schematic illustration of the lactococcal vector for EspB expression. The EspB gene is 
inserted into the parent plasmid pTREX1, downstream of the lactococcal promoter P1 between 
between Bgl II and Spe I restriction sites.  
 
The DNA sequence encoding the EspB gene of E. coli O157:H7 was retrieved from 
the GenBank (Accession no: NC_002655). This sequence was adapted to the 
preferential codon use of L. lactis and artificially synthesized by Genscript (New York, 
USA). The EspB coding sequence was then inserted into the lactococcal expression 
plasmid pTREX1 (Robinson et al., 1997a), downstream of the P1 constitutive promoter, 
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between Bgl II and Spe I restriction sites (Figure 2.1). The resulting pT:CYT:EspB 
plasmid was introduced in L. lactis MG1363 by electroporation (Wells et al., 1993). The 
resulting strain was designated LL-pT:CYT:EspB. 
2.3.3. EspB purification 
E. coli DH5α harboring the pCVD468 was used for the recombinant EspB 
expression and purification (Karpman, 2002 #16). Briefly, the transformed bacteria 
were induced with 1 mM isopropyl-β-d-thiogalactopyranoside and the recombinant 
his-tagged protein was purified by nickel affinity chromatography. 
2.3.4. L. lactis protein extraction  
A saturated overnight culture of the strain LL-pT:CYT:EspB was grown as described 
earlier. Bacteria were harvested by centrifugation at 5000 g for 2 minutes. The cell wall 
was disrupted by resuspending the pellet in Tris-EDTA buffer (10 mM Tris HCl [pH 
8.0], 1 mM EDTA) containing lysozyme (1 mg/ml), and incubating them for 1 hour at 
37°C. After incubation, the digested cells were mechanically homogenized using a 24G 
needle and a clear lysate was obtained by centrifugation of the mixture at 5000 g for 2 
minutes.  
2.3.5. Immunizations 
Two groups of 6 week-old BALB/c mice were intragastrically immunized with either 
LL-pT:CYT:EspB (n=5) or LL-pTREX1 (n=4). The latter is L. lactis MG1363 containing 
the empty vector pTREX1 (sham control). L. lactis cultures were grown overnight in 
GM17E at 30°C. Saturated cultures were harvested by centrifugation and concentrated 
10-fold in buffered M9 salts (Schotte et al., 2000). Each group of mice received three 
cycles of intragastric immunizations with three-week intervals. Each immunization 
cycle consisted of five inoculations of 2 x 109 cfu on five consecutive days. Twenty-one 
days after the last oral immunization all mice were systemically boosted by the 
intraperitoneal injection (i.p.) with 50 μg of purified EspB in incomplete Freund’s 
adjuvant (Sigma-Aldrich). Serum and feces were collected 10 days after each oral 
immunization and after the systemic boost. 
2.3.6. Preparation of serum and faecal samples for ELISA 
Blood was taken and after 1 hour of incubation at 37°C, serum was collected, 
inactivated at 56°C for 30 min, and subsequently treated with kaolin (Sigma-Aldrich). 
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Therefore, 4 volumes of a kaolin suspension (25% [w/v] in PBS) were added to 1 
volume of serum and incubated at room temperature for 30 min. The suspension was 
centrifuged at 5500 g for 10 min, and the supernatant was diluted in ELISA dilution 
buffer, yielding a final serum dilution of 1/10. Immediately after collection, faecal 
pellets were suspended at a concentration of 0.1 g/ml in PBS supplemented with 1% 
(w/v) BSA and complete protease inhibitors (Roche Applied Sciences, Penzberg, 
Germany). After overnight stirring at 4°C, the suspension was centrifuged at 7200 g for 
10 minutes and the supernatant was used for faecal specific IgA detection by ELISA. 
2.3.7. ELISA for EspB-specific antibodies 
A direct ELISA was developed for the detection of EspB-specific antibodies in serum 
or faecal samples. An ELISA plate (Polysorp, Nunc) was coated with 5 μg/ml of 
recombinant EspB in PBS and incubated for 2 hours at 37°C. After incubation, the 
remaining binding sites were blocked by PBS supplemented with 0.2% (v/v) Tween®80. 
Two-fold dilution series of serum or faecal suspensions, starting from the dilution 1:10, 
were prepared in ELISA dilution buffer and were added to the plate, which was 
incubated for 2 hours at 37°C. Subsequently, the wells were treated for 1 hour with 
optimal dilutions of rabbit anti-mouse Ig (for serum) or goat anti-mouse IgA (for 
faeces) labelled with horseradish peroxidase (Dako). The reaction was developed by 
adding ABTS solution containing H2O2 (Roche diagnostics). The optical density was 
spectrophotometrically measured at 405 nm (OD405). Between each incubation step, 
plates were washed three times with PBS supplemented with 0.2% Tween®20. The cut-
off values were calculated as the mean OD405 –value of all sera or faecal suspensions 
(dilution 1:10) at day 0, increased with 3 times the standard deviation. The antibody 
titre is the inverse of the highest dilution that still had an OD405 higher than the 
calculated cut-off value. 
2.3.8. Statistical analysis  
Poisson regression, a model for regression analysis, was used to compare serum or 
faecal titres of individual mice of both groups. Data analysis was performed using 
STATA software, version 11. 
2.4. Results, discussion and conclusion 
L. lactis has been used before for delivery of oral vaccines to the intestinal immune 
system (Kim et al., 2006; Robinson et al., 1997b; Steidler et al., 2003). Here we 
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investigated the mucosal immune responses in mice after oral immunization with an 
L. lactis strain, genetically modified to express the EHEC antigen EspB (LL-
pT:CYT:EspB). EspB expression was quantified in the cytoplasmic contents of LL-
pT:CYT:EspB using a specific sandwich ELISA: 113± 42 ng per 2 x 109 cfu. This rather low 
concentration of EspB expression by L. lactis could be attributed to the cytoplasmic 
targeting of the protein expression, since L. lactis possesses at least two cytoplasmic 
house-keeping proteases, clpP (Frees & Ingmer, 1999) and FtsH (Nilsson et al., 1994), 
as well as DnaK, a cytoplasmic chaperone that may promote proteolysis by 
maintaining the protein in an unfolded state (Koch et al., 1998). 
 
 
 
 
 
 
 
Figure 2.2. EspB-specific antibody titers in serum and feces of the mice immunized orally using 
either LL-pT:CYT:EspB (n=5) or LL-TREX1 (n=4), 10 days after the intraperitoneal boost with 
purified EspB. * = P< 0.0001 
 
No specific antibody responses were detected in the serum or the feces following 
oral immunization with LL-pT:CYT:EspB. Responses remained absent after the third 
cycle of oral immunization. Hence, we further investigated whether priming or oral 
tolerance had been induced against EspB upon the oral administration of LL-
pT:CYT:EspB. Oral tolerance is a state of local and systemic immune unresponsiveness 
that is induced by oral uptake of an innocuous antigen such as food proteins (Andre et 
al., 1975; Iwamoto & Nakao, 1995; Swarbrick et al., 1979). Therefore, the orally 
preimmunized mice were systemically boosted by an i.p. injection of 50 μg of purified 
EspB. Ten days after the systemic boost, specific serum total-Igs and faecal IgA (Figure 
2.2) were detected in both groups. However, the levels of the specific antibodies were 
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significantly higher in the group which received LL-pT:CYT:EspB compared to the 
control group (P< 0.0001). This indicates that oral immunization of BALB/c mice with 
LL-pT:CYT:EspB resulted in a mucosal priming of the immune system against EspB 
and not in oral tolerance. A similar finding was reported by Lamont et al. (Lamont et 
al., 1989), where systemic and intestinal priming of BALB/c was induced by oral 
administration of small doses (10-50μg) of ovalbumin. In conclusion, our results show 
the potential of recombinant L. lactis expressing EspB to be used in EHEC challenge 
experiments. Nevertheless, optimization of the antigen expression is required to obtain 
higher immune responses upon oral immunization.  
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expressing EspB induces protective immune 
responses against Escherichia coli O157:H7 in a 
murine model of colonization 
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3.1. Abstract 
In Chapter 2, we described the construction of a recombinant L. lactis strain 
expressing the EHEC antigen, EspB in the cytoplasmic compartment. However, oral 
immunization of mice with this strain induced weak priming of the immune system. 
This outcome was attributed to the rather low levels of EspB expressed by this 
recombinant strain. Therefore, in the present study we optimized the expression of 
EspB in L. lactis by secreting the antigen either under constitutive or nisin-inducible 
control. Indeed, oral immunization of mice with the EspB-secreting strains 
successfully induced specific mucosal and systemic antibody responses. These 
responses were associated with mixed Th1/Th2 cell responses in Peyer’s Patches and 
mesenteric lymph nodes. Moreover, immunized mice exhibited significant protection 
against E. coli O157:H7 colonization, as indicated by the reduced amount and/or 
duration of the bacterial fecal shedding. Our results demonstrate the protective 
potential of EspB as an oral vaccine against EHEC infection. Additionally, the study 
demonstrates the efficient delivery of recombinant EspB by the generally regarded as 
safe bacterium L. lactis. The safety profile of L. lactis as a vaccine vehicle can 
particularly be beneficial to children and elderly as high-risk groups for HUS 
incidence.  
3.2 Introduction  
In the previous chapter we described the constitutive cytoplasmic expression of 
EspB in L. lactis. However, oral immunization of mice using this recombinant strain 
induced weak priming of the immune system. This outcome was attributed to the low 
levels of EspB expressed by this strain. In the present study, we describe the optimized 
expression of EspB in L. lactis. Additionally, we describe the specific immune 
responses elicited in mice upon oral immunization with the recombinant strains and 
the protection conferred against a challenge infection with E. coli O157:H7.  
3.2. Material and method 
3.2.1. Bacteria, plasmids and culture conditions 
A summary of the bacterial strains and plasmids used in this study is shown in 
Table 3.1. L. lactis was grown at 30°C in liquid M17 medium (Difco) supplemented with 
0.5% glucose. Erythromycin or chloramphenicol was added at concentrations of 5 and 
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10 μg/ml, respectively. E. coli NCTC12900 was grown at 37°C in Luria-Bertani broth 
(Difco) supplemented with 80, 15 and 100 µg/ml of novobiocin, naladixic acid and 
streptomycin, respectively. 
3.2.2. Constructions of the EspB-expressing L. lactis strains 
Plasmids pT:SEC-EspB and pNZ:SEC-EspB were constructed for constitutive or 
nisin-inducible secretion of EspB, respectively (Table 3.1 and Figure 3.1).  
 
Table 3.1. Bacterial strains and plasmid vectors  
Plasmid or strain Description Reference 
L. lactis subsp. 
cremoris MG1363 
A derivative of the dairy starter strain 
NCDO712, which was cured of all resident 
plasmids 
Gasson, 1983 
L. lactis NZ9000 L. lactis subspecies cremoris MG1363 carrying 
nisR and nisK genes on the chromosome 
Kuipers et al., 1998 
LL-pTREX L. lactis subspecies cremoris MG1363 carrying 
plasmid pTREX 
Chapter 2 
LL-pNZ8150 L. lactis NZ9000 carrying  plasmid pNZ8150 This study 
LL-pT:CYT:EspB L. lactis subspecies cremoris MG1363 carrying 
plasmid pT:CYT:EspB 
Chapter 2 
LL-pT:SEC:EspB L. lactis subspecies cremoris MG1363 carrying 
plasmid pT:SEC:EspB 
This study 
LL-pNZ:SEC:EspB L. lactis NZ9000 carrying plasmid 
pNZ:SEC:EspB 
This study 
E. coli NCTC12900 Shiga toxin-negative mutant of E. coli 
O157:H7,
 
Nov
R
, Nal
R 
and Str
R
 
Woodward et al., 2003 
pTREX1 
 
Lactococcal expression plasmid containing P1 
promoter with downstream start codon and 
Wells and Schofiled, 
1996 
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 secretion signal (SPUsp45), Em
R
 
pNZ8150 
 
 
Lactococcal expression plasmid containing 
PnisA promoter with downstream start 
codon, Cm
R
 
Mierau & 
Kleerebezem, 2005 
pT:CYT:EspB Modified pTREX1 containing P1 promoter with 
downstream espB gene, Em
R
 
Chapter 2 
pT:SEC:EspB Modified pTREX1 containing P1 promoter with 
downstream secretion signal (SPUsp45) and 
espB. Em
R
 
This study 
pNZ:SEC:EspB Modified pNZ8150 containing PnisA promoter 
with downstream secretion signal (SPUsp45) 
and espB. Cm
R
 
This study 
NalR, StrR, CmR, EmR is resistance against naladixic acid, streptomycin, 
chloramphenicol and erythromycin, respectively. 
 
For construction of plasmid pT:SEC-EspB, the espB gene was PCR amplified from 
plasmid pT:CYT-EspB using sequence-specific primer pairs (forward 5´-
GGGGGATCCAACACTATCGATAACACTCAAG-3´; reverse: 5´-GGGACTAGTTTAACCAGCAA 
GACG-3´). pT:CYT-EspB carries a codon optimized espB gene of E. coli O157:H7 
(Genbank Accession no: NC_002655), adapted to the preferential codon use of L. lactis. 
The amplified espB gene was inserted downstream of the secretion signal peptide 
SPUsp45 at the BamHI/SpeI ends of pTREX1 (Figure 3.1). For the construction of          
plasmid pNZ:SEC-EspB, espB along with SPUsp45 (SPUsp45-espB) was PCR amplified     
from pT:SEC-EspB using sequence-specific primer pairs (forward 5´-
ATGAAAAAAAAGATTATCTCAGC-3´; reverse: 5´-GGGACTAGTTTAACCAGCAAGACG-3)´and 
was inserted at the ScaI/SpeI ends of plasmid pNZ8150 (Figure 3.1). Plasmids pT:SEC-
EspB and pNZ:SEC-EspB were used to transform electrocompetent L. lactis MG1363 
and L. lactis NZ9000 (Wells et al., 1993) to obtain the recombinant strains LL- pT:SEC-
EspB and LL- pNZ:SEC-EspB, respectively (Table 3.1).   
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Figure 3.1. espB gene cloning for secretion of EspB in L. lactis. (A) The expression plasmid 
pTREX1 containing the constitutive promoter P1 and the secretion peptide signal SP-Usps45 was 
used for the insertion of the espB coding sequence between BamHI and SpeI restriction sites to 
form the plasmid pT:SEC:EspB. (B) The expression plasmid pNZ8150 containing the nisin-
inducible promoter PnisA was modified by inserting a fragment combining the espB gene to an 
upstream secretion signal (SPUsp45-espB) between ScaI and SpeI restriction sites to form the 
plasmid pNZ:SEC:EspB.     
 
3.2.3.  Induction and quantification of EspB expression in L. lactis  
Overnight cultures of the inducible LL-pNZ:SEC:EspB strain or the constitutive, LL-
pT:CYT:EspB and LL-pT:SEC:EspB strains were inoculated in GM17 broth at dilutions 
of 1:25 and 1:100, respectively. All strains were grown to an optical density at 600 nm of 
 Oral immunization with Lactococcus lactis-expressing EspB induces  
protective immune responses against Escherichia coli O157:H7 in a murine model of colonization 
 
 
109 
 
0.4, at which, nisin (10 ng/ml) was added to the culture medium of LL-pNZ:SEC:EspB. 
LL-pT:CYT:EspB and LL-pT:SEC:EspB cells were harvested by centrifugation and 
resuspended in buffered-GM9 (BGM9) medium (Schotte et al., 2000). After a further 
4h incubation, cells or supernatant of equal culture volumes were collected for each 
strain. L. lactis cell lysates were enzymatically obtained as described in Chapter 2. EspB 
was detected and quantified in cell lysates and supernatants of the L. lactis cultures 
using a specific sandwich ELISA, as described in Chapter 2.  
3.2.4. Oral immunization of mice with the EspB-expressing L. lactis strains 
Six-week-old female BALB/c mice were used in the animal experiments. All 
experimental and animal management procedures were approved by the animal care 
and ethics committee of Ghent University, Belgium. The lactococcal strains were 
grown and induced as described above. Cells of the inducible strain were washed twice 
with sterile PBS to remove the traces of nisin. Groups of nine mice were immunized 
orally with LL-pT:SEC:EspB, LL-pNZ:SEC:EspB, purified EspB, LL-pTREX1, LL-pNZ8150 
or the inoculation medium BGM9 (Schotte et al., 2000). Mice received a primary 
immunization and a single booster immunization, with three weeks interval. For each 
of the immunizations, an oral inoculum of 100 µl BGM9 containing 2   109 CFU of the 
proper lactococcal strain or 5 µg of purified EspB was given to each mouse daily for 
three consecutive days.  
3.2.5. EspB-specific antibodies 
Total serum EspB-specific immunoglobulins (total-Ig) and faecal IgA were 
measured 10 days after the booster immunization. Preparation of serum and fecal 
extracts as well as the ELISA procedures were performed as described in Chapter 2. 
The cut-off values were calculated as the mean OD405 –value of all sera or faecal 
suspensions (dilutions 1:10 and 1:5, respectively) at day 0, increased with 3 times the 
standard deviation. The antibody titre is the inverse of the highest dilution that still 
had an OD405 higher than the calculated cut-off value. 
3.2.6. Cytokine ELISA’s 
Peyer’s patches (PP) and mesenteric lymph node (MLN) lymphocytes were isolated 
from immunized mice (n=3), 10 days after the booster immunization. Cells were 
resuspended at a concentration of 1.5×106 cells/ml in complete RPMI-1640 medium 
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(Sebastiani et al., 2001) and cultured in 96-well plates. Cells were restimulated with 
EspB (final concentration: 10 µg/ml) for 48h. Thereafter, supernatants were collected 
and assayed for murine INF-γ, IL-4 and IL-10 by quantitative ELISA using the mouse 
Th1/Th2 ELISA Ready-SET-Go® kit (eBioscience), according to the manufacturer’s 
instructions. 
3.2.7. Challenge with E. coli O157:H7 
Groups of seven mice were immunized as described above. Ten days after the 
booster immunization, mice of each group were randomly divided into two subgroups, 
of which, one subgroup (n=4) received streptomycin (5 g/L) in drinking water 24 hours 
before infection and till the end of the experiment, while the other subgroup (n=3) was 
not treated with streptomycin. These subgroups represent two models of varying 
colonization intensities, since streptomycin treatment enhances EHEC colonization in 
mice by clearing the competing intestinal flora (Wadolkowski et al., 1990). Mice were 
challenged by intragastric inoculation of 1010 CFU of E. coli NCTC12900 in 100 µl of PBS 
containing 20% sucrose. Faecal excretion of E. coli NCTC12900 was monitored at 2-3 
days interval, by both conventional bacterial plating and immuno-magnetic 
separation, as previously described (Walle et al., 2011). 
3.2.8.  Statistical analyses 
Statistical analyses were performed using GraphPad Prism 6 software (GraphPad 
Software Inc.). One-way analysis of variance (ANOVA) with Bonferroni post-hoc test 
was used to analyze the differences in EspB expression levels among the strains as well 
as the differences in antibody titers, cytokine ratios and duration of fecal shedding 
among the groups. Pair-wise comparison of individual cytokine levels among 
immunized and control groups were analyzed using Student’s t-test. Two-way ANOVA 
with Bonferroni post-hoc test was used to analyze the differences in fecal loads of 
E. coli NCTC12900 over time among the groups. Differences with a P< 0.05 were 
considered statistically significant. 
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3.3. Results 
3.3.1. ELISA quantification of EspB expression by the recombinant L. lactis 
strains 
EspB was detected only in the cell lysate of LL-pT:CYT:EspB, while it was detected 
in both cell lysates and supernatants of LL-pNZ:SEC:EspB and LL-pT:SEC:EspB (Table 
3.2). The detection of EspB in cell lysates of the EspB-secreting strains corresponds to 
the presence of the cytoplasmic precursor of the mature (secreted) protein. The total 
amount of EspB expressed by the secreting strains LL-pNZ:SEC:EspB and LL-
pT:SEC:EspB (both cytoplasmic and secreted) was respectively 56- and 25-fold higher 
than that expressed by the cytoplasmic expression strain LL-pT:CYT:EspB (P< 0.05). 
The nisin-inducible LL-pNZ:SEC:EspB strain showed a 2.2-fold higher total EspB 
expression than the constitutive LL-pT:SEC:EspB strain (P< 0.05) (Table 3.2). Both LL-
pNZ:SEC:EspB and LL-pT:SEC:EspB were used for the immunization experiments. 
 
Table 3.2. ELISA quantification of EspB production by the recombinant L. lactis  
strains  
Strain Expression features 
 
EspB expression in fractions of cultures 
(µg/ml)
†
 
Cell lysate Supernatant Total 
LL-pT:CYT:EspB Constitutive cytoplasmic 0.082± 0.02 ND
*
 0.082± 0.02
a
 
LL-pNZ:SEC:EspB Nisin-inducible secretion 0.83± 0.19 3.8± 1.1 4.63± 1.29
a
 
LL-pT:SEC:EspB Constitutive secretion 0.15± 0.05 1.9± 0.4 2.05± 0.45
a
 
 
 
†
 Culture density approximately equal to 8 x 10
8
 cfu/ml. Data represent means ± standard 
deviation of three independent measurements.  
a
 Significant differences among the strains using one way-ANOVA with Bonferroni post-hoc 
test (P ˂ 0.05).  
 * 
ND; non detectable 
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3.3.2. EspB-secreting L. lactis strains induce specific antibody responses after 
oral administration to mice 
Mice orally immunized with either LL-pNZ:SEC:EspB or LL-pT:SEC:EspB showed 
significantly higher levels of EspB-specific serum total-Igs (P˂ 0.0001) and faecal IgA 
(P˂ 0.0001) compared to those immunized with the corresponding control strains, LL-
pNZ8150 and LL-pTREX1, respectively (Figure 3.2). The highest antibody responses 
were elicited by the nisin-inducible strain LL-pNZ:SEC:EspB compared to the 
constitutive strain LL-pT:SEC:EspB (P˂ 0.0001). Mice immunized with purified EspB 
showed no significant difference in total serum total-Ig and faecal IgA compared to 
those receiving the BGM9 medium.  
3.3.3. Oral immunization with L. lactis-secreting EspB induces mixed Th1/Th2 
immune response  
To characterize the cellular immune responses induced by the oral immunization 
with the EspB-secreting L. lactis strains, the production of INF-γ (Th1 cytokine), IL-4 
(Th2 cytokine) (Neurath et al., 2002)] and IL-10 (a broadly expressed anti-
inflammatory cytokine) (Neurath et al., 2002; Saraiva & O'Garra, 2010) was measured in 
PP (Figure 3.3A) and MLN (Figure 3.3C) lymphocytes after in vitro restimulation with 
EspB. Lymphocytes of both LL-pT:SEC:EspB and LL-pNZ:SEC:EspB immunized mice 
showed a significant higher production of all cytokines compared to those immunized 
with LL-pTREX1 and LL-pNZ8150, respectively (P< 0.0001). This finding indicates a 
mixed Th1/Th2 cell response. Mice immunized with purified EspB showed no 
significant increase in cytokine production compared to those received the BGM9 
medium. 
To determine the Th1/Th2 cell-type dominance, the IL-4/INF-γ ratio was further 
analyzed for PP (Figure 3.3B) and MLN (Figure 3.3D) lymphocytes. The ratio in both 
LL-pNZ:SEC:EspB and LL-pT:SEC:EspB immunized mice was greater than one and was 
significantly higher than the baseline ratios shown by control mice immunized with 
the respective empty vector strain or with the BGM9 medium. This finding indicates a 
dominance of the Th2 response. 
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Figure 3.2. Antibody responses in mice immunized with EspB-secreting lactococci. Groups of 
mice (n=9) were immunized using the constitutive strain LL-pT:SEC:EspB, the inducible strain 
LL-pNZ:SEC:EspB or purified EspB. Corresponding control groups were immunized using LL-
pTREX1, LL-pNZ8150 or the oral inoculation medium, BGM9. Ten days after the booster 
immunization serum and fecal samples were assayed by ELISA for the presence of EspB-specific 
total-Ig (A) or IgA (B) respectively. Data present the mean ± SD. Statistical differences were 
determined using one-way ANOVA with Bonferroni post-hoc test (* p < 0.0001; NS= non 
significant difference).  
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Figure 3.3. Cytokine responses of Peyer’s Patches (PP) (A and B) and mesenteric lymph nodes 
(MLN) (C and D) lymphocytes from mice orally immunized with EspB-secreting L. lactis. Ten 
days after the booster immunization, lymphocytes were isolated from PP and MLN of mice 
(n=3) of immunized mice; restimulated with EspB, and assayed for production of IFN-γ, IL-4 
and IL-10 cytokines. Data present the mean ± SD. Asterisks indicate significant difference 
between the immunization groups LL-pT:SEC:EspB, LL-pNZ:SEC:EspB and EspB compared to 
the control groups LL-pTREX1, LL-pNZ8150 and BGM9, respectively (P< 0.05). Statistical 
differences were determined using Student’s t-test (P< 0.05). IL-4/INF-γ ratios were calculated 
to determine the dominant T-helper response in PP (B) and MLN lymphocytes (D). Data 
present the mean ± SD. Asterisks indicate significant difference between the immunization 
groups LL-pT:SEC:EspB and LL-pNZ:SEC:EspB compared to the respective control groups LL-
pTREX1 and LL-pNZ8150, or to the BMG9 control group (P< 0.05). Statistical differences were 
determined using one-way ANOVA with Bonferroni post-hoc test (P< 0.05). 
 
 
 
 Oral immunization with Lactococcus lactis-expressing EspB induces  
protective immune responses against Escherichia coli O157:H7 in a murine model of colonization 
 
 
115 
 
3.3.4. Oral immunization with L. lactis-secreting EspB protects mice against 
E. coli O157:H7 colonization 
Comparisons of E. coli O157:H7 fecal counts among the immunization groups   
within either the streptomycin-treated (Figure 3.4A) or the non-streptomycin-treated 
(Figure 3.4B) challenge groups show significantly reduced counts in LL-pNZ:SEC:EspB 
and LL-pT:SEC:EspB groups in comparison to LL-pNZ8150 and LL-pTREX1 groups, 
respectively, or to the BGM9 group, at most of the time points (P< 0.05). This 
reduction was significantly higher in the LL-pNZ:SEC:EspB immunization group 
compared to the LL-pT:SEC:EspB group (P< 0.05) (Figures 3.4 A and B).   
Additionally, comparisons of the durations of E. coli O157:H7 fecal shedding among 
the streptomycin-treated immunization groups show a significantly shorter duration 
in the LL-pNZ:SEC:EspB group (11.52 ± 2.87 days) compared to LL-pNZ8150 and BGM9 
groups (30.5 ± 1.73 and 29.75 ± 1.5 days, respectively) (P< 0.05). However, the duration 
of fecal shedding shown by the LL-pT:SEC:EspB group was not significantly shorter 
than that of the LL-pTREX1 or the BGM9 group (26.75 ± 1.5 days versus 29.75 ± 1.5 
days). Within the non-streptomycin-treated immunization groups, the duration of 
fecal shedding shown by the LL-pNZ:SEC:EspB group (11.52 ± 2.87  days) and the LL-
pT:SEC:EspB group (16 ± 1.73 days) was significantly shorter than that of the LL-
pNZ8150 group (19.3 ± 2.31 days) and the LL-pTREX1 group (22 days), respectively or 
than that of the BGM9 group (22 days) (P< 0.05). The shorter duration of fecal 
shedding shown by the LL-pNZ:SEC:EspB group in comparison to the LL-pT:SEC:EspB 
group was significant (P< 0.05).  
3.4. Discussion and conclusion 
We have previously described the constitutive cytoplasmic expression of EspB in L. 
lactis (LL-pT:CYT:EspB) (Chapter 2). However, oral vaccination of BALB/c mice with 
this strain induced a weak priming the immune system. This outcome was attributed 
to the low amount of EspB expressed by LL-pT:CYT:EspB, presumably due to the 
antigen degradation by the lactococcal cytoplasmic proteases (Frees & Ingmer, 1999; 
Koch et al., 1998; Nilsson et al., 1994). Therefore, in the present study we hypothesized 
that secretion could allow EspB to escape cytoplasmic proteolysis and thus would 
result in a higher expression yield. 
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Figure 3.4. Kinetics of fecal shedding of E. coli O157:H7 in mice immunized orally with EspB 
secreting lactococci. Ten days after the booster immunization, groups of immunized mice were 
orally challenged with 10
10
 cfu of E. coli NCTC12900 (a non-toxigenic mutant of E. coli O157:H7), 
either under oral streptomycin treatment condition (n=4) (A) or without streptomycin 
treatment (n=3) (B). Data present the mean ± SD. Data points in rectangles indicate a 
significant difference between the LL-pT:SEC:EspB and pNZ:SEC:EspB immunization groups 
compared to the respective control groups LL-pTREX1 and LL-pNZ8150 or to the BGM9 control 
group (P< 0.05). Asterisks indicate statistical differences between the LL-pT:SEC:EspB and LL-
pNZ:SEC:EspB immunization groups (P< 0.05). Data present the mean ± SD. Statistical 
differences were determined using two-way ANOVA with Bonferroni post-hoc test (P< 0.05). 
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Additionally, we compared a nisin-inducible and a constitutive expression system 
for the highest protein expression. In accordance with our hypothesis, secretion of 
EspB either under constitutive (LL-pT:SEC:EspB) or inducible (LL-pNZ:SEC:EspB) 
conditions resulted in a great enhancement of the total antigen yield compared to the 
cytoplasmic expression by LL-pT:CYT:EspB (56- and 25-fold increase, respectively). A 
similar enhancement of the total protein yield by secretion in comparison to 
cytoplasmic expression has been reported for the expression of the staphylococcal 
nuclease (Bermudez-Humaran et al., 2003) and the Brucella abortus ribosomal protein 
L7/L12 (Ribeiro et al., 2002) in L. lactis.  
The immune response induced by the EspB-secreting lactococci is expected to be 
influenced by EspB expression levels, which are at least two times higher for the nisin-
inducible strain, LL-pNZ:SEC:EspB compared to the constitutive strain, LL-
pT:SEC:EspB. On the other hand, LL-pT:SEC:EspB is capable of constant secretion of 
EspB during the intestinal passage, which may compensate for the higher expression 
levels of LL-pNZ:SEC:EspB, whereas LL-pNZ:SEC:EspB may not continue EspB 
secretion along the entire duration of its intestinal passage as nisin is absent in vivo. 
However, the highest immune responses were obtained by the inducible LL-
pNZ:SEC:EspB strain. In this regard, previous reports have demonstrated the ability of 
nisin-inducible expression systems to continue protein expression for at least ten 
hours after removal of nisin from the culture medium (Bermudez-Humaran et al., 
2003). Additionally, considering that the reported transit time of L. lactis throughout 
the mouse gastrointestinal tract is approximately 12 hours (Kimoto et al., 2003), it is 
highly likely that both strains had a comparable persistence of EspB secretion in vivo, 
while the higher responses induced by LL-pNZ:SEC:EspB are a direct result of its 
higher capacity for EspB expression. 
Unlike the mice immunized with the EspB-expressing L. lactis strains, those 
immunized with purified EspB did not show specific immune responses, even though 
EspB was given at a dose approximately equal to that present in the inoculum of LL-
pT:SEC:EspB (5 µg). This finding could be explained by the ability of L. lactis to 
maintain metabolic activity (Drouault et al., 1999; Huibregtse et al., 2007; Steidler et 
al., 2000) and de novo secretion of recombinant proteins (Huibregtse et al., 2007; 
Steidler et al., 2000) during its gastrointestinal passage, leading to the delivery of 
higher amounts of EspB than those measured in the administered inocula (Hou et al., 
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2011). Additionally, purified EspB could have been influenced by the degrading effects 
of the gastrointestinal acidity and enzymes, a bottleneck that can be overcome by 
using L. lactis as an antigen delivery vector. Moreover, L. lactis exhibits adjuvant 
effects (Yam et al., 2008), which can enhance the immune response to recombinant 
EspB in comparison to the purified protein (Adel-Patient et al., 2005; Chatel et al., 
2001; Marelli et al., 2011). These arguments support the pharmacological and the 
immunological value of L. lactis as an oral antigen delivery system (Cho et al., 2007; 
Robinson et al., 1997; Saez et al., 2012). 
To characterize the cellular immune responses induced by oral immunization of 
mice with the EspB-secreting strains, we isolated lymphocytes from PP and MLN, the 
main inductive sites of the gut mucosal immune system (Pabst & Rothkotter, 2006) 
and measured the production of INF-γ (Th1 cytokine) and IL-4 (Th2 cytokine) 
(Neurath et al., 2002) after stimulating the cells with EspB in vitro. Both cytokines were 
produced by lymphocytes of immunized mice, indicating the induction of a mixed 
Th1/Th2 cell response. Previous reports have similarly described a mixed Th1/Th2 cell 
response to antigens orally delivered by L. lactis (Cauchard et al., 2011; Robinson et al., 
1997; Villena et al., 2008). Additionally, analysis of the IL-4:INF-γ ratio’s indicated a 
dominance of the Th2 response. The Th2 dominance corresponds well with the 
induced mucosal IgA responses, since Th2 cells and cytokines are known to contribute 
to mucosal IgA class switching in PP and MLN (Okahashi et al., 1996; Yamamoto et al., 
1996).  
Reduced intestinal colonization is considered an important criterion for 
protection against EHEC virulence (Judge et al., 2004a; Oliveira et al., 2012). Our 
findings show that oral immunization of mice with the EspB-secreting L. lactis strains 
resulted in a reduction of E. coli O157:H7 fecal shedding. Moreover, the reduced 
bacterial shedding was consistent in two infection models of varying colonization 
intensities indicating the efficacy and the reproducibility of our vaccination approach. 
This pattern of protection could be correlated with an intestinal EspB-specific IgA 
response, which is consistent with the protective role of secretory IgA in mucosal 
infections (Pavot et al., 2012). Previous mucosal immunization studies involving T3SS 
proteins demonstrated a reduction in the fecal shedding of EHEC after oral challenge 
(Amani et al., 2011; Babiuk et al., 2008; Gu et al., 2011; Judge et al., 2004b; Fan et al., 
2012; Wan et al., 2011). Indeed, in these studies, the protection against intestinal 
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colonization was accompanied by the detection of specific IgA antibodies in the feces 
of immunized mice. In fact, IgA antibodies seem to be important for protection, since 
in some of these studies, protection could not be afforded by parenteral immunization, 
which elicited systemic antibody responses, but not intestinal IgA responses (Babiuk et 
al., 2008; Fan et al., 2012; Wan et al., 2011). With regard to EspB, previous reports have 
described the protective effect of parenteral vaccination with formulations containing 
EspB (Vilte et al., 2011; Yekta et al., 2011). However, these studies were performed in 
cattle, a species in which IgG responses contribute largely to intestinal mucosal 
protection. The present study, however, is the first to describe the protective potential 
of EspB upon oral vaccination.  
In conclusion, oral immunization of mice with recombinant L. lactis secreting 
EspB induces specific mucosal and systemic immune responses and confers protection 
against an E. coli O157:H7 challenge infection. These findings demonstrate the 
feasibility of an oral vaccine based on the recombinant expression of EspB in L. lactis 
to control EHEC infection. The safety profile of L. lactis as a vaccine delivery vector can 
particularly be beneficial to children and elderly, the high-risk groups for HUS 
complications (Griffin & Tauxe, 1991) 
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4.1. Abstract 
Lactococcus lactis has recently emerged as an efficient system for the oral delivery 
of various prophylactic and therapeutic molecules. However, previous studies 
described a moderate capacity of L. lactis to survive the gastrointestinal (GI) passage. 
Improving the GI survival of L. lactis can directly enhance its efficiency as a live 
delivery vector. Therefore, we first evaluated the sensitivity of L. lactis to some 
potentially harmful digestive factors, including bile and the pancreatic enzymes, 
trypsin, lipase and amylase. Secondly, we evaluated the capacity of aluminium 
hydroxide (a bile acid binder) and camostat mesylate (a trypsin inhibitor) to protect 
L. lactis against bile toxicity and trypsin hydrolysis, respectively. The experiments were 
designed to mimic the physiological conditions described in the small intestine of pigs, 
a model species with a particular resemblance to human in regard to GI physiology. 
Incubation of L. lactis with intestinal concentrations of porcine bile resulted in a 
marked decrease in its survival, compared to the non-bile-treated controls (P< 0.0001). 
Moreover, the physiological pH ranges in the small intestine were found to influence 
the survival of L. lactis in bile since a significantly lower survival of the bacterium was 
observed at pH 5.5 compared to pH 6.8 (P< 0.0001). This finding indicates a positive 
correlation between bile toxicity and acidity. Similar to bile, incubation of L. lactis with 
trypsin, amylase and lipase at their physiological concentrations was found to 
significantly decrease the survival of L. lactis (P< 0.0001). The effect of trypsin was 
most pronounced with a 80% decrease in L. lactis survival versus 51% and 40% for 
amylase and lipase, respectively (P<0.001). The presence of aluminium hydroxide and 
camostat mesylate could significantly improve the survival of L. lactis in bile and 
trypsin solutions, respectively (P<0.05). We finally demonstrated that oral co-
administration of aluminium hydroxide and camostat mesylate with L. lactis can 
improve the survival of the bacterium in the GI tract of pigs. This was indicated by a 
38- and 24-fold increase in the L. lactis counts retrieved from jejunal and ileal contents, 
respectively, of treated pigs compared to untreated (P<0.001). Our results represent an 
early proof of concept for the feasible use of aluminium hydroxide and camostat 
mesylate as ingredients of oral L. lactis formulations, in order to improve the GI 
survival of the bacterium and subsequently enhance its efficacy in the intestinal 
delivery of antigens.   
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5.1. Introduction 
Lactococcus lactis is a Gram-positive bacterium that offers a potential platform for 
the oral delivery of various therapeutic and prophylactic molecules (Berlec et al., 2012). 
The bacterium has been widely used in food industry and is generally recognized as 
safe (GRAS) for human consumption (Casalta & Montel, 2008). This safety profile has 
particularly encouraged the utilization of L. lactis for the development of a new 
generation of safe oral delivery vectors. Additionally, L. lactis is an efficient cell factory, 
capable of recombinant expression and mucosal delivery of a wide variety of target 
proteins (Bahey-El-Din et al., 2010). Today, there is a vast collection of reports 
describing the use of live recombinant L. lactis for the intestinal delivery of therapeutic 
proteins (Steidler et al., 2000; Vandenbroucke et al., 2004; Zhuang et al., 2008), 
allergens (Adel-Patient et al., 2005; Huibregtse et al., 2007) and vaccine antigens 
(Cauchard et al., 2011; Cho et al., 2007; Robinson et al., 2004), with prominent 
therapeutic and protective outcomes in murine models. Furthermore, the therapeutic 
use of recombinant L. lactis for the intestinal delivery of human IL-10 has recently been 
the subject of clinical trials in patients with Crohn’s disease (Braat et al., 2006) and 
moderate ulcerative colitis (ActoGenix press release, 2009). Besides the efficient 
delivery of protein antigens, the ability of L. lactis to deliver DNA vaccines to 
enterocytes has recently been demonstrated in mice models (de Azevedo et al., 2012; 
Guimaraes et al., 2005; Innocentin et al., 2009).  
One of the most important factors for the efficient oral delivery of protein and DNA 
molecules by bacteria is their ability to survive the GI conditions (Bahey-El-Din & 
Gahan, 2011). Previous studies in humans have demonstrated a low recovery of L. lactis 
from ileum (Vesa et al., 2000) or stool (Klijn et al., 1995) in comparison to Bacillus 
stearothermophilus (Klijn et al., 1995) and Lactobacillus fermentum (Klijn et al., 1995; 
Vesa et al., 2000), which are known for their tolerance to GI transit. Also studies in 
mouse (Drouault et al., 1999) and pig (Drouault et al., 2002; Termonts, 2005) models 
demonstrated a severe reduction in the recovery of orally administered L. lactis, 
particularly from stomach, duodenum and jejunum in comparison to ileum and the 
large intestine. This low survival rate in the posterior GI tract indicates a detrimental 
influence of the physiological conditions encountered in these gastrointestinal 
compartments on the survival of L. lactis during its GI passage. Enteric-coating is a 
well-established technology that overcomes the detrimental effect of gastric acidity on 
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orally delivered drug molecules, has been explored for the protection of various live 
probiotic bacteria (Klayraung et al., 2009; Stadler & Viernstein, 2003) and bacterial 
vectors, including L. lactis (Edwards et al., 2010; Huyghebaert et al., 2005; Poelvoorde 
et al., 2008). Nevertheless, exploring additional strategies for the protection of L. lactis 
against the deleterious intestinal conditions is necessary for a more efficient delivery of 
protein and DNA molecules to intestinal targets. The successful application of such 
protective strategies requires the identification of these digestive factors, which 
influence the viability of L. lactis in the small intestine most.  
In the present study we performed a series of in vitro experiments to evaluate the 
individual effects of some potentially harmful intestinal digestive factors, including 
bile and the pancreatic enzymes, trypsin, amylase and lipase, on L. lactis survival. 
Additionally, we demonstrated the capacity of aluminium hydroxide (an oral bile acid 
binder) and camostat mesylate (a synthetic ester with oral bioavailability as a trypsin 
inhibitor) to protect L. lactis in vitro against bile and trypsin toxicity, respectively. All 
the in vitro experiments were performed with respect to the physiological conditions 
described in the small intestine of pigs. This allowed us to validate in vivo in piglets the 
capacity of aluminium hydroxide and camostat mesylate to protect L. lactis against bile 
toxicity and trypsin hydrolysis, respectively. Interestingly, the pig is considered a good 
experimental model for human, particularly in biomedical research (Kristy N. Kuzmuk, 
2011; Litten-Brown et al., 2010) and more specifically in gastrointestinal research. 
Several anatomical and physiological features of the digestive system are highly similar 
between pigs and humans (Darragh & Moughan, 1995; Eubanks et al., 2006; Moughan 
PJ, 1992; Rowan et al., 1994). Therefore, findings of our study can have important 
implications for the development of oral formulations that enable an increased survival 
of L. lactis in the intestinal tract and thus a more efficient intestinal delivery of target 
molecules using this GRAS bacterium.   
5.2. Materials and Methods 
5.2.1. Bacterial strain, growth conditions and survival determination 
L. lactis subspecies cremoris MG1363 is a plasmid free derivative of the dairy starter 
strain NCDO712 (Gasson, 1983) and is the particular lactococcal strain used for 
mucosal delivery of biomolecules (Bermudez-Humaran et al., 2011). In the present 
study, we used a L. lactis MG1363 strain that carries an erythromycin resistance 
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cassette on the pTREX1 plasmid and that was selected for rifampicin resistance based 
on a spontaneous mutation. The strain was routinely grown overnight at 30°C in liquid 
M17 medium (Difco, Michigan, USA), supplemented with 0.5% glucose, 5 μg/ml 
erythromycin and 100 μg/ml rifampicin (GM17EMR). A saturated ON culture contains 
approximately 2x109 CFU/ml. L. lactis survival was assessed by conventional plating; 
ten-fold dilution series were plated in duplicates or triplicates on GM17EMR plates.  
5.2.2. Animals and sampling procedures 
Five to six week-old pigs (Belgian Landrace x Piétrain) were used for collection of 
bile and intestinal contents as well as for the in vivo experiment. All the experimental 
procedures were undertaken in accordance with the regulations of the animal welfare 
and the ethics committee of the University of Ghent, Belgium. Euthanasia was 
performed by intravenous injection of pentobarbital (24mg/kg; Nembutal, Sanofi Santé 
Animale, Brussels, Belgium). For isolation of intestinal contents, ligations were applied 
immediately after euthanasia to prevent mixing of duodenal, jejunal and ileal contents, 
which thereafter, were separately collected. Hepatic bile was collected from the 
gallbladder under aseptic conditions. 
5.2.3. Total bile acids measurement 
The total molar concentration of bile acids was measured in hepatic bile or in 
intestinal contents using a colorimetric enzymatic cycling assay kit (Total Bile Acids 
Assay Kit, Bioquant, California, USA). Briefly, in the presence of Thio-NAD, the 
enzyme 3α-hydroxysteroid dehydrogenase (3α-HSD) converts bile acids to 3-keto 
steroids and Thio-NADH. The reaction is reversible and 3α-HSD can convert 3-keto 
steroids and Thio-NADH to bile acids and Thio-NAD. In the presence of excess NADH, 
the enzyme cycling occurs efficiently and the rate of formation of Thio-NADH is 
determined by measuring the specific change of absorbance at 405 nm. 
5.2.4. Survival and protection of L. lactis in porcine bile and pancreatic 
enzymes in vitro  
For evaluation of survival in bile, bacterial cells of one ml of a saturated overnight 
L. lactis culture (starting culture) were resuspended in physiological saline (0.9% 
NaCl), complemented with different molar concentrations of bile acids, that 
approximately correspond to those measured in the different compartments of the 
small intestine (duodenum, jejunum and ileum). Non-bile-treated control culture was 
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prepared by resuspending cells of one ml of the starting culture in physiological saline 
in absence of bile. For evaluation of survival in pancreatic enzymes, cells of three 
independent starting cultures were resuspended in PBS individually containing 
porcine trypsin, amylase or lipase (Sigma, Missouri, USA), at concentrations of 2.2, 70 
and 10 IU/ml, respectively. These concentrations approximately correspond to the 
physiological concentrations of these enzymes in the small intestine of pigs 
(Hedemann & Jensen, 2004). Non-enzyme-treated control cultures were prepared for 
each enzyme from its respective starting culture. For amylase and lipase, PBS was 
supplemented with 0.9 mM Ca2+ and 0.49 mM Mg2+ to ensure functionality of the 
enzymes.  
For protection of L. lactis against bile toxicity, cells of one ml of a saturated 
overnight culture were resuspended in saline solution containing the highest molar 
concentration of bile detected in the small intestine, together with a dose-gradient (0 –
 80 mg/ml) of aluminium hydroxide (Sigma, Missouri, USA). For protection against 
trypsin hydrolysis, L. lactis cells were suspended in PBS containing 2.2 IU/ml of 
porcine trypsin (Sigma, Missouri, USA), together with a dose-gradient (0 – 250 μg/ml) 
of camostat mesylate (Santa Cruz, California, USA). 
 In the experiments involving bile, pH of the experimental solutions was adjusted 
either to 5.5 or 6.8, using HCl or NaOH solutions, in order to respectively mimic the 
physiological pH of duodenum or jejunum and ileum, as described for pigs (Snoeck et 
al., 2004). In the experiments involving pancreatic enzymes, pH was adjusted to 6.8. 
Since the effect of pH on the activity of pancreatic enzymes is well studied (Beck, 1973), 
we considered applying the intestinal pH at which these enzymes can be most active in 
vivo (Beck, 1973). All mixtures were allowed to incubate for two hours at 37°C with 
mild agitation. The incubation time chosen corresponds to the average retention time 
of feed in the small intestinal compartments of growing pigs (Wilfart et al., 2007). 
Plating to evaluate the survival as described above followed the incubation.  
5.2.5. In vivo validation of the protective effect of aluminium hydroxide and 
camostat mesylate on L. lactis survival  
To validate the protective effect of aluminium hydroxide and camostat mesylate on 
the survival of L. lactis in the GI tract, pigs of two experimental groups (n=3 per group), 
received a 20 mg tablet of the proton pump inhibitor, rabeprazolum (Pariet®, Janssen-
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cilag, Berchem, Belgium), 12 hours before oral administration of L. lactis. This 
procedure was performed to neutralize the effect of gastric acidity in animals of both 
experimental groups. Pigs were then deprived of food until the administration of the 
bacteria. L. lactis inocula were prepared by resuspending the pellet of 500 ml of a 
saturated overnight culture (approximately 6 x 1011 CFU) in 20 ml of buffered GM9 
medium (Schotte et al., 2000). One group of pigs received a lactococcal inoculum 
supplemented with aluminium hydroxide and camostat mesylate at the clinical doses 
recommended for human (1200 mg and 50 mg, respectively). The second group 
received a lactococcal inoculum that contained no protectants. Eight hours following 
the oral administration of L. lactis, pigs were euthanized and samples of duodenal, 
jejunal and ileal contents were collected and kept on ice until plating.  
5.2.6. Statistical analysis 
All data are expressed as mean ± SD. The in vitro experiments were all performed in 
triplicates, on three independent occasions. Data of the in vitro experiments are 
presented as survival percentages, which were calculated separately for each replicate 
based on CFU counts as follows: (CFU of the test culture ÷ CFU of the starting culture) 
× 100. Two-way analysis of variance (ANOVA) was used to analyse the toxic effect of 
bile on L. lactis survival and the protective effect of aluminium hydroxide against bile 
toxicity, in relation to the intestinal pH. One-way ANOVA was used to analyse the 
protective effect of camostat mesylate on trypsin hydrolysis. ANOVA was followed by 
Tukey’s post hoc tests to perform multiple comparisons among pre-selected groups. 
An unpaired t-test was used to compare the survival percentages of enzyme-treated 
and non-enzyme-treated L. lactis cultures and to compare the intestinal counts of 
L. lactis in orally treated and non-treated pigs.  
5.3. Results 
5.3.1. Influence of bile on the viability of L. lactis in porcine small intestine 
We first measured the physiological concentration of bile acids in the different 
parts of the small intestine of pigs (n=3). The highest concentration of bile acids was 
measured in duodenal contents (14.4 ± 0.5 mM), followed by jejunal (9.5 ± 0.7 mM) 
and ileal contents (4.5 ± 0.4 mM). Accordingly, to evaluate the effect of bile on the 
survival of L. lactis, bile freshly collected from gallbladder of pigs was added to L. lactis 
suspensions at final concentrations of 15 mM, 10 mM and 5 mM of bile acids (Figure 
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4.1). Each of these intestinal concentrations of bile has resulted in a significant 
decrease in L. lactis survival in comparison to the non-bile-treated (0 mM) control 
culture (P< 0.0001). The survival percentages were significantly lower for every higher 
concentration of bile acids, indicating a concentration-dependent pattern of bile 
toxicity (P< 0.0001). Interestingly, the survival of L. lactis in bile was significantly lower 
at pH 5.5 compared to pH 6.8 for all bile concentrations (P<0.0001), indicating a 
positive correlation between bile toxicity and acidity (Figure 4.1).   
 
 
 
 
 
 
 
 
 
Figure 4.1. Survival of L. lactis in prevalent intestinal concentrations of bile acids under 
intestinal pH range in vitro. L. lactis was incubated for 2 h with 15, 10 or 5 mM of porcine bile 
under pH of 5.5 or 6.8. Survival is calculated based on CFU counts, as a percentage of the 
starting culture. Data represent the mean ± SD of three independent experiments. Significant 
differences among the conditions are indicated by a different capital letter (P< 0.0001). 
 
5.3.2. Influence of the pancreatic enzymes on the viability of L. lactis in 
porcine small intestine  
Exposure of L. lactis to the porcine pancreatic enzymes, trypsin, amylase or lipase, 
at activity levels mimicking those described in the small intestine of pigs, has resulted 
in a significant decrease in L. lactis survival in comparison to the non-enzyme-treated 
control cultures (P< 0.0001) (Figure 4.2). The highest enzymatic influence on L. lactis 
survival was observed for trypsin in comparison to the other enzymes (20% ± 2.52% 
versus 49% ± 5.86% and 60% ± 7.51% survival for lipase and amylase, respectively; P< 
0.0001). 
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Figure 4.2. In vitro survival of L. lactis in pancreatic enzymes. L. lactis was incubated for 2 
hours with trypsin (2.2 IU/ml), amylase (70 U/ml) or lipase (10 U/ml). Survival is expressed as a 
percentage of the CFUs in the starting culture. Data represent the mean ± SD of three 
independent experiments. *indicates a statistical difference between enzyme-treated and non-
enzyme-treated control cultures (P< 0.0001).   
 
5.3.3. Protection of L. lactis from bile toxicity using aluminium hydroxide 
Aluminium hydroxide was capable of protecting L. lactis from bile toxicity in a 
concentration-dependent manner (Figure 4.3). Each concentration of aluminium 
hydroxide resulted in a significant increase in L. lactis viability compared to the non-
protected control or to lower concentrations of the protectant (P< 0.0001). 
At the concentrations of 20 and 40 mg/ml of aluminium hydroxide, L. lactis survival 
was significantly higher at pH 5.5 compared to 6.8 (P< 0.0001). This finding indicates a 
positive correlation between the protective effect of aluminium hydroxide at these 
concentrations and the acidic pH of 5.5. At pH 5.5, full protection of L. lactis viability is 
achieved at a concentration of 40 mg/ml aluminium hydroxide, whereas at pH 6.8 this 
was only achieved at a concentration of 80 mg/ml.  
5.3.4. Protection of L. lactis from trypsin toxicity using camostat mesylate 
As shown in Figure 4.4, the oral trypsin inhibitor camostat mesylate protected 
L. lactis from the hydrolytic effect of porcine trypsin in a concentration-dependent 
manner. Each concentration of camostat mesylate resulted in a significant increase of 
L. lactis viability compared to the non-protected control or to lower concentrations of 
the protectant (P< 0.05). Complete viability of L. lactis was retained in the presence 
200 µg/ml camostat mesylate. 
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Figure 4.2. In vitro protection of L. lactis from bile toxicity using aluminium hydroxide.  
L. lactis cells were incubated for 2 h with bile containing 15 mM of bile acids and different 
concentrations of aluminium hydroxide either at pH 5.5 or 6.8. Survival is calculated based on 
CFU counts, as a percentage of the starting culture. Data represent the mean ± SD of three 
independent experiments. Significant differences (P<0.01) between the conditions are indicated 
by a different capital letter. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. In vitro protection of L. lactis from trypsin digestion using camostat mesylate. 
L. lactis was incubated for 2 h with 2.2 IU/ml of trypsin and different concentrations of 
camostat mesylate. Survival is calculated based on CFU counts, as a percentage of the starting 
culture. Data represent the mean ± SD of three independent experiments. Significant 
differences (P< 0.05) are indicated with a different capital letter. 
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5.3.5. Oral co-administration of aluminium hydroxide and camostat mesylate 
with L. lactis improves its GI survival in pigs 
We finally validated the capacity of aluminium hydroxide and camostat mesylate to 
improve the survival of L. lactis in vivo. Pigs receiving L. lactis in combination with 
camostat mesylate and aluminium hydroxide, showed higher counts of L. lactis in their 
intestinal contents, compared to those receiving L. lactis only (figure 4.5). The counts 
were 38 and 24 times higher (P< 0.0001) in jejunal and ileal contents of camostat 
mesylate- and aluminium hydroxide-treated pigs respectively. These results indicate 
the validity of these protectants for increasing L. lactis survival in the GI tract pigs. 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. Protection of L. lactis in the gastrointestinal tract of pigs by co-administering 
aluminium hydroxide and camostat mesylate. Pigs received an oral dose of 6x10
11
 CFU of L. 
lactis in the presence (treated group, n=3) or absence of aluminium hydroxide and camostat 
mesylate (control group, n=3). Data represent mean bacterial counts (log 10) per millilitre 
intestinal content of each individual animal 8 hrs after inoculation (presented by dots) and the 
group mean + SD (presented by horizontal lines). * indicates a statistical difference between 
control and treated (P< 0.0001). 
 
5.4. Discussion  
L. lactis is a GRAS bacterium with a clinical potential for the intestinal delivery of 
therapeutic and prophylactic molecules (Berlec et al., 2012). Nevertheless, a relatively 
low survival of L. lactis has been observed in the small intestine (Drouault et al., 1999; 
Drouault et al., 2002; Termonts, 2005), suggesting a detrimental effect of the intestinal 
physiological conditions on its viability. In order to investigate this issue, we 
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performed a series of in vitro experiments to determine the survival of L. lactis in bile 
and the major pancreatic enzymes. Additionally we explored the possibility of 
protecting L. lactis against the highly toxic effects of bile and trypsin. Notably, our 
experimental conditions were chosen to mimic the physiological conditions 
encountered in the small intestine of pigs, a species with a known relevance to human 
in regard to GI anatomy and physiology (Darragh & Moughan, 1995; Eubanks et al., 
2006; Moughan PJ, 1992; Rowan et al., 1994).  
Bile is a digestive secretion that represents a serious challenge for the survival of 
bacteria in the small intestine (Begley et al., 2005a). First, we determined the prevalent 
physiological concentrations of bile acids in the different parts of the pig small 
intestine. Concentrations of 14.4 ± 0.5 mM, 9.5 ± 0.7 mM and 4.5 ± 0.4 mM were 
measured for duodenum, jejunum and ileum, respectively. Interestingly, these 
concentrations corresponds well with those described in literature for human GI tract 
(15 mM, 10 mM and 4 mM, respectively) (Marteau et al., 1997). Furthermore, it has 
been shown that the chemical composition of bile is highly conserved among humans 
and pigs (Begley et al., 2005b). Together, these findings further support the relevance 
of the pig as a model species for studying the survival of L. lactis in the GI tract. 
Thereafter, we evaluated the survival of L. lactis following the incubation with freshly 
isolated porcine bile with the bile acid concentrations adjusted to mimic those 
measured in the small intestine of pigs under physiological conditions. The exposure 
of L. lactis to these concentrations of bile acids resulted in a marked decrease of its 
survival, indicating toxicity. Previous studies have reported the susceptibility of 
L. lactis subspecies cremoris to the presence of bile salts in the growth medium (Kim et 
al., 1999; Kimoto-Nira et al., 2009; Kimoto et al., 2003). However, it is rather difficult to 
compare our findings to those described in these reports due to the significant 
variations in the applied experimental conditions. Nevertheless, to our knowledge, the 
present study is the first to evaluate bile toxicity to L. lactis under physiological 
conditions. Additionally, we observed a positive correlation between acidity and bile 
toxicity, since the viability of L. lactis was significantly lower at pH 5.5 compared to pH 
6.8. A similar finding has also been reported for Lactobacillus, where a higher toxicity 
of glyco-conjugated bile acids was observed at acidic pH (Desmet et al., 1995). These 
findings indicate a role of acidic pH in augmenting bile toxicity to these bacterial 
species. Although several mechanisms have been described for the bactericidal effect 
of bile, including direct dissociation of membrane lipids and proteins (Coleman et al., 
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1980), interrupted permeability and fluidity across the bacterial cell membrane or 
altered activity of critical membrane-bound enzymes and increased trans-membrane 
flux of divalent cations, leading to cell death (Fujisawa & Mori, 1996; Noh & Gilliland, 
1993), the specific mechanism by which acidic pH augments bile toxicity to bacteria 
remains to be elucidated.  
Another group of factors, which could potentially influence the survival of L. lactis 
in the small intestine, are the pancreatic digestive enzymes. Indeed, incubation of 
L. lactis with trypsin, amylase or lipase, at activities described for these enzymes in the 
small intestine of pigs under normal physiological conditions, resulted in a reduced 
survival of L. lactis. This observation can be explained by the chemical composition of 
the Gram-positive cell wall, which reveals several potential substrates for the specific 
hydrolytic actions of these enzymes (Shockman & Barrett, 1983). For instance, lipase 
can hydrolyse phospholipids of the cytoplasmic membrane, amylase can hydrolyse the 
glycosidic bounds between N-acetylmuramide and N-acetylglucosamine in the cell 
wall, while trypsin can hydrolyse the integral membrane protein. Subsequently, 
degradation of these structural components can result in loss of cell wall integrity and 
eventually cell death. Among the tested pancreatic enzymes, we found that trypsin 
exerts the most detrimental effect on L. lactis survival. Previously, Drouault and co-
workers have reported the susceptibility of L. lactis to trypsin hydrolysis (Drouault et 
al., 1999). However, they described a dramatic decrease in L. lactis viability after 30 
minutes of incubation with trypsin (0.0012 – 0.012 %), whereas our results show a 20% 
survival after two hours of incubation. This difference is probably a result of a high 
concentration/activity of trypsin in their study in comparison with the physiological 
levels respected in our study.  
Thereafter, and in light of our findings on the deleterious effects of bile and trypsin 
on L. lactis survival, we performed a second set of in vitro experiments to evaluate the 
capacity of aluminium hydroxide and camostat mesylate to overcome bile toxicity and 
trypsin hydrolysis, respectively. Aluminium hydroxide is known for its capacity to bind 
bile acids (Clain et al., 1977) and has been clinically used for the treatment of bile salt-
mediated diarrhea and bile-reflux gastritis (Maton & Burton, 1999). Our findings show 
that aluminium hydroxide could protect L. lactis from bile toxicity. Additionally, we 
observed a higher protective effect for aluminium hydroxide at pH 5.5 compared to 
pH 6.8, at the concentrations of 20 and 40 mg/ml. Aluminium hydroxide typically 
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shows an enhanced bile acid binding capacity at acidic pH (Mangnall et al., 1986). This 
feature can be particularly useful for protection of L. lactis in the duodenum and 
jejunum, where a low pH and a high concentration of bile are simultaneously 
encountered. Edwards and Slater have previously reported the use of cholestyramine, a 
bile acid binding resin, to protect a live Salmonella typhimurium vector against bile 
toxicity in vitro (Edwards & Slater, 2009; Edwards et al., 2010). However, our 
preliminary experiments showed a negative effect of cholestyramine on L. lactis 
viability (data not shown), which on the contrary, has not been observed for 
aluminium hydroxide. Camostat mesylate is a synthetic ester that can inhibit trypsin 
activity in vivo following oral administration. Currently, it is clinically used for the 
treatment of pancreatitis (Kanoh et al., 1989) and reflux esophagitis (Sasaki et al., 1989) 
in Japan. Thus, we considered investigating the efficiency of camostat mesylate to 
counteract the detrimental effect of trypsin on L. lactis survival. Our results show a 
protective effect of camostat mesylate on L. lactis against trypsin hydrolysis. In regard 
to amylase and lipase, unfortunately, the approach of using enzyme inhibitors to 
protect L. lactis against their hydrolytic effects could not be evaluated. Although 
numerous inhibitors have been identified to pancreatic amylase, none of them has 
been proven efficacious in vivo (de Sales et al., 2012), while orlistat, the only clinically 
approved oral lipase inhibitor (Heck et al., 2000), is not commercially available for 
research use.    
After demonstrating the protective effects of aluminium hydroxide and camostat 
mesylate on L. lactis survival against bile toxicity and trypsin hydrolysis, respectively in 
vitro, we next validated the capacity of these protectants to improve the GI survival of 
L. lactis in vivo. Oral co-administration of aluminium hydroxide and camostat 
mesylate with L. lactis has increased the viability of the bacterium in the small 
intestine of pigs (38 and 24 fold-increased L. lactis counts in jejunal and ileal contents, 
respectively). These findings have direct implications for the development of oral 
formulations that can be used clinically to improve the GI survival of L. lactis and 
subsequently improve its efficiency in the intestinal delivery of biomolecules. The 
clinical application of live oral delivery vectors is generally performed either in a liquid 
formulation containing acid-neutralizing buffers or in enteric-coated capsules. The 
former is particularly favoured in preliminary clinical trials that are performed to 
establish efficacy and safety before pursuing the procedures to select and optimize an 
enteric-coating strategy (Kirkpatrick et al., 2005; Launay et al., 2009; McKenzie et al., 
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2008; Sack et al., 1997). Our findings support the use of aluminium hydroxide and 
camostat mesylate in oral liquid formulations of L. lactis in order to improve its 
efficiency as a live delivery vector. Furthermore, they provide a basis for further 
development of enteric-coated capsules that can simultaneously release aluminium 
hydroxide and camostat mesylate with L. lactis so as to improve its survival in the 
small intestine. A similar approach has been described for the use of cholestyramine as 
a composite of enteric-coated tablets to protect a live Salmonella Typhimurium vaccine 
vector against bile toxicity upon enteric release (Edwards & Slater, 2009; Edwards et 
al., 2010).  
5.5. Conclusion 
The present study shows that the in vitro exposure of L. lactis to the physiological 
concentrations of bile, trypsin, amylase and lipase, as described the small intestine of 
pigs, can significantly reduce the survival of L. lactis. Given the high similarity of 
human and porcine GI physiology, these findings could explain the low survival of L. 
lactis following the passage through the human GI tract. Furthermore, we 
demonstrated in vitro the capacity of the bile acid binder, aluminium hydroxide and 
the oral trypsin inhibitor, camostat mesylate to protect L. lactis against bile toxicity 
and trypsin hydrolysis respectively. Finally, we proved the concept of using camostat 
mesylate and aluminium hydroxide in oral L. lactis formulation to improve its GI 
survival. These findings have significant implications for the design of oral liquid or 
enteric-coated formulations that ensure a higher survival of L. lactis in the GI tract and 
to subsequently enhance its efficiency in the intestinal delivery of prophylactic and 
therapeutic molecules. 
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5.1. General discussion 
5.1.1. Oral vaccination to control enterohemorrhagic Escherichia coli 
(EHEC) infection:   
Currently, there is not a single vaccine approved for use against EHEC infection in 
humans (Garcia-Angulo et al., 2013). However, two parenteral vaccines were recently 
licensed to control EHEC infection in cattle, the main reservoir for the bacteria 
(Escherichia coli Bacterial Extract SPR® in the US, based on bacterial outer membrane 
siderophore receptor and porin (SRP) proteins and EconicheTM in Canada, based on 
T3SS proteins). Econiche was the result of several studies demonstrating that 
parenteral vaccination with multiple T3SS proteins reduced faecal excretion of EHEC. 
Either a combination of EspA, EspB and Tir or, one of those former proteins combined 
with intimin were effective (Allen et al., 2011; McNeilly et al., 2010; Peterson et al., 2007; 
Potter et al., 2004; Smith et al., 2009; Vilte et al., 2011). However, at least three 
subsequent intramuscular immunizations were needed to significantly reduce the 
number of bacteria shed in the faeces, the number of animals excreting bacteria as well 
as the duration of shedding. Two vaccinations could not significantly reduce the 
number of shedders (Van Donkersgoed et al., 2005). This showed the need for 
improvement of vaccines and vaccination strategy.  
T3SS proteins are in particular promising candidates, since the induction of 
specific immune responses against them can interfere with the process of intestinal 
colonization (Garcia-Angulo et al., 2013). A vast collection of preclinical vaccination 
studies have been conducted, mainly in mice models, to target EHEC infection in 
humans (Garcia-Angulo et al., 2013). These studies demonstrated that also mucosal 
immunizations (nasal and oral) using T3SS proteins such as Intimin, Tir, EspA or their 
combinations reduced the fecal shedding of EHEC (Amani et al., 2011; Babiuk et al., 
2008; Fan et al., 2012; Gu et al., 2011; Judge et al., 2004; Wan et al., 2011). The protection 
was accompanied by the appearance of specific IgA in the feces of immunized mice. In 
fact, IgA seem to be important for protection, since in some of these studies, 
protection could not be afforded by parenteral immunization, which elicited serum 
IgG, but not intestinal IgA responses (Babiuk et al., 2008; Fan et al., 2012; Wan et al., 
2011).  
Our immunization studies (Chapters 2 and 3), were the first to target the 
induction of a specific systemic and intestinal immune response against the T3SS 
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protein EspB via oral immunization. In agreement with other immunization studies 
involving T3SS antigens (intimin, Tir and EspA), mice orally immunized with EspB 
showed protection against colonization by E. coli O157:H7. This protection could be 
correlated with the detection of EspB-specific IgA in their feces (Chapter 3). Although 
EspB exhibits marked immunogenicity in the course of natural human and animal 
infections as well as in experimental infections (Li, Frey et al. 2000, Karpman, Bekassy 
et al. 2002, Cataldi, Yevsa et al. 2008, Asper, Karmali et al. 2011), the potential of the 
antigen for mucosal immunization has been evaluated in only one other study. In that 
study nasal immunization of mice using EspB resulted in the induction of specific IgG 
and IgA responses in serum and lung lavage, respectively (Cataldi et al., 2008). 
However, our studies are the first to describe the potential of EspB as an oral vaccine 
candidate. 
5.1.2. Lactococcus lactis for oral delivery of vaccine antigens: lessons from         
the case of  EspB 
5.1.2.1. Cytoplasmic expression versus secretion 
As we describe in Chapter 2, the cytoplasmic expression of EspB in L. lactis has 
resulted in a low antigen yield, which is probably the main reason why a weak 
immune-priming was obtained by this recombinant strain upon oral immunization. 
Indeed, L. lactis possess at least two cytoplasmic proteases (ClpP and FtsH) (Frees & 
Ingmer, 1999; Nilsson et al., 1994), in addition to DnaK, the cytoplasmic chaperon that 
promotes antigen proteolysis by maintaining the unfolding state (Koch et al., 1998). 
These factors can cause degradation of heterologous antigens designated to 
cytoplasmic expression, resulting in low expression yields (Bermudez-Humaran et al., 
2003b; Ribeiro et al., 2002). On the other hand, secretion of antigens allows them to 
escape cytoplasmic proteolysis, since researchers have previously observed that the 
cytoplasmic precursors of the secreted antigens are resistant to the action of 
cytoplasmic proteases compared to the proteins initially designated to cytoplasmic 
expression (Le Loir et al., 2005). Thus, secretion increases antigen yield and delivery as 
it allows the continuous release of antigens by viable bacteria and simultaneously 
accumulates the antigen in the cytoplasm (precursor of the secreted antigen) 
(Bermudez-Humaran et al., 2003a; Bermudez-Humaran et al., 2003b; Ribeiro et al., 
2002). The latter can significantly contribute to antigen delivery, providing that a part 
of the L. lactis inoculum gets lysed in the gastrointestinal tract, leading to the release 
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of the antigen content of the cytoplasm. Therefore, in Chapter 3, we explored 
secretion as a strategy to enhance the expression yield and the delivery of EspB by the 
bacteria. Indeed, secretion of EspB in L. lactis has markedly enhanced the overall 
expression levels (cytoplasmic and secreted) compared to cytoplasmic expression (56 -
 25-fold increase). Unlike what was observed with cytoplasmic expression of EspB, 
optimized expression of EspB in L. lactis, via antigen secretion, has allowed the 
induction of complete immune responses in mice upon oral immunization 
5.1.2.2. Constitutive versus inducible expression systems  
Antigen expression in L. lactis can be done using either constitutive or inducible  
expression systems (Bahey-El-Din et al., 2010b). Although several inducible expression 
systems have been developed for L. lactis, the nisin-inducible expression system 
(NICE) is the most characterized and commonly used system for antigen delivery. 
Constitutive expression systems would imply the continuous synthesis and release of 
antigens by viable lactococci in situ. On the other hand, inducible systems require the 
presence of the inducer in the medium to sustain antigen synthesis. Thus, since 
inducers are absent in vivo, antigen release in situ may not be sustained. 
Notwithstanding this limitation, in vitro studies show that nisin-inducible expression 
systems produce larger amounts of antigen compared to constitutive counterparts 
(Bermudez-Humaran et al., 2004; Chatel et al., 2001). 
The work presented in Chapter 3, provide the first comparison between the 
constitutive and nisin-inducible expression systems for their capacity for oral antigen 
delivery, as indicated by the strength of the resultant immune responses. Indeed, in 
vitro analysis of EspB expression using either constitutive or nisin-inducible expression 
systems shows that the overall expression of EspB by the latter is approximately        
two-folds higher than by the former. Both recombinant strains were used in oral 
immunization studies. Results were in agreement with the higher capacities for 
antigen expression, in that the nisin-inducible recombinant strain induced the higher 
antibody responses. In light of these findings, it seems that the sustainability of in situ 
antigen release by the constitutive strain does not constitute an advantage over nisin-
inducible strains in mice. This could be explained by the findings of a previous study, 
where antigen synthesis by nisin-inducible expression systems continued in vitro for 
up to 10 hours after the removal of nisin from the culture medium (Bermudez-
Humaran et al., 2003b). Considering that the transit time of L. lactis in the mouse 
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gastrointestinal tract is approximately 12 hours and that the immune inductive sites 
are reached within one hour (Drouault et al., 1999), it is likely that the 
immunologically important antigen release by either the constitutive or the nisin-
inducible strain is comparably long in mice in vivo. However, further investigations are 
required to determine whether a similar outcome can be obtained in larger species 
with a longer transit time such as humans. For instance, in pigs with a normal 
gastrointestinal transit, an average time of 9 hours is required for the majority of the 
bacteria to reach the ileum, where the immune inductive sites locate (Steidler et al., 
2003). Thus, despite a lower antigen expression levels likely obtained by constitutive 
expression systems, they are probably more suitable for L. lactis-based vaccines in 
humans and pigs. In addition, constitutive systems can readily secrete antigens in vivo 
without the need for a prior nisin induction in vitro. The induction step can be a 
limiting factor for application of a vaccine in practice.  
5.1.2.3. The immunomodulatory effect of L. lactis on mucosal immune 
responses 
Besides the mechanical delivery of antigen to mucosal targets, a desirable advantage   
of vaccine delivery vectors is their ability to modulate the quality of the immune 
responses elicited to the antigens. In this regard, studies involving the mucosal 
delivery of vaccine antigens using L. lactis have described mixed Th1/Th2 cell 
responses against these antigens (Cauchard et al., 2011; Robinson et al., 1997; Villena et 
al., 2008). In agreement with these reports, oral delivery of EspB using recombinant 
L. lactis strains induced mixed Th1/Th2 response in Peyer’s patches and mesenteric 
lymph nodes of immunized mice (Chapter 3). Lymphocytes of these organs 
simultaneously secreted IFN-γ and IL-4 (Th1 and Th2 marker cytokines, respectively) 
in an in vitro antigen recall assay. It is well-established that the type of T helper 
response induced by a vaccine is mainly determined by dendritic cells. In vitro studies 
have shown the ability of L. lactis to induce dendritic cell maturation (Audouy et al., 
2007; Yam et al., 2008), and secretion of the cytokines that potentially direct the 
differentiation of naive Th cells to both Th1 and Th2 cell types (IFN-γ and IL-12, and IL-
6 and IL-10, respectively)(Latvala et al., 2008).   
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5.1.3. Towards the validation of the L. lactis-based EHEC vaccine in porcine 
models of infection: the issue of gastrointestinal survival 
We have demonstrated the protective potential of our vaccine strains in a mouse 
model of colonization. Although mice models are basically acceptable to study the 
pathogenicity of EHEC and to evaluate EHEC vaccines, there is not a single animal 
model that mimics the complete pathogenicity of EHEC (Mohawk & O'Brien, 2011). 
The EHEC infection models developed in gnotobiotic pigs mimics the human 
pathogenicity to a larger extent (Francis et al., 1986; Tzipori et al., 1986; Tzipori et al., 
1989; Tzipori et al., 2004; Zhang et al., 2009). More and more data support that pigs are 
a suitable model species to human in biomedical research (Kristy N. Kuzmuk, 2011; 
Litten-Brown et al., 2010; Meurens et al., 2012). Pigs share several physiological, 
anatomical and immunological similarities with human compared to murine species 
(Bailey et al., 2013; Dawson et al., 2013; Peter A . McAnulty 2011). Accordingly, the 
evaluation of oral vaccines that target diseases in pig models can be feasible to validate 
their efficacy prior the initiation of human clinical trials. However, several reports have 
described the low capacity of L. lactis to survive the passage through human and 
porcine gastrointestinal tracts (Drouault et al., 2002; Klijn et al., 1995; Termonts, 2005; 
Vesa et al., 2000). Although this reflects the sensitivity of the bacteria to the 
physiological conditions encountered during the alimentary passage, limited studies 
have studied the survival of L. lactis in these conditions (Termonts, 2005). 
Thus, in the present thesis (Chapter 4), we studied the detrimental effects of 
gastrointestinal conditions on L. lactis survival in vitro. Importantly, in our 
experimental design, we have considered mimicking the prevalent physiological levels 
of these factors in the small intestine, as described for healthy young pigs. We 
identified bile and trypsin as two detrimental factors for L. lactis survival. Accordingly, 
we explored the utilization of two protectants, aluminum hydroxide (Bile acid binder) 
and camostat mesylate (trypsin inhibitor) to protect L. lactis against bile toxicity and 
trypsin hydrolysis, respectively. A particularly interesting advantage of aluminium 
hydroxide and camostat mesylate is their bioactivity in vivo. The former is well-known 
for the treatment of bile salt-mediated diarrhea and bile-reflux gastritis (Maton & 
Burton, 1999), while the latter is currently used in Japan for the treatment of 
pancreatitis (Kanoh et al., 1989) and reflux esophagitis (Sasaki et al., 1989). On the 
basis of these effects, we evaluated for the first time the capacity of these protectants 
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to protect L. lactis in vivo in pigs against bile toxicity and trypsin hydrolysis, 
respectively. Interestingly, oral co-administration of aluminium hydroxide and 
camostat mesylate with L. lactis can improve the survival of the bacterium in the 
gastrointestinal tract of pigs. This was indicated by a 38- and 24-fold increase in the 
number of the bacteria retrieved from jejunal and ileal contents, respectively, of 
treated pigs compared to untreated controls.   
5.2. Future perspectives:  
In the present thesis, we describe the development and preclinical evaluation of the 
efficacy of an oral vaccine against EHEC infections. However, further steps either in 
design or in efficacy validation should be pursued to prepare the vaccine to clinical 
trials on human subjects. 
5.2.1. Validation of vaccine efficacy in porcine models   
As discussed above, pigs are generally considered as good models for humans in 
biomedicine. Additionally, pig models of EHEC pathogenicity are the closest to the 
human disease. Therefore, evaluation of efficacy of our oral EHEC vaccine in pigs is a 
feasible step towards the extrapolation of the vaccine to human application. An 
immunization study in pigs will particularly validate the protective efficacy of EspB-
specific mucosal IgA antibodies against EHEC colonization. The co-administration of 
aluminum hydroxide and camostat mesylate can improve the delivery of EspB using 
the recombinant L. lactis strains.                 
5.2.2. Vaccine design: the issue of biological containment  
Regulatory bodies are concerned about introducing genetically modified 
microorganisms in human medicine. Especially, the horizontal transfer of virulence 
and antibiotic resistance genes is a likely event if the modified microorganism 
disseminates in the environment without control. Consequently, strategies for 
biological containment must be applied before a live bacteria-based vaccine is 
approved for clinical trials. In the majority of the published studies involving L. lactis 
as a live vector for oral vaccine delivery, plasmid expression systems have been used 
(Wells and Mercenier 2008). Since these plasmids carry antibiotic resistance genes, 
they are unacceptable for clinical application. This problem can be solved by 
integrating the antigen gene in the chromosome of L. lactis (Bahey-El-Din et al., 
2010a). This would ensure the stability of the recombinant strain and eliminate the 
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need for antibiotic resistance markers. However, biological containment strategies 
which prevent the bacterial vaccine vector from maintaining viability ex vivo offer the 
most satisfactory solution. Active and passive biological containment strategies have 
been published for several microorganisms. Active containment systems involve the 
use of genes that are tightly regulated and are expressed only under certain conditions 
producing a toxin or a product that kills the host cell (Kaplan et al., 1999; Knudsen et 
al., 1995; Torres et al., 2000). On the other hand, passive containment systems depend 
on the requirement of essential metabolites where the mutant organism cannot grow 
in their absence (auxotrophy). Ideally, the metabolite should be absent outside the 
body. (Sorensen, Larsen et al. 2000). Active containment systems usually have a 
bactericidal effect while passive systems are usually bacteriostatic. Thymidine 
auxotrophy containment is a model system that is being integrated in the 
ActioBioticsTM technology, which was developed by the biotechnology company 
ActoGenix.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
154 
 
5.3. References  
A-B 
Allen, K. J., Rogan, D., Finlay, B. B., Potter, A. A. & Asper, D. J. (2011). Vaccination with 
type III secreted proteins leads to decreased shedding in calves after experimental infection 
with Escherichia coli O157. Can J Vet Res 75, 98-105. 
Amani, J., Mousavi, S. L., Rafati, S. & Salmanian, A. H. (2011). Immunogenicity of a plant-
derived edible chimeric EspA, Intimin and Tir of Escherichia coli O157:H7 in mice. Plant Sci 180, 
620-627. 
Audouy, S. A. L., van Selm, S., van Roosmalen, M. L. & other authors (2007). Development 
of lactococcal GEM-based pneumococcal vaccines. Vaccine 25, 2497-2506. 
Babiuk, S., Asper, D. J., Rogan, D., Mutwiri, G. K. & Potter, A. A. (2008). Subcutaneous and 
intranasal immunization with type III secreted proteins can prevent colonization and shedding 
of Escherichia coli O157:H7 in mice. Microbial pathogenesis 45, 7-11. 
Bahey-El-Din, M., Casey, P. G., Griffin, B. T. & Gahan, C. G. (2010a). Efficacy of a 
Lactococcus lactis DeltapyrG vaccine delivery platform expressing chromosomally integrated 
hly from Listeria monocytogenes. Bioengineered bugs 1, 66-74. 
Bahey-El-Din, M., Gahan, C. G. M. & Griffin, B. T. (2010b). Lactococcus lactis as a Cell 
Factory for Delivery of Therapeutic Proteins. Curr Gene Ther 10, 34-45. 
Bailey, M., Christoforidou, Z. & Lewis, M. C. (2013). The evolutionary basis for differences 
between the immune systems of man, mouse, pig and ruminants. Veterinary immunology and 
immunopathology 152, 13-19. 
Bermudez-Humaran, L. G., Cortes-Perez, N. G., Le Loir, Y., Gruss, A., Rodriguez-Padilla, 
C., Saucedo-Cardenas, O., Langella, P. & Montes de Oca-Luna, R. (2003a). Fusion to a 
carrier protein and a synthetic propeptide enhances E7 HPV-16 production and secretion in 
Lactococcus lactis. Biotechnology progress 19, 1101-1104. 
Bermudez-Humaran, L. G., Langella, P., Commissaire, J., Gilbert, S., Le Loir, Y., 
L'Haridon, R. & Corthier, G. (2003b). Controlled intra- or extracellular production of 
staphylococcal nuclease and ovine omega interferon in Lactococcus lactis. Fems Microbiol Lett 
224, 307-313. 
Bermudez-Humaran, L. G., Cortes-Perez, N. G., Le Loir, Y., Alcocer-Gonzalez, J. M., 
Tamez-Guerra, R. S., de Oca-Luna, R. M. & Langella, P. (2004). An inducible surface 
presentation system improves cellular immunity against human papillomavirus type 16 E7 
antigen in mice after nasal administration with recombinant lactococci. Journal of medical 
microbiology 53, 427-433. 
Cataldi, A., Yevsa, T., Vilte, D. A., Schulze, K., Castro-Parodi, M., Larzabal, M., Ibarra, C., 
Mercado, E. C. & Guzman, C. A. (2008). Efficient immune responses against Intimin and EspB 
of enterohaemorragic Escherichia coli after intranasal vaccination using the TLR2/6 agonist 
MALP-2 as adjuvant. Vaccine 26, 5662-5667. 
Cauchard, S., Bermudez-Humaran, L. G., Blugeon, S., Laugier, C., Langella, P. & 
Cauchard, J. (2011). Mucosal co-immunization of mice with recombinant lactococci secreting 
VapA antigen and leptin elicits a protective immune response against Rhodococcus equi 
infection. Vaccine 30, 95-102. 
 
C-J 
Chatel, J. M., Langella, P., Adel-Patient, K., Commissaire, J., Wal, J. M. & Corthier, G. 
(2001). Induction of mucosal immune response after intranasal or oral inoculation of mice with 
Lactococcus lactis producing bovine beta-lactoglobulin. Clin Diagn Lab Immun 8, 545-551. 
General discussion and future perspectives  
 
155 
 
Dawson, H. D., Loveland, J. E., Pascal, G. & other authors (2013). Structural and functional 
annotation of the porcine immunome. BMC genomics 14, 332. 
Drouault, S., Corthier, G., Ehrlich, S. D. & Renault, P. (1999). Survival, physiology, and lysis 
of Lactococcus lactis in the digestive tract. Appl Environ Microb 65, 4881-4886. 
Drouault, S., Juste, C., Marteau, P., Renault, P. & Corthier, G. (2002). Oral treatment with 
Lactococcus lactis expressing Staphylococcus hyicus lipase enhances lipid digestion in pigs with 
induced pancreatic insufficiency. Appl Environ Microbiol 68, 3166-3168. 
Fan, H. Y., Wang, L., Luo, J. & Long, B. G. (2012). Protection against Escherichia coli O157:H7 
challenge by immunization of mice with purified Tir proteins. Molecular biology reports 39, 
989-997. 
Francis, D. H., Collins, J. E. & Duimstra, J. R. (1986). Infection of Gnotobiotic Pigs with an 
Escherichia coli O157-H7 Strain Associated with an Outbreak of Hemorrhagic Colitis. Infection 
and immunity 51, 953-956. 
Frees, D. & Ingmer, H. (1999). ClpP participates in the degradation of misfolded protein in 
Lactococcus lactis. Molecular microbiology 31, 79-87. 
Garcia-Angulo, V. A., Kalita, A. & Torres, A. G. (2013). Advances in the development of 
enterohemorrhagic Escherichia coli vaccines using murine models of infection. Vaccine 31, 
3229-3235. 
Gu, J., Ning, Y. Y., Wang, H. G. & other authors (2011). Vaccination of attenuated EIS-
producing Salmonella induces protective immunity against enterohemorrhagic Escherichia coli 
in mice. Vaccine 29, 7395-7403. 
Judge, N. A., Mason, H. S. & O'Brien, A. D. (2004). Plant cell-based intimin vaccine given 
orally to mice primed with intimin reduces time of Escherichia coli O157 : H7 shedding in feces. 
Infection and immunity 72, 168-175. 
 
K-N 
Kanoh, M., Ibata, H., Miyagawa, M. & Matsuo, Y. (1989). Clinical Effects of Camostat in 
Chronic-Pancreatitis. Biomed Res-Tokyo 10, 145-150. 
Kaplan, D. L., Mello, C., Sano, T., Cantor, C. & Smith, C. (1999). Streptavidin-based 
containment systems for genetically engineered microorganisms. Biomolecular engineering 16, 
135-140. 
Klijn, N., Weerkamp, A. H. & Devos, W. M. (1995). Genetic Marking of Lactococcus lactis 
Shows Its Survival in the Human Gastrointestinal Tract. Appl Environ Microb 61, 2771-2774. 
Knudsen, S., Saadbye, P., Hansen, L. H., Collier, A., Jacobsen, B. L., Schlundt, J. & 
Karlstrom, O. H. (1995). Development and testing of improved suicide functions for biological 
containment of bacteria. Appl Environ Microbiol 61, 985-991. 
Koch, B., Kilstrup, M., Vogensen, F. K. & Hammer, K. (1998). Induced levels of heat shock 
proteins in a dnaK mutant of Lactococcus lactis. J Bacteriol 180, 3873-3881. 
Kristy N. Kuzmuk, L. B. S. (2011). Pigs as a model for biomedical sciences. MF Rothchild, A 
Ruvinsky (Eds), The genetics of the pig, CAB International, Wallingford, 426–444. 
Latvala, S., Pietila, T. E., Veckman, V., Kekkonen, R. A., Tynkkynen, S., Korpela, R. & 
Julkunen, I. (2008). Potentially probiotic bacteria induce efficient maturation but differential 
cytokine production in human monocyte-derived dendritic cells. World journal of 
gastroenterology : WJG 14, 5570-5583; discussion 5581-5572. 
Le Loir, Y., Azevedo, V., Oliveira, S. C. & other authors (2005). Protein secretion in 
Lactococcus lactis: an efficient way to increase the overall heterologous protein production. 
Microb Cell Fact 4, 2. 
Chapter 5 
156 
 
Litten-Brown, J. C., Corson, A. M. & Clarke, L. (2010). Porcine models for the metabolic 
syndrome, digestive and bone disorders: a general overview. Animal 4, 899-920. 
Maton, P. N. & Burton, M. E. (1999). Antacids revisited- A review of their clinical 
pharmacology and recommended therapeutic use. Drugs 57, 855-870. 
McNeilly, T. N., Mitchell, M. C., Rosser, T., McAteer, S., Low, J. C., Smith, D. G., Huntley, 
J. F., Mahajan, A. & Gally, D. L. (2010). Immunization of cattle with a combination of purified 
intimin-531, EspA and Tir significantly reduces shedding of Escherichia coli O157:H7 following 
oral challenge. Vaccine 28, 1422-1428. 
Meurens, F., Summerfield, A., Nauwynck, H., Saif, L. & Gerdts, V. (2012). The pig: a model 
for human infectious diseases. Trends Microbiol 20, 50-57. 
Mohawk, K. L. & O'Brien, A. D. (2011). Mouse models of Escherichia coli O157:H7 infection 
and shiga toxin injection. Journal of biomedicine & biotechnology 2011, 258185. 
Nilsson, D., Lauridsen, A. A., Tomoyasu, T. & Ogura, T. (1994). A Lactococcus lactis Gene 
Encodes a Membrane-Protein with Putative Atpase Activity That Is Homologous to the 
Essential Escherichia coli Ftsh Gene-Product. Microbiol-Uk 140, 2601-2610. 
 
P-T 
Peter A . McAnulty , A. D. D., Niels-Christian Ganderup , and Kenneth L . Hastings 
(2011). A Comparative Assessment of the Pig, Mouse and Human Genomes. The Minipig in 
Biomedical Research (Book), 323–342. 
Peterson, R. E., Klopfenstein, T. J., Moxley, R. A., Erickson, G. E., Hinkley, S., 
Bretschneider, G., Berberov, E. M., Rogan, D. & Smith, D. R. (2007). Effect of a vaccine 
product containing type III secreted proteins on the probability of Escherichia coli O157:H7 
fecal shedding and mucosal colonization in feedlot cattle. Journal of food protection 70, 2568-
2577. 
Potter, A. A., Klashinsky, S., Li, Y. L. & other authors (2004). Decreased shedding of 
Escherichia coli O157 : H7 by cattle following vaccination with type III secreted proteins. 
Vaccine 22, 362-369. 
Ribeiro, L. A., Azevedo, V., Le Loir, Y., Oliveira, S. C., Dieye, Y., Piard, J. C., Gruss, A. & 
Langella, P. (2002). Production and targeting of the Brucella abortus antigen L7/L12 in 
Lactococcus lactis: a first step towards food-grade live vaccines against brucellosis. Appl Environ 
Microb 68, 910-916. 
Robinson, K., Chamberlain, L. M., Schofield, K. M., Wells, J. M. & Le Page, R. W. (1997). 
Oral vaccination of mice against tetanus with recombinant Lactococcus lactis. Nature 
biotechnology 15, 653-657. 
Sasaki, I., Suzuki, Y., Naito, H. & other authors (1989). Effect of Camostat in the Treatment 
of Reflux Esophagitis after Gastrectomy- an Experimental-Study in Rats and a Pilot Clinical-
Study. Biomed Res-Tokyo 10, 167-173. 
Smith, D. R., Moxley, R. A., Peterson, R. E., Klopfenstein, T. J., Erickson, G. E., 
Bretschneider, G., Berberov, E. M. & Clowser, S. (2009). A two-dose regimen of a vaccine 
against type III secreted proteins reduced Escherichia coli O157:H7 colonization of the terminal 
rectum in beef cattle in commercial feedlots. Foodborne Pathog Dis 6, 155-161. 
Steidler, L., Neirynck, S., Huyghebaert, N., Snoeck, V., Vermeire, A., Goddeeris, B., Cox, 
E., Remon, J. P. & Remaut, E. (2003). Biological containment of genetically modified 
Lactococcus lactis for intestinal delivery of human interleukin 10. Nature biotechnology 21, 785-
789. 
Termonts, S. (2005). Optimization of lactococcus lactis mediated delivery of cytokines PhD 
dissertation  
General discussion and future perspectives  
 
157 
 
Torres, B., Jaenecke, S., Timmis, K. N., Garcia, J. L. & Diaz, E. (2000). A gene containment 
strategy based on a restriction-modification system. Environmental microbiology 2, 555-563. 
Tzipori, S., Wachsmuth, I. K., Chapman, C., Birner, R., Brittingham, J., Jackson, C. & 
Hogg, J. (1986). The Pathogenesis of Hemorrhagic Colitis Caused by Escherichia coli O157-H7 
in Gnotobiotic Piglets. Journal of Infectious Diseases 154, 712-716. 
Tzipori, S., Gibson, R. & Montanaro, J. (1989). Nature and Distribution of Mucosal Lesions 
Associated with Enteropathogenic and Enterohemorrhagic Escherichia coli in Piglets and the 
Role of Plasmid-Mediated Factors. Infection and immunity 57, 1142-1150. 
Tzipori, S., Sheoran, A., Akiyoshi, D., Donohue-Rolfe, A. & Trachtman, H. (2004). 
Antibody therapy in the management of Shiga toxin-induced hemolytic uremic syndrome. Clin 
Microbiol Rev 17, 926-+. 
 
V-Z 
Van Donkersgoed, J., Hancock, D., Rogan, D. & Potter, A. A. (2005). Escherichia coli 
O157:H7 vaccine field trial in 9 feedlots in Alberta and Saskatchewan. The Canadian veterinary 
journal La revue veterinaire canadienne 46, 724-728. 
Vesa, T., Pochart, P. & Marteau, P. (2000). Pharmacokinetics of Lactobacillus plantarum 
NCIMB 8826, Lactobacillus fermentum KLD, and Lactococcus lactis MG 1363 in the human 
gastrointestinal tract. Aliment Pharm Therap 14, 823-828. 
Villena, J., Medina, M., Raya, R. & Alvarez, S. (2008). Oral immunization with recombinant 
Lactococcus lactis confers protection against respiratory pneumococcal infection. Can J 
Microbiol 54, 845-853. 
Vilte, D. A., Larzabal, M., Garbaccio, S. & other authors (2011). Reduced faecal shedding of 
Escherichia coli O157:H7 in cattle following systemic vaccination with gamma-intimin C-280 
and EspB proteins. Vaccine 29, 3962-3968. 
Wan, C. S., Zhou, Y., Yu, Y., Peng, L. J., Zhao, W. & Zheng, X. L. (2011). B-cell epitope KT-12 
of enterohemorrhagic Escherichia coli O157:H7: a novel peptide vaccine candidate. Microbiol 
Immunol 55, 247-253. 
Yam, K. K., Pouliot, P., N'diaye, M. M., Fournier, S., Olivier, M. & Cousineau, B. (2008). 
Innate inflammatory responses to the Gram-positive bacterium Lactococcus lactis. Vaccine 26, 
2689-2699. 
Zhang, Q., Donohue-Rolfe, A., Krautz-Peterson, G., Sevo, M., Parry, N., Abeijon, C. & 
Tzipori, S. (2009). Gnotobiotic piglet infection model for evaluating the safe use of antibiotics 
against Escherichia coli O157:H7 infection. The Journal of infectious diseases 199, 486-493. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
SUMMARY  
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary 
161 
 
Oral vaccination provides a practical and effective approach for disease prevention. 
Considering that the majority of infectious pathogen gain access to the body through 
the gut mucosa, the induction of mucosal immune responses constitutes a key strategy 
for protection (discussed in Chapter 1). However, the efficient delivery of oral vaccines 
is confronted with several challenges. These include the susceptibility of vaccine 
antigens to degradation by gastrointestinal enzymes, the difficulty in passing the 
epithelial barrier, the poor uptake of most soluble antigens by antigen-presenting cells 
with insufficient maturation of these cells, and the induction of tolerance instead of 
immunity. Therefore, strategies for efficient delivery of oral vaccines have been actively 
explored (reviewed in Chapter 1). Lactococcus lactis is a Gram-positive lactic acid 
bacterium that offers a valuable platform for the delivery of oral vaccines. The 
bacterium has been widely used in fermented and dairy food industry. However, 
during the last two decades, and with the advances in genetic engineering and 
molecular biology, scientists have explored the utilization of the bacteria as a live-
vector for oral vaccine delivery. This technological trend has been particularly 
motivated by the well-established safety of the bacterium (classified as a generally 
regarded as safe “GRAS” organism by FDA) for oral consumption, as well as its 
amenability to genetic modification. Today, a vast collection of reports are available 
describing the oral delivery of vaccine antigens using L. lactis, an approach that 
successfully resulted in the induction of protective mucosal and systemic immune 
responses against various pathogens (reviewed in Chapter 1). The value of L. lactis     
as a live-vector for oral vaccine delivery particularly lies in its ability to synthesize and 
release antigens at the intestinal immune-inductive sites, as well as its adjuvant effects, 
which enhance the immune responses to vectored antigens.  
In the present thesis we explored some preclinical aspects of the utilization of 
L. lactis for the development of an oral vaccine against enterohemorrhagic   
Escherichia coli (EHEC) infection. As reviewed in Chapter 1, EHEC constitutes a 
subset of enteropathogenic E. coli that has been responsible for frequent outbreaks of 
hemorrhagic colitis and hemolytic uremic syndrome worldwide. The latter represents 
a serious public health threat, as it the most common cause of renal failure in children 
and causes high fatalities among both children and elderly. Antibiotic treatment seems 
to exert no beneficial effects in the management of the hemolytic uremic syndrome. 
Even more, several reports have linked antibiotic therapy to disease exacerbation. 
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Thus, vaccination remains the most suitable approach to control the infection. 
Unfortunately, there is currently no approved vaccine against EHEC infections.   
In Chapter 2, we describe our first attempt to express the EHEC antigen, EspB in 
L. lactis for oral vaccination purposes. EspB is a major protein of the type three   
secretion system employed by EHEC to colonize the small intestine. Additionally, the 
protein shows a remarkable immunogenicity in the course of both experimental        
and natural infections. Thus, the induction of mucosal immune responses, particularly 
IgA antibodies, against EspB can interfere with the EHEC colonization process and 
thus prevent the associated diseases. EspB was successfully expressed in the 
cytoplasmic compartment of the bacteria. However, oral immunization of BALB/C 
mice using the recombinant cytoplasmic expression strain did not elicit detectible 
levels of serum total-Igs and fecal IgA antibodies. Since weak priming of the immune 
system can be one of the reasons for the absence of humoral antibodies, we next 
applied an intraperitoneal booster immunization using purified EspB. Interestingly, 
ten days after the booster immunization both serum Igs and fecal IgA were detected   
in the mice orally immunized using EspB-expressing L. lactis, but not in those   
receiving the control strain. This finding indicates that the mucosal immune system of 
the orally immunized mice was primed against EspB. However, further optimization of 
the recombinant vaccine strain would be required to elicit complete immune 
responses upon oral prime-boost immunizations. In Chapter 3, we describe the 
optimization of EspB expression in L. lactis by constructing recombinant strains 
designated for EspB secretion in the extracellular medium. Unlike cytoplasmic 
expression, secretion allows antigens to escape cytoplasmic proteolysis, which likely 
resulted in low expression levels and poor delivery of EspB in our first study. 
Additionally, we compared constitutive and nisin-inducible expression systems for the 
highest antigen expression yield. Indeed, secretion of EspB in L. lactis, under either 
constitutive or inducible conditions, has markedly enhanced the expression levels 
compared to cytoplasmic expression (25- and 56-fold increase, respectively). Notably, 
the nisin-inducible secretion system showed a two-fold increase in EspB expression 
compared to the constitutive one. Thereafter, we evaluated the capacity of the          
two expression systems in inducing immune responses upon immunizing BALB/c   
mice orally using the corresponding recombinant strains (Chapter 3). Mice 
immunized using either strains showed a significant increase in EspB-specific serum 
total Igs or fecal IgA compared to control mice. The highest antibody responses were 
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obtained using the nisin-inducible strain. Next, the cellular immune responses induced 
by the oral immunization of mice using L. lactis secreting EspB was characterized in 
Peyer’s patches and mesenteric lymph nodes of immunized mice. Lymphocytes 
isolated from these sites showed the production of both Th1 and Th2 cytokines (IFN-γ 
and Il-4 and IL-10, respectively) in an in vitro antigen-recall assay. This indicates the 
induction of a mixed Th/Th2 response. Nevertheless, IL-4:IFN-γ ratio analysis showed 
a Th2 bias. The Th2 dominance is consistent with the induction of intestinal IgA. 
Furthermore, the protection conferred by the oral immunization using L. lactis 
secreting EspB was evaluated during a challenge infection using E. coli O157:H7 strain. 
Indeed the immune responses induced by the vaccine strains were capable of 
protecting the immunized mice against intestinal colonization by EHEC. This pattern 
of protection can be correlated to the detected IgA antibody responses, which could 
interfere with the attachment of EHEC to the intestinal epithelium. Altogether, these 
findings demonstrate the potential of EspB as candidate for oral vaccination against 
EHEC infection, as well as the efficiency of L. lactis as a delivery vector.  
Chapter 4 describes our first steps towards the validation of our EHEC vaccine in 
pigs. Although mice models of EHEC colonization are acceptable for the evaluation of 
EHEC vaccines, they do not fully mimic the EHEC pathogenicity in humans. Pigs offer 
an alternative animal model, in which EHEC pathogenicity in humans is fairly 
reproducible. In addition, from an immunological standpoint, pigs share a higher 
degree of similarity with humans than the latter do with mice. Therefore, validation of 
vaccines targeting human diseases in pig models can be a feasible step towards the 
translation of their application in humans, particularly in the case of EHEC infection. 
Despite these facts, there is not a single report published on the use of a L. lactis-based 
vaccine in pig model. A possible reason is the previously reported low survival of the 
bacteria in the porcine gastrointestinal tract. To address this issue, we evaluated the 
sensitivity of L. lactis to some potentially harmful digestive factors, including bile and 
the major pancreatic enzymes, trypsin, lipase and amylase. Thereafter, we evaluated 
the capacity of aluminium hydroxide (a bile acid binder) and camostat mesylate (a 
trypsin inhibitor) to protect L. lactis against bile toxicity and trypsin hydrolysis, 
respectively. These experiments were designed to mimic the physiological conditions 
described in the small intestine of pigs. Incubation of L. lactis with freshly isolated 
porcine bile resulted in a marked reduced survival of the bacteria. Moreover, a positive 
correlation between bile toxicity and acidity was observed. L. lactis survival was also 
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influenced by the pancreatic enzymes. Among these enzymes, trypsin reduced L. lactis 
survival the highest (20% versus 49% and 60% survival for amylase and lipase, 
respectively). The presence of aluminium hydroxide and camostat mesylate could 
significantly improve the survival of L. lactis in bile and trypsin solutions, respectively. 
Furthermore, we demonstrated that oral co-administration of aluminium hydroxide 
and camostat mesylate with L. lactis can improve the survival of the bacterium in the 
GI tract of pigs. This was indicated by a 38- and 24-fold increase in the L. lactis-counts 
retrieved respectively from jejunal and ileal contents of treated pigs. Our results proof 
the concept of using bile and pancreatic enzyme inhibitors in oral formulations of L. 
lactis to improve the survival of the bacterium in the gastrointestinal tract of pigs and 
to subsequently enhance its efficiency in oral vaccine delivery. In a next step the 
vaccine should be validated in a pig model of EHEC infection considering the 
physiological and the immunological similarities among pigs and humans, it would be 
interesting to extend our findings to humans.    
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Aangezien de meerderheid van de infectieuze pathogenen het lichaam 
binnenkomen via het darmslijmvlies, is het induceren van een immuunrespons ter 
hoogte van de darmmucosa een belangrijke strategie om te beschermen tegenover 
deze pathogenen. Orale vaccinatie is de meest aangewezen methode om deze 
immuunrespons te bekomen. (besproken in Hoofdstuk 1). Er zijn echter meerdere 
uitdagingen die moeten overwonnen worden om efficiënte orale vaccins te bekomen. 
Ondermeer de gevoeligheid van vaccinantigenen voor afbraak door de 
gastrointestinale pH, enzymen en galzouten, de gebrekkige passage doorheen de 
darmbarrière, de gebrekkige opname van oplosbare antigenen door antigeen-
presenterende cellen met onvolledige activatie van deze laatste waardoor eerder 
tolerantie dan immuniteit ontstaat. Daarom werden verschillende strategieën 
onderzocht om tot een efficiënte orale vaccinatie te komen (gereviewed in Hoofdstuk 
1).  
Lactococcus lactis is een Gram-positieve melkzuurbacterie die een interessante 
vector is voor orale toediening van antigenen. Inderdaad, deze bacterie wordt veel 
gebruikt in de gefermenteerde levensmiddelen- en zuivelindustrie. De laatste twee 
decennia onderzochten wetenschappers het gebruik van de bacterie als een levende 
vector voor orale vaccinatie, ondermeer dankzij de vooruitgang in genetische 
engineering en moleculaire biologie. Het onderzoek werd enerzijds gemotiveerd door 
de vaststelling dat de bacterie veilig is voor orale consumptie (ingedeeld als een 
“GRAS” organisme door de FDA) en anderzijds door haar geschiktheid voor genetische 
modificatie. Inmiddels bestaan er een groot aantal rapporten die beschrijven hoe de 
orale toediening van vaccinantigenen met behulp van L. lactis met succes leidde tot de 
inductie van beschermende mucosale en systemische immuunresponsen tegen 
verschillende pathogenen (gereviewed in Hoofdstuk 1). De waarde van L. lactis als 
levende vector voor orale toediening van een vaccin ligt vooral in haar mogelijkheid 
om antigenen te synthetiseren en vrij te geven ter hoogte van het mucosa-geassocieerd 
lymfoïd weefsel in de dunne darm, maar ook in haar adjuvanseffecten die de 
immuunrespons tegen antigenen versterken. 
In deze thesis onderzochten we of L. lactis het potentieel heeft om gebruikt te 
worden als een oraal vectorvaccin tegen enterohemorragische Escherichia coli (EHEC). 
Zoals beschreven in Hoofdstuk 1 zijn EHEC een groep van pathogene E. coli die 
verantwoordelijk zijn voor frequente uitbraken van hemorragische colitis en het 
hemolytisch uremisch syndroom. Dit laatste is een ernstige bedreiging voor de 
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volksgezondheid aangezien het de meest voorkomende oorzaak is voor acuut nierfalen 
bij kinderen en het voor een hoog sterftecijfer zorgt bij kinderen en ouderen. 
Antibioticabehandeling schijnt geen gunstig effect te hebben in de behandeling van 
EHEC infecties. Sterker nog, verschillende rapporten linken antibioticabehandeling 
aan verergering van de ziekte. Vaccinatie is dus de meest geschikte aanpak voor de 
controle van infecties. Helaas is er momenteel geen vaccin geregistreerd tegen EHEC 
infecties bij de mens. 
In Hoofdstuk 2 beschrijven we onze eerste poging om het EHEC antigeen, EspB, 
tot expressie te brengen in L. lactis. EspB is een belangrijk eiwit van het type drie 
secretiesysteem dat door EHEC gebruikt wordt om de dunne darm te koloniseren. 
Daarenboven vertoont dit eiwit een opmerkelijke immunogeniciteit, zowel bij 
experimentele als natuurlijke besmettingen. Daarom wordt EspB beschouwd als een 
potentiële vaccinkandidaat. De inductie van mucosale immuunresponsen, in het 
bijzonder IgA, tegen EspB kan interfereren met het kolonisatieproces van EHEC en kan 
op die manier de eraan gerelateerde ziekte voorkomen.  
EspB werd succesvol tot expressie gebracht in het cytoplasma van L. lactis. Echter, 
orale immunisatie van BALB/c muizen met deze recombinante stam induceerde geen 
waarneembare hoeveelheden Ig’s in het serum en IgA antistoffen in de faeces.  
Aangezien een zwakke stimulatie van het immuunsysteem één van de redenen kan zijn 
voor de afwezigheid van humorale antilichamen, pasten we vervolgens een 
intraperitoneale booster-immunisatie toe met behulp van opgezuiverd EspB. Tien 
dagen na de booster-immunisatie werden zowel serum Ig’s als faecale IgA gedetecteerd 
in de muizen die geïmmuniseerd werden met de EspB-producerende L. lactis, maar 
niet in deze die de controlestam toegediend kregen. Deze bevinding wijst erop dat het 
mucosaal immuunsysteem van de oraal geïmmunizeerde muizen wel degelijk 
geprimed werd tegen EspB. Het toonde echter ook aan dat er verdere optimalisatie van 
de recombinante vaccinstam nodig was om een completere immuunrespons te kunnen 
induceren via prime-boost immunisaties.  
In Hoofdstuk 3 beschrijven we de optimalisatie van de EspB-expressie in L. lactis 
door het ontwikkelen van recombinante stammen die EspB uitscheiden in het 
extracellulair medium. Anders dan bij cytoplasmatische expressie laat secretie de 
antigenen toe te ontsnappen aan cytoplasmatische proteolyse, die vermoedelijk 
resulteerde in lage expressieniveaus en een te beperkte beschikbaarheid van EspB voor 
het immuunsysteem om tot een duidelijke immuunrespons te komen in onze eerste 
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studie. Bijkomend vergeleken we de expressieniveaus van antigenen in constitutieve en 
nisine-geïnduceerde expressiesystemen. De secretie van EspB, in constitutieve of 
induceerbare omstandigheden, leidde inderdaad tot opmerkelijk hogere 
expressieniveaus in vergelijking met de cytoplasmatische expressie, namelijk 
respectievelijk 25 en 56 keer hoger. De verhoging in expressieniveau was dus dubbel zo 
groot bij het nisine-induceerbaar secretiesysteem in vergelijking met het constitutief 
systeem. Nadien evalueerden we het vermogen van de twee expressiesystemen om 
immuunresponsen te induceren in BALB/c muizen na immunisatie door orale 
toediening van de recombinante stammen (Hoofdstuk 3). Muizen, die geïmmuniseerd 
werden met een van beide stammen, toonden een significante toename van EspB-
specifieke totale Ig’s in het serum of van IgA in de faeces in vergelijking met de 
controlemuizen. De hoogste antilichaamresponsen werden verkregen met de nisine-
induceerbare stam. Vervolgens werd de cellulaire immuunrespons, die door middel 
van orale immunisatie van muizen met EspB-uitscheidende L. lactis geïnduceerd 
werden, gekarakteriseerd in Peyerse platen en mesenteriale lymfeknopen. Lymfocyten 
uit deze weefsels geïsoleerd produceerden na in vitro restimulatie met EspB zowel Th1 
cytokines (IFN-γ) als Th2 cytokines (IL-4 en IL-10). Dit wijst op de inductie van een 
gemengde Th1/Th2 respons. Desalniettemin toont de IL-4:IFN-γ ratio een bias naar 
Th2, een typisch kenmerk voor immuunresponsen ter hoogte van het darmslijmvlies. 
De Th2-dominantie is consistent met de inductie van intestinaal IgA. Verder werd de 
beschermende immuniteit van de orale immunisatie met de EspB secreterende L. lactis 
tegen een challenge-infectie met de E. coli O157:H7 stam geëvalueerd. De 
immuunresponsen die geïnduceerd werden door de vaccinstammen waren in staat om 
de geïmmuniseerde muizen te beschermen tegen kolonisatie van de darm door EHEC. 
De graad van bescherming kon gecorreleerd worden met de EspB-specifieke IgA 
responsen. Waarschijnlijk interfereren deze antistoffen met de aanhechting van EHEC 
aan het darmepitheel. Al deze bevindingen samen tonen het potentieel aan van EspB 
als kandidaat voor orale vaccinatie tegen EHEC-infectie en van L. lactis als vector voor 
targeting van het darm-geassocieerd mucosaal immuunsysteem.   
In Hoofdstuk 4 worden de eerste stappen gezet naar het gebruik van ons EHEC 
vaccin in het varken. Niettegenstaande muismodellen van EHEC infectie aanvaardbaar 
zijn voor de evaluatie van vaccins die het kolonisatieproces als doelwit hebben, 
bootsen ze de pathogeniciteit van EHEC in de mens niet volledig na. Daarentegen 
bieden varkens een alternatief diermodel waarin EHEC pathogeniciteit in mensen 
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behoorlijk reproduceerbaar is. Vanuit immunologisch standpunt zijn er trouwens meer 
overeenkomsten tussen varkens en de mens dan tussen de mens en muizen. Daardoor 
kan validatie van vaccins voor menselijke ziektes in varkensmodellen een nuttige stap 
zijn in de omzetting van de toepassing voor mensen, in het bijzonder in het geval van 
een EHEC infectie.  
Desondanks is er tot hiertoe geen enkel rapport gepubliceerd dat L. lactis- 
gebaseerde vaccins evalueert in een varkens infectiemodel. Een mogelijke reden is de 
eerder gerapporteerde lage overlevingskans van de bacterie in het spijsverteringsstelsel 
van varkens. In verband hiermee evalueerden we de gevoeligheid van L. lactis voor een 
aantal potentieel schadelijke spijsverteringsfactoren, zoals gal en de voornaamste 
pancreasenzymen: trypsine, lipase en amylase. Daarna evalueerden we het vermogen 
van aluminiumhydroxide (een galzuurbinder) en camostat mesylaat (een trypsine-
inhibitor) om L. lactis te beschermen, tegen respectievelijk de toxiciteit van gal en de 
hydrolyse door trypsine. Voor deze experimenten werden de fysiologische condities 
nagebootst die beschreven zijn in de dunne darm van varkens. Incubatie van L. lactis 
met vers verzamelde varkensgal leidde tot een duidelijk verlaagde overlevingsgraad 
van de bacteriën. Hierbij werd een positieve correlatie gezien tussen toxiciteit van de 
gal en zuurtegraad. Hoe lager de pH hoe toxischer de gal was. De overleving van 
L. lactis werd ook verlaagd door alle geteste pancreasenzymen. Van deze enzymen had 
trypsine de grootste negatieve invloed op de overleving van L. lactis (20% versus 49% 
voor amylase en 60% voor lipase). De aanwezigheid van aluminiumhydroxide en 
camostat mesylaat kon de overleving van L. lactis in respectievelijk gal- en trypsine-
oplossingen significant verbeteren. Daarenboven toonden we aan dat orale toediening 
van aluminiumhydroxide en camostat mesylaat samen met L. lactis de overleving van 
deze laatste in het spijsverteringsstelsel van varkens bevordert met respectievelijk 38-
maal in het jejunuminhoud en 24-maal in ileuminhoud van behandelde varkens. Onze 
resultaten bewijzen het concept van het gebruik van aluminiumhydroxide en camostat 
mesylaat in orale formuleringen van L. lactis om de overleving van de bacterie in het 
spijsverteringsstelsel van varkens te verhogen en bijgevolg de efficiëntie voor orale 
toediening van het vectorvaccin te bevorderen. Gezien de fysiologische en 
immunologische overeenkomsten tussen varkens en de mens, kunnen deze 
bevindingen ook gebruikt worden om de doeltreffendheid van L. lactis-gebaseerde 
vaccins in het humaan spijsverteringsstelsel te verbeteren.  
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